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GENERAL INTRODUCTION
Hepatocellular carcinoma (HCC) is the  fth most common cancer in the world and 
the third most common cause of cancer mortality1. Despite the high numbers of 
patients diagnosed worldwide (the estimated number of people is 0.5 million cases 
per year), HCC continue to pose challenging clinical problems. The assessment of 
the tumor and treatment options needs a multi-disciplinary approach in which the 
surgeon plays a central role. The aim of this thesis is to update on the incidence, 
etiology, diagnostic and treatment modalities in patients with HCC. 
Incidence
It is a disease with a highly uneven geographical distribution. In North America and 
several European countries, HCC is uncommon and the estimated death rate is less 
than 5/100.000 inhabitants/year 2,3. This in contrast to countries in the east and Africa 
where the incidence rates exceeds 30/100.000/year. An article of McGlynn4 about 
international trends and patterns of primary liver cancer suggested that developed 
countries (low endemic areas) have experienced an increase in primary liver cancer 
incidence whereas developing countries (high endemic areas) have experienced a 
decline. For example, the incidence increases in the United Kingdom 5, France 6 and 
the United States7. Publications describing epidemiological, treatment and survival 
 gures are mostly derived from a selected group of patients 8-11. This may be of lim-
ited relevance. Therefore, a population-based study was performed to determine 
whether the reported changes in incidence were also observed in the Netherlands 
including all patients with HCC between 1989 and 2000. Treatment and survival pat-
terns were also investigated between 1989 and 1998 in the Netherlands (Chapter 
II). 
Etiology 
Although solid experimental evidence for a single causative agent of HCC is lacking, 
there is a clear association of HCC with viral infections, including hepatitis B (HBV) 
and hepatitis C virus (HCV), alcoholic liver disease, haemochromatosis, tyrosinae-
mia, and long term use of a atoxin, oral contraceptives or anabolic steroids. This 
epidemiological evidence has lead to the hypothesis that cirrhosis resulting from 
any cause is the seedbed for HCC 12. There are likely to be co-factors that modify the 
risk of known risk factors. In addition, in the western world, a signi cant proportion 
of patients with HCC arise in a non-cirrhotic liver. In case of a non-cirrhotic liver, 
a signi cant proportion of these patients lack a recognized risk factor. It is known 
that Helicobacter species can be carcinogenic. The possible relationship between 
the presence of Helicobacter species in the non-cirrhotic liver and stomach of pa-
tients with hepatocellular carcinoma and the detection of Helicobacter species was 
explored (Chapter III). 
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Diagnosis
Liver cirrhosis is present in the majority of patients with HCC 13,14. Cirrhosis is a pro-
cess of liver  brosis that is characterized by architectural distortion and the develop-
ment of nodules ranging from regenerative nodules to hepatocellular carcinoma 15. 
The complexity of the di erent parenchymal changes makes it di  cult to detect 
and characterize liver lesions suspected for HCC with imaging procedures as ultra-
sonography, CT and MRI 16. There is a growing interest in the development of in vivo 
methods of assessing functional and metabolic parameters in normal and diseased 
tissues 17,18. Positron emission tomography with  uorine-18-deoxyglucose (18FDG-
PET) is one example of such a technique. PET is currently not widely available, mainly 
because of its high costs. Recently, alternative techniques for 18FDG imaging have 
become available: SPECT (Single Photon Emission Tomography) using special high-
energy collimators and coincidence detection using adapted multi-head gamma 
cameras (3, 4). These techniques are less costly than PET. To which extent gamma 
camera coincidence imaging can be used for clinical purpose is currently being 
investigated for various applications, including oncological diagnostics (5). We per-
formed a prospective clinical pilot study to investigate the additive value of 18FDG 
imaging by SPECT using special high-energy collimators and coincidence detection 
using adapted multi-head gamma cameras in patients with HCC. (Chapter IV). In 
patients with a focal liver lesion in whom the diagnosis is uncertain, a biopsy can be 
considered. The incidence of needle tract seeding among those with con rmed HCC 
is around 2% 22. Moreover, it may be di  cult for a pathologist to distinguish liver cell 
adenomas from primary liver cell carcinomas. The false negative rate in a centre of 
excellence is about 10%. 22 We developed a liver tissue micro-array, and investigated 
various cellular biomarkers in order enhance the possibility to discriminate liver cell 
adenomas from carcinomas. This study is described in Chapter V.
Treatment 
The prognosis of untreated patients with HCC is discouraging. However, early treat-
ment may alter survival and to date surgical resection seems to be the gold standard. 
Series describe 5-year survival rates between 20 and 80%, depending on the inclu-
sion criteria for treatment. Most of these series are coming from the eastern part of 
the world and southern Europe. Patients with HCC in these parts of the world have 
liver cirrhosis as underlying disease in 90 to 100%. Sofar, the prognosis of HCC in 
non-cirrhotic livers has not been studied extensively. We performed a study of pa-
tients with HCC in a non-cirrhotic liver and evaluated the e ect of surgical treatment 
on survival (Chapter VI). 
Due to the loss of functional reserve in the cirrhotic liver only 20% of patients with 
HCC and cirrhosis can tolerate partial liver resection. If the liver function is decom-
pensated due to cirrhosis, orthotopic liver transplantation is the preferred treatment 
for HCC o ering a 5-year survival comparable to other indications for transplanta-
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tion in well-selected patients. However, the paucity of donor organs necessitates the 
development of alternative treatment modalities. Local thermal ablation methods 
(Radiofrequency, Cryoablation, Interstitial Laser Coagulation (ILC) are well-known 
and upcoming alternative treatment modalities with promising results. One of the 
major drawbacks of thermal ablation methods is the size of the tumor. To increase 
the e ect of thermal ablation we performed a prospective clinical trial of ILC with 
temporary arterial occlusion in patients with HCC (Chapter VII). Because of the prac-
tical drawbacks of ILC and the success of RFA described by others we adapted our 
technique of thermal ablation and subsequently performed a prospective study us-
ing RFA as a local ablation method (Chapter VIII). Even when local tumor control can 
be achieved (as in complete resection), recurrence rates are as high as 80%. Since 
HCC is a chemo- and radiation insensitive tumor, resection or local thermal ablation 
are the only modalities o ering chance for cure. For intra-hepatic recurrences, re-
resection and ablation are accepted. Little is known about resection of extra-hepatic 
disease. Our experience in this  eld is described in Chapter IX and compared with 
 ndings from an extensive review of the literature. 
HCC is relatively insensitive for chemotherapy and radiotherapy. Other systemic 
treatment modalities are being studied. In pre-clinical studies Somatostatin (SS) an-
alogues have been demonstrated to inhibit the growth of a wide variety of tumours 
in vivo and in vitro. To date the results published on the e  cacy of SS on survival of 
patients with HCC are con icting. Some studies do not display a bene cial e ect on 
the survival of patients with unresectable HCC’s 23-25, while others report a signi cant 
survival bene t 26-28. Placebo controlled randomized trials do not show a signi cant 
bene t of SS on patient survival 23,29. In none of these studies it was investigated 
whether HCC tumours expressing SS-Rs may form a subgroup at the genetic level 
changing the sensitivity for SS treatment. To investigate the ssr in HCC and to test 
whether speci c genetic alterations are associated with ssr-positive or ssr-negative 
HCC’s, we examined protein (over) expression of tumour suppressor genes (p16, p53 
and Rb1) by immunohistochemistry. In addition, the proliferative capacity was ex-
amined by immunostaining of Ki67 and the DNA ploidy status (aneuploidy) by using 
 uorescent in situ hybridization (FISH) with a chromosome 1-speci c repetitive DNA 
probe. These results indicate the existence of ssr in human HCC and may help to 
clarify a correlation between ssr expression and patient characteristics, tumour size, 
underlying liver disease or alterations of investigated proto-oncogenes. (Chapter X)
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ABSTRACT
To examine recent trends of hepatocellular carcinoma (HCC) in an unselected patient 
population in the Western world, cancer registration data of HCC in the Netherlands 
were analysed. Trends in incidence, mortality, treatment and survival, according to 
gender, age, stage of disease and period of diagnosis were studied. 
We found no rising age-standardised incidence of HCC in the Netherlands during 
1989 and 2000. In men older than 75 years, there was a signi cant increase. Mortality 
due to primary liver cancer increased in 1989-2000. There was no change in treatment 
pattern (1989-1998), whereas 73% of patients with HCC received no cancer-related 
therapy during this period of analysis. Twelve percent of the patients underwent 
either partial liver resection or orthotopic liver transplantation. This low percentage 
suggests that patients with HCC must be analysed and discussed in specialised cen-
tres to minimise the number of patients not receiving possible curative therapy. 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the  fth most common cancer in the world and 
the third most common cause of cancer mortality. The estimated number of people 
who develop HCC is 564,000 cases/year worldwide [1]. In North America and several 
European countries, HCC is uncommon and the estimated death rate is less than 
5/100,000 inhabitants/year [2,3]. However, the incidence has been increasing in 
low-endemic areas, as has been reported for the United Kingdom [4], France [5] and 
the United States [6]. Most of the publications regarding incidence, treatment and 
prognosis of patients with HCC are derived from selected groups of patients [7-10]; 
because these may be of limited relevance, we performed a population-based study 
in the Netherlands including all patients with HCC diagnosed between 1989 and 
2000. Trends in incidence, mortality, treatment and survival, according to gender, 
age, stage of disease and period of diagnosis were studied. 
PATIENTS AND METHODS
Incidence, treatment and mortality. 
Incidence (1989-2000) and treatment (1989-1998) data regarding liver tumours were 
provided by the population-based Netherlands Cancer Registry, for which 9 regional 
cancer registries collect data. All liver malignancies diagnosed and treated from 1989 
onward in people living in the Netherlands, have been registered nation-wide [11]. 
Upon noti cation by the pathological laboratories or the hospital medical records 
departments, the registration clerks actively collect data (diagnosis, staging and 
treatment) on all new patients. Data are collected from the medical records of the 
various hospitals, usually within 6 months of diagnosis. Primary liver cancer was clas-
si ed as HCC, cholangiocarcinoma, angiosarcoma, other sarcomas or tumours not 
otherwise speci ed. Due to privacy regulations, death certi cates cannot be used as 
an additional source of noti cation of cancer cases in the Netherlands. Despite the 
lack of this noti cation source, the infrastructure of the Netherlands health care sys-
tem and the noti cation procedures used have made it possible to establish a cancer 
registry with high completeness (96.2%) [12,13]. In the case of multiple tumours, the 
same rules were applied as those recommended by the International Association of 
Cancer Registries [14]. 
We calculated age-speci c and age-standardised incidence rates. For the age-
standardised rates the European population was used as a standard (European 
Standardised Rates, ESR). Treatment was scored as follows: surgery included partial 
liver resection or liver transplantation, chemotherapy was systemic or regional, 
other therapies included local ablation, systemic or local therapy (other than che-
motherapy) and radiation. Statistics Netherlands provided mortality data. Trends in 
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incidence and mortality were estimated by calculating the Estimated Annual Per-
centage Change (EAPC) [15]. Mortality data are based on all primary liver cancers. 
Due to di erent coding during the study period, it was impossible to examine the 
mortality trends for the histological subgroups. For calculating age-standardized 
incidence rates in European cancer registries between 1978 and 1997 we used data 
of the EUROCIM (European cancer incidence and mortality) database. Only regis-
tries with data since 1978 were included. Age-adjustment was performed by direct 
standardization according to the European Standard Population (ESR: European 
Standardized Rate)[16].
Survival 
Follow-up of cancer patients was completed in two regional cancer registries: the Am-
sterdam Cancer Registry, Comprehensive Cancer Centre Amsterdam (CCCA) and the 
Eindhoven Cancer Registry, Comprehensive Cancer Centre South (CCCS). Therefore, 
survival analyses were restricted to these registries. Together these covered an area of 
about 3.5 million inhabitants (+/- 25% of the total population in the Netherlands at that 
time). In addition to passive follow-up in the hospitals, active follow-up was done, us-
ing regional municipal databases and the national bureau for genealogy. The database 
of the bureau for genealogy contains data of all people deceased in the Netherlands. 
Follow-up was complete at least until 1 January 1999. Survival was analysed according 
to gender, age, tumour stage and treatment. Patients were staged according to the 
UICC staging system [17]. We calculated Kaplan-Meier curves: to analyse di erences 
between subgroups the log-rank test was used. To calculate variation in survival within 
Europe, data of the EUROCARE database (a concerted action among European can-
cer registries) were used [18]. Patients diagnosed with primary liver cancer between 
1990 and 1994 in European population-based cancer registries were included. For 
international comparison and for comparison with clinical studies, cases incidentally 
discovered at autopsy were excluded, as were those known to registries from the 
death-certi cate-only (DCO). In case of multiple metachronous tumours, only the  rst-
of 29 years, approximately 3 patients yearly. The inci-
dence was highest for men older than 75 years (12/
100 000/year). Despite the low incidence rate, there was
a large variation in incidence within the Netherlands,
especially among males. Among males, the age-stan-
dardised incidence rates were 2.5/100 000 in highly ur-
banised areas and only 0.7/100 000 in rural areas. These
differences were only found for HCC and not for the
other primary liver cancers. The incidence of HCC in
several countries in Europe is given in Table 1. The in-
cidence of HCC was relatively low in England, Norway
and the Netherlands, and relatively high in France
(North), Italy (Varese), Spain (Navarra) and Switzer-
land (Geneva).
3.2. Treatment
Between 1989 and 1998, twelve percent (n ¼ 197) of
the total HCC population underwent a partial liver re-
section or orthotopic liver transplantation (OLT) (Table
2). There was no difference in the resection rate between
males and females. During the 10-year study period, the
resection rate remained stable. Patients younger than 45
years of age (n ¼ 132) had the highest resection rate
(33%). Patients older than 75 years (n ¼ 416) had the
lowest resection rate (5%). Seventy-three percent did not
get any form of cancer-related treatment; this did not
change during the study period.
3.3. Survival
Table 3 gives the estimated 5-year survival rates ac-
cording to Kaplan–Meier, stratified according to age
and treatment. Survival was best for patients with a
resected tumour. Survival of patients diagnosed during
1989–1993 was the same as the survival of patients di-
agnosed during 1994–1998 (data not shown). No dif-
ference in survival was found either in the untreated
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Fig. 1. Proportional distribution of the histological subtypes of primary liver cancer in the Netherlands (1989–1998). NMC: not microscopically
confirmed; HCC: hepatocellular carcinoma; CC: cholangiocarcinoma.
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diagnosed tumour was included for survival analysis. In EUROCARE, relative survival 
rates are computed. Relative survival is an estimation of disease-speci c survival. It is 
calculated as the ratio of the observed to the expected survival rates. Expected survival 
rates were calculated from life tables for regional male and female populations with 
the same 5-year age distribution. Since the age distribution of patients di ers between 
countries, the survival rates were adjusted to a common age structure.
RESULTS
Incidence
Between 1989 and 2000, 3048 primary liver cancers were recorded in the Netherlands. 
Liver cancer was about twice as common in males as in females. HCC was the predomi-
nant histology (64%) followed by cholangiocarcinoma (10%). In 16% of the cases the 
disease was not microscopically con rmed. The remaining 10% were angiosarcomas, 
of 29 years, approximately 3 patients yearly. The inci-
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group or in the surgically treated group between these
two time intervals.
There was no difference in a 5-year survival rate be-
tween males and females or between patients younger
than 60 years and those older than 60 years. Five-year
survival of patients with tumour stage I/II or III (13%)
was significantly better than for those with tumour stage
IV (1%). In the surgically treated group, there was also a
difference in 5-year survival between tumour stage I/II
and tumour stage III (48% and 24%, respectively,
P ¼ 0:06). In the group of patients who did not receive
surgery or chemotherapy, patients with tumour stage I/
II and III had a 2-year survival rate of 14% and 18%,
respectively, and both groups had a 5-year survival rate
of only 2%. Patients with tumour stage IV had
the poorest survival (2-year survival-rate of 3% and no
5-year survivors). Relative 1- and 5-year survival of
patients with HCC in the Netherlands was average
compared with other European countries (Table 4).
4. Discussion
The results of this study show that the incidence of
HCC in the Netherlands was stable during 1989–2000.
This is in contrast with recent publications that de-
scribed an increased incidence in other low-endemic
areas [4–6,20]. An article of McGlynn et al. [21] about
0
1
2
3
4
5
6
7
8
9
10
11
12
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
year
ES
R
30-44 years
45-59 years
60-74 years
75 years and older
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Table 1 Incidence rates of HCC in Europe (patients/100 000/year); source: EUROCIM
MALE FEMALE
1988-1992 1993-1997 1988-1992 1993-1997
Estonia 1.72 2.34 0.65 0.84
England 1.30 1.65 0.38 0.51
Finland 3.35 3.28 1.29 1.01
France-North 9.31 9.94 0.97 0.88
Germany-Saarland 1.86 3.30 0.50 0.84
Iceland 3.29 3.34 0.64 1.27
Italy-Varese 10.40 14.10 2.23 2.26
Norway 1.46 1.36 0.58 0.56
Slovenia 2.87 3.34 0.55 0.85
Spain-Navarra 4.82 7.66 0.66 1.42
Sweden 3.67 3.40 1.49 1.33
Switzerland-Geneva 11.32 8.89 1.16 1.61
Scotland 2.27 3.02 0.55 0.72
The Netherlands 1.54 1.70 0.50 0.52
HCC, hepatocellular carcinoma.
group or in the surgically treated group between these
two time intervals.
There was no difference in a 5-year survival rate be-
tween males and females or between patients younger
than 60 years and those older than 60 years. Five-year
survival of patients with tumour stage I/II or III (13%)
was significantly better than for those with tumour stage
IV (1%). In the surgically treated group, there was also a
difference in 5-year survival between tumour stage I/II
and tumour stage III (48% and 24%, respectively,
P ¼ 0:06). In the group of patients who did not receive
surgery or chemotherapy, patients with tumour stage I/
II and III had a 2-year survival rate of 14% and 18%,
respectively, and both groups had a 5-year survival rate
of only 2%. Patients with tumour stage IV had
the poorest survival (2-year survival-rate of 3% and no
5-year survivors). Relative 1- and 5-year survival of
patients with HCC in the Netherlands was average
compared with other European countries (Table 4).
4. Discussion
The results of this study show that the incidence of
HCC in the Netherlands was stable during 1989–2000.
This is in contrast with recent publications that de-
scribed an increased incidence in other low-endemic
areas [4–6,20]. An article of McGlynn et al. [21] about
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P ¼ 0:06). In the group of patients who did not receive
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II and III had a 2-year survival rate of 14% and 18%,
respectively, and both groups had a 5-year survival rate
of only 2%. Patients with tumour stage IV had
the poorest survival (2-year survival-rate of 3% and no
5-year survivors). Relative 1- and 5-year survival of
patients with HCC in the Netherlands was average
compared with other European countries (Table 4).
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intern tion l trends and patterns of primary liver cancer
suggested that developed countries have experienced an
increase in primary liver cancer incidence, whereas de-
veloping countri s have experienced a decline. The ap-
parent changes in liver cancer rates as described
worldwide are not fully understood. Possible explana-
tions for the rise in low-endemic areas may be the rise of
hepatitis C viral (HCV) infections, improved survival of
cirrhotic patients, and a better diagnostic work-up [21–
25]. Another possible explanation for the rise is the in-
creased proportion of immigrants from high-endemic
areas. The relatively high proportion of immigrants
from high-risk areas in the world could explain the high
rates in urbanised areas in our study. However, during
our 12-year study period, the incidence of HCC in ur-
banised areas also remained stable (data not shown).
The geographical variation in different incidence rates
within Europe strongly correlates with the prevalence of
hepatitis infection and the prevalence of liver cirrhosis
from any cause [3]. Therefore, the incidence rates in
France, Italy, Switzerland and Spain are markedly
higher than in the other European countries (Table 1).
Diagnostic work-up has changed over time. Com-
puted tomography and high-resolution magnetic reso-
nance imaging (MRI) of the liver have facilitated the
diagnosis of liver malignancies. One may consider that if
there is an increase for all primary liver cancers this
reflects a better diagnostic work-up of liver malignan-
cies. This could be an explanation for the increasing
incidence for both intrahepatic cholangiocarcinoma and
HCC in the US and the UK [4,6,26,27]. We did not find
an increasing trend for HCC, cholangiocarcinoma or
any other primary liver malignancies (Fig. 1). These
data support the concept that a better diagnostic work-
up for patients or the accuracy of registration probably
did not influence the incidence rate in our study.
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Fig. 5. Age-standardised mortality rates due to primary liver cancer in the Netherlands (1989–2000). ESR: European standardised rates.
Table 1
Incidence rates of HCC in Europe (patients/100 000/year); source: EUROCIM
Male Female
1988– 92 19 3–1997 1988–1992 1993–1 97
Estonia 1.72 2.34 0.65 0.84
England 1.30 1.65 0.38 0.51
Finland 3.35 3.28 1.29 1.01
France-North 9.31 9.94 0.97 0.88
Germany-Saarland 1.86 3.30 0.50 0.84
Iceland 3.29 3.34 0.64 1.27
Italy-Varese 10.40 14.10 2.23 2.26
No way 1.46 1.36 0.58 0.56
Slovenia 2.87 3.34 0.55 0.85
Spain-Navarra 4.82 7.66 0.66 1.42
Sweden 3.67 3.40 1.49 1.33
Switzerland-Geneva 11.32 8.89 1.16 1.61
Scotland 2.27 3.02 0.55 0.72
The Netherlands 1.54 1.70 0.50 0.52
HCC, hepatocellular carcinoma.
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other sarcomas, or tumours not otherwise speci ed. The percentages of the three larg-
est groups, i.e. HCC, cholangiocarcinoma and tumours not microscopically con rmed, 
remained stable over time (1989-1998) (Figure 1). Between 1989 and 2000, 1964 new 
patients with HCC were registered in the Netherlands. The male/female ratio was 2.4:1. 
The age-standardised incidence rate (ESR) did not show a signi cant trend in these 12 
years (Figure 2). In 2000 the ESR for males was 1.6/100,000 and for females 0.3/100,000. 
Figures 3 and 4 show the age-speci c trends of HCC incidence. Besides in males older 
than 75 years, there was no signi cant increase of incidence.
Table 2 Treatment patterns of patients with HCC in the Netherlands according to age and time of diagnosis
Age
(years)
Treatment 1989-1993
n   %
1994-1998
n   %
1989-1998
n   %
< 45 Surgery 26  (37%) 17  (28%) 43  (33%)
Chemotherapy 12  (17%) 11  (18%) 23  (17%)
Other therapy 6  (8%) 7  (11%) 13  (10%)
No therapy 27  (38%) 26  (43%) 53  (40%)
71  (100%) 61 (100%) 132  (100%)
45-59 Surgery 20  (17%) 40  (23%) 60  (20%)
Chemotherapy 9  (7%)  18  (10%) 27  (9%)
Other therapy 16  (13%) 15  (8%) 31  (10%)
No therapy 77  (63%) 103  (59%) 180  (60%)
122  (100%) 176  (100%) 298  (100%)
60-74 Surgery 28  (8%) 46  (11%) 74  (10%)
Chemotherapy 19  (5%) 15  (4%) 34  (4%)
Other therapy 28  (8%) 46  (11%) 74  (10%)
No therapy 278  (79%) 309  (74%) 587  (76%)
353  (100%) 416  (100%) 769 (100%)
>75 Surgery 8  (4%) 12  (5%) 20  (5%)
Chemotherapy 2  (1%) 3  (1%) 5  (1%)
Other therapy 12  (6%) 19  (9%) 31  (7%)
No therapy 172  (89%) 188  (85%) 360  (87%)
194  (100%) 222 (100%) 416  (100%)
Total Surgery 82  (11%) 115  (13%) 197  (12%)
Chemotherapy 42  (6%) 47  (5%) 89  (6%)
Other therapy 62  (8%) 87  (10%) 149  (9%)
No therapy 554  (75%) 626  (72%) 1180  (73%)
740  (100%) 875  (100%) 1615  (100%)
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Mortality due to primary liver cancer increased (Figure 5). This trend was present 
both in males and in females (males EAPC = 3.1%, females EAPC = 4.6%) [19].This was 
mainly caused by an increase in mortality in patients aged 60 or older. The age distri-
bution has remained relatively stable throughout the study period. Two percent of all 
HCCs were diagnosed under the age of 29 years, about 3 patients yearly. The incidence 
was highest for men older than 75 years (12/100,000/year). Despite the low incidence 
rate there was a large variation in incidence within the Netherlands, especially among 
males. Among males the age standardised incidence rates were 2.5/100,000 in highly 
urbanised areas and only 0.7 in rural areas. These di erences were only found for HCC 
and not for the other primary liver cancers. The incidence of HCC in several countries in 
Europe is given in Table 1. The incidence of HCC was relatively low in England, Norway 
and the Netherlands, and relatively high in France (North), Italy (Varese), Spain (Navarra) 
and Switzerland (Geneva).
Treatment
Between 1989 and 1998, twelve percent (n=198) of the total HCC population under-
went a partial liver resection or orthotopic liver transplantation (OLT) (Table 2). There 
was no di erence in resection rate between males and females. During the 10-year 
study period, the resection rate remained stable. Patients younger than 45 years of age 
(n=132) had the highest resection rate (33%). Patients older than 75 years (n=416) had 
the lowest resection rate (5%). Seventy three percent did not get any form of cancer-
related treatment; this did not change during the study period.
Survival
Table 3 gives the estimated 5-year survival rates according to Kaplan Meier, strati ed 
according to age and treatment. Survival was best for patients with a resected tumour. 
Survival of patients diagnosed during 1989-1993 was the same as the survival of pa-
tients diagnosed during 1994-1998 (results not shown). Nor in the untreated group 
nor in the surgically-treated group a di erence was found in survival between these 
two time intervals. 
There was no di erence in 5-year survival rate between males and females or between 
patients younger than 60 years and those older than 60 years. Five-year survival of 
Table 3 Survival patterns according to age and treatment in CCCS (comprehensive cancer centre south) and CCCA (comprehensive cancer centre 
amsterdam) of patients diagnosed with HCC between 1989-1998.
Treatment 5-year survival
age < 60 years
5-year survival
age >60 years
5-year survival
total population 
Surgery 31% 25% 29%
Chemotherapy 5% 6% 6%
Other therapy 0% 0% 0%
No therapy 2% 2% 2%
Overall 5% 5% 5%
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patients with tumour stage I/II or III (13%) was signi cantly better than for those with 
tumour stage IV (1%). In the surgically-treated group, there was also a di erence in 
5-year survival between tumour stage I/II and tumour stage III (48% and 24%, respec-
tively, p=0.06). In the group of patients who did not receive surgery or chemotherapy, 
patients with tumour stage I/II and III had a 2-year survival rate of 14% and 18%, re-
spectively and both had a 5-year survival rate of only 2%. Patients with tumour stage 
IV had the poorest survival (2-year survival-rate of 3 % and no 5-year survivors). Rela-
tive 5-year survival of patients with HCC in the Netherlands was average compared to 
other European countries (Table 4).
DISCUSSION
The results of this study show that the incidence of HCC in the Netherlands was 
stable during 1989 - 2000. This is in contrast with recent publications that described 
an increased incidence in other low-endemic areas [4-6,20]. An article of McGlynn 
and colleagues about international trends and patterns of primary liver cancer, sug-
gested that developed countries have experienced an increase in primary liver cancer 
incidence whereas developing countries have experienced a decline [21]. The appar-
ent changes in liver cancer rates as described world-wide are not fully understood. 
Possible explanations for the rise in low-endemic areas may be the rise of hepatitis C 
Table 4 Survival rates in Europe (1990-1994);Source:EUROCARE
COV. MALE FEMALE OVERALL
(%) No of cases surv No of cases surv No of cases surv
Estonia 100 138 3% 107 1% 245 2%
England 59 2222 6% 1370 8% 3592 7%
Finland 100 613 4% 597 4% 1210 4%
France-North 4 628 7% 145 9% 773 7%
Germany 2 133 5% 77 6% 210 5%
Italy 14 4004 7% 1825 8% 5829 7%
Norway 100 247 3% 190 4% 437 3%
Slovenia 100 162 6% 78 4% 240 5%
Spain 6 881 10% 349 10% 1230 10%
Sweden 100 1215 3% 967 3% 2182 3%
Switzerland 13 137 6% 43 0% 180 5%
Scotland 100 515 4% 321 5% 836 4%
The Netherlands 23 268 6% 91 3% 359 5%
COV: Coverage of the country
surv: 5-year relative survival rate
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viral (HCV) infections, improved survival of cirrhotic patients, and a better diagnostic 
work-up [21-25]. Another possible explanation for the rise is the increased proportion 
of immigrants from high-endemic areas. The relatively high proportion of immigrants 
from high-risk areas in the world could explain the high rates in urbanised areas in our 
study. However, during our 12-year study period, the incidence of HCC in urbanised 
areas also remained stable (results not shown).
The geographic variation in di erent incidence rates within Europe strongly correlates 
with the prevalence of hepatitis infection and the prevalence of liver cirrhosis by any 
cause [3]. Therefore, the incidence rates in France, Italy, Switzerland and Spain are 
markedly higher than in the other European countries (Table 1).
Diagnostic work-up has changed over time. Computed tomography and high-reso-
lution MRI of the liver have facilitated the diagnosis of liver malignancies. One may 
consider that if there is an increase for all primary liver cancers this re ects a better 
diagnostic work-up of liver malignancies. This could be an explanation for the increas-
ing incidence for both intrahepatic cholangiocarcinoma and HCC in the United States 
and the United Kingdom [4,6,26,27]. We did not  nd an increasing trend for HCC, cho-
langiocarcinoma or any other primary liver malignancies (Fig.1). These data support 
the concept that a better diagnostic work-up for patients or accuracy of registration 
probably did not in uence the incidence rate in our study. 
The terms HCC and primary liver cancer are often used interchangeably. In Japan, 
94% of all primary liver cancers were HCC [25], compared with 64% in our study and 
74% in the USA [6]. Therefore it is more accurate to describe the primary liver cancers 
separately if the population is based on Western-world standards. Di erences in study 
design might explain the di erence between our results and studies reporting an in-
crease of HCC [4-6,20,22,28]. 
The study of El-Serag and colleagues [6] used the data on incidence from the Surveil-
lance, Epidemiology and End Results (SEER) Program of the National Cancer Institute 
and found a rising incidence. Since this database accounts for 14% of the American 
population, it may not re ect the U.S.A. as a whole (SEER regions are more urban and 
have a higher proportion of foreign-born persons than the general U.S. population) 
[6,29]. El-Serag and colleagues [6] analysed mortality and data on hospitalisation. The 
results of these two measures were similar to the observed increasing incidence rate of 
HCC. This strengthens the internal validity of the observed increasing incidence trend. 
However, it has been stated that analyses on mortality data are not very reliable if one 
analyses a subgroup of cancer [22] and the data on hospitalisation were of a speci c 
subgroup of the population; i.e. U.S. veterans, mainly men. We found a signi cant rise 
of mortality due to primary liver cancer. This is in contrast to the stable incidence rate 
of the primary liver cancers during the same period (Figure 1). An increasing incidence 
in the period before this study with long-time survivors, is a very unlikely explana-
tion in this usually rapid fatal disease. In a recent update of the study of El-Serag and 
colleagues [29], the incidence of HCC continues to increase in the United States, with 
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rates increasing the fastest in white men 45 to 54 years of age. If age-adjusted rates 
are analysed, age-speci c trends can be diverse. Therefore, we analysed our data ac-
cording to speci c age groups in both sexes ( gures 3 and 4). In males older than 75 
years, there was a signi cant increase. We have not a conclusive explanation for this 
phenomenon. An aging population is an unlikely explanation for this increase in HCC 
since it did not a ect females. The most likely explanation is that the increase of HCC 
incidence in males older than 75 years is confound by the small numbers of patients 
(323 patients in 12 years). It may also re ect an in ux of male immigrants in the last 
decades. An increase of HCV infection during the seventies is another suggestion 
however this does not explain the sex di erence. After HCV infection it takes about 
25 years to develop liver cirrhosis. Afterwards there is an incidence of 1 or 2 percent 
annually to develop HCC.
In our study, a high proportion of patients with HCC (73%) did not receive cancer-
related treatment. In the USA, e.g., 51% of the HCC patients received no treatment [10]. 
To our knowledge, there are no other western data on the percentage of patients who 
received treatment without any referral bias. In view of the promising local ablation 
methods [30] and the successful living related liver transplantation program [31], the 
percentage of patients receiving no treatment may decline in the near future. In our 
series, however, there was no trend towards this phenomenon. Of all patients, 12% 
were treated by partial liver resection or OLT. This is interesting because this percent-
age is in the absence of any referral bias. In experienced centres, the reported resec-
tion rates (not including OLT) are, e.g., 37% [8], 49% [32] and even 67% [33]. Resection 
rates of patients with HCC without referral bias are scarce in the literature. Cance and 
colleagues [10] (data representing approximately 14% of the estimated cases of car-
cinomas of the liver and biliary tract diagnosed in the USA) found a resection rate of 
17%, excluding the patients who underwent OLT. We have the impression that our per-
centage (12%) with either partial liver resection or OLT is low. Reasons for this low per-
centage need to be explored. The underlying liver disease (60-95%) [34-36], the older 
age of patients (75% older than 60 years in this study) and the usually large tumour 
diameter of patients without underlying liver cirrhosis (mean 9 and 10 cm) [37,38] are 
known drawbacks for resection. However, liver cirrhosis is nowadays not an absolute 
contra-indication for even major liver resections in specialised centres [39]. Liver resec-
tion in the elderly patients with HCC has short- and long-term results comparable to 
those of younger patients, if well selected and if they receive specialised postopera-
tive care [40,41]. Despite the usually large tumour diameter in the non-cirrhotic liver, 
5-year survival rates of 40% after partial liver resection have been reported [37,38]. To 
minimize the number of patients not receiving possible curative therapy, we suggest 
that all patients with HCC must at least be discussed in specialised centres, o ering 
consultation service. 
The 5-year survival rate of 29% after resection/OLT is rather low compared to the 
5-year survival rates found in the literature. It is di  cult to explain this di erence since 
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the survival after resection or OLT is highly in uenced by underlying liver disease, vas-
cular invasion, size and number of the tumour nodules. This is exactly the reason why 
the TNM classi cation [17] does not have prognostic power in patients with HCC [42]. 
However, the survival rate in our study is interesting because, in contrast to previous 
studies, it is without any referral bias. Previous reports have demonstrated that women 
appear to have better survival outcomes from HCC than men [10,43]. In the current 
report, enhanced survival among women was not observed; this was seen in all treat-
ment modalities and the untreated group. Cance and colleagues [10] suggested that 
especially women with tumour stage II and III had a better survival than men, however, 
even in this subgroup we did not  nd better survival rates for females. Table 4 gives 
the relative survival rates at 5 years among several European countries between 1990 
and 1994 (EUROCARE III). There are small intercountry di erences in survival. Survival 
rates were slightly higher in England, Italy and France than in the other countries. It is 
unclear if the intercountry di erences are a result of di erences in stage at diagnosis 
and/or more aggressive therapeutic approaches, or a methodological di erence (com-
pleteness) [44]. 
In conclusion: This is (to our knowledge) the  rst study that reports on incidence 
data and treatment patterns of a whole country. In contrast to previous reports of sub 
populations in non-endemic areas, we found no age-standardised rising incidence of 
HCC in the Netherlands between 1989 and 2000. There was no change in treatment 
pattern. Seventy-three percent of patients with HCC received no therapy and only 12% 
of the patients underwent either partial liver resection or OLT. This low percentage 
suggests that patients with HCC must be analysed and discussed in specialised centres 
to minimise the number of patients not receiving possible curative therapy. 
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Chapter III
Detection of identical Helicobacter DNA in 
the stomach and in the non-cirrhotic liver of 
patients with hepatocellular carcinoma 
Eur J Gastroenterol Hepatol 2003; 15:1171–1174 
1 tumour >5cm,
or > 3 tumours
Child A Child B/C
Resection/
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ABSTRACT
Objectives: Studies have implied the presence of Helicobacter species in the human 
liver. The possible relationship between the presence of Helicobacter species in the 
non-cirrhotic liver of patients with hepatocellular carcinoma (HCC) and the detec-
tion of Helicobacter species in their stomach was explored. 
Patients and methods: A 16S rDNA-based polymerase chain reaction (PCR) fol-
lowed by DNA sequence analysis of the obtained PCR fragments was performed on 
51 surgically obtained non-cirrhotic liver specimens and 14 gastric samples. 
Results: Analysis indicated a signicant di erence in the presence of Helicobacter-
species-specic DNA in the liver of patients with HCC compared with controls. Se-
quence analysis of these PCR products obtained from HCC patients indicated that 
they were related most closely to the 16S rDNA sequence of Helicobacter pylori but 
that they always di ered at the same two positions. This same aberrant Helicobacter-
species-specic 16S rDNA could be isolated in gastric samples of patients with HCC.
Conclusion: These data suggest that gastric colonization with a specic subset of 
Helicobacter strains is associated with the induction of HCC, either directly via colo-
nization of the liver or indirectly, e.g. via secretion of specic toxins by Helicobacter 
residing in the stomach. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is one of the most common cancers in men and 
its incidence is increasing in low-endemic areas, such as the UK [1], France [2] and 
the USA [3]. Depending on the geographical location, the prevalence of HCC arising 
from non-cirrhotic liver varies between 9 and 54% [4]. A signicant proportion of 
patients with non-cirrhotic liver lack a recognized risk factor. 
In 1994 it was reported that hepatic colonization with a spiral-shaped, Gram-neg-
ative bacterium was associated with chronic active hepatitis and high incidence of 
hepatocellular tumours in A/JCr mice [5,6]. Since then, several investigators have 
reported on a putative hepatic Helicobacter colonization in patients with various 
liver diseases [7–16]. In most of these studies, a causative relationship between the 
presence of Helicobacter in the liver and the occurrence of HCC is suggested, but 
others doubt such a relation and attribute it to selection bias, small sample numbers, 
and secondary infection of the diseased liver with gastric Helicobacter [17]. 
To our knowledge, there are no published data that correlate the presence of the 
hepatic Helicobacter isolates with the presence/absence of gastric Helicobacter in 
HCC patients. This demands further studies to explore the possibility of a relation-
ship between Helicobacter species that colonize the liver and HCC in humans, and to 
relate these ndings with that of a possible Helicobacter species in their stomach. 
PATIENTS AND METHODS 
Patients
All consecutive patients with colorectal metastases or HCC in non-cirrhotic liver were 
included in our study. At the time when patients underwent liver resection, sterile, 
non-tumourous liver tissue was sampled. Twenty patients with HCC in non-cirrhotic 
liver (seven (35%) female, 13 (65%) male; median age 61 years) and 31 patients 
with colorectal liver metastases as a control group (11 (35%) female, 20 (65%) male; 
median age 62 years) were studied. Histological examination of the resected liver 
specimen conrmed the presence of HCC or colorectal metastases and the absence 
of liver cirrhosis. Nine patients who underwent liver resection because of HCC gave 
informed consent to obtain gastric samples. Liver samples and gastric samples were 
stored in liquid nitrogen until further use. 
DNA extraction
DNA was extracted from the frozen liver and stomach tissue using the commercially 
available Wizard Genomic DNA Purication System (Promega, Madison, WI, USA) and 
stored at –808C until required for polymerase chain reaction (PCR) amplication. Poly-
merase chain reaction amplication, cloning and sequencing of 16S rDNA, and 16S 
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rDNA data analysis. The extracted DNA was used in a nested PCR. To increase sensitiv-
ity, samples were rst subjected to PCR amplifying eubacterial 16S rDNA sequences 
using primer 16SEubacF and 16SEubacR (Table 1). The amplication products were 
subsequently used in Helicobacter-specic PCR using primers HelicospeciesF and 
HelicospeciesR (Table 1), which are located within the fragment amplied in the rst 
reaction. Primers HelicospeciesF and HelicospeciesR gave positive reaction with all 
ten gastric and ve enterohepatic Helicobacter species tested. The presence of cagA 
and cagE as a marker for the cag pathogenicity island was assessed by PCR with 
primers listed in Table 1. 
PCR was performed, essentially as described in previous studies [18], using the PCR 
Core System (Promega), using 1 unit Tag DNA polymerase, 1.5 mM MgCl2, 0.2 mM 
of each nucleotide and 10 pmol of each primer. Amplication was performed in a 
total volume of 50 l following the PCR programme as described in Table 1. The nucle-
otide sequence of the PCR fragments was determined by direct DNA sequencing 
and checked against the GenBank databases using the Blast program at the National 
Center for Biotechnology Institute (NCBI, www.ncbi.nlm.nih.gov\blast) for the pres-
ence of homologous sequences. Water processed together with the liver samples 
was always included in order to exclude contamination. As controls, ve gastric bi-
opsy samples from patients with Helicobacter pylori-related gastric complaints but 
without HCC, and the puried DNA from the H. pylori reference strain 26695 [19] 
were used. PCR on the beta-globulin gene (Table 1) was performed on all samples to 
exclude false-negative PCR due to inhibition. 
Table I
Oligonucleotide primers used to amplify the 16s rRNA gene and beta-globulin
Primer Primer sequence (5’-3’) Amplicon size Cycle
16sEubacF CTTTACGCCCATTTAATCCG 500 bp 95 °C(30’’), 60 °C(30”)*, 72 °C(1’), 20 cycles
16sEubacR AGAGTTTGATCCTGGTTCAG 95 °C(30’’), 50 °C(30”), 72 °C(1’), 20 cycles
HelicospeciesF aacgatgaagcttctagcttgctag 400 bp 95 °C(30’’), 50 °C(30”), 72 °C(1’), 40 cycles
HelicospeciesR gtgcttattcgttagataccgtcat
Beta-GlobulinF ACACAACTGTGTTCACTAGC 329 bp 95 °C(30’’), 50 °C(30”), 72 °C(1’), 40 cycles
Beta-GlobulinR326
Cag A-F
Cag A-R
Cag E-F
Cag E-R
CATCAGGAGTGGACAGATCC
GCCACTACTACCACCGACAT
CGTTGTGAGCCTGTGAGTTG
TGTTGGTTTCCCTGAAACT
AGCTTGGCTCTAATAATCCT
436 BP
756 BP
95 °C(30’’), 52 °C(30”), 72 °C(1’), 40 cycles
95 °C(30’’), 52 °C(30”), 72 °C(1’), 40 cycles
All PCR programs end with a 10 min extension step at 72°C 
* After every cycli the annealing temperature was decreased with 0.5 °C. 
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RESULTS 
Nested PCR showed that nine (45%) of the 20 HCC patient liver samples were posi-
tive, whereas only three (9.6%) of the 31 samples from the control group were posi-
tive. This di erence was highly signicant (Pearson chi-squared test, P < 0.004). The 
sequences obtained from the positive PCR samples gave identical sea quences; the 
sequence obtained was related most closely to that of H. pylori but always di ered 
at two base pair positions from the sequence of the H. pylori a reference strain 
(Table 2). We were also able to obtain a gastric biopsy sample from nine of the 20 
HCC patients, of which three (33%) samples tested positive for H. pylori in routine 
diagnostic culture procedures. This was in agreement with the three (33%) of nine 
gastric samples that tested positive in nested PCR. One patient was infected with a 
cag-positive strain and two patients were infected with a cag-negative strain. None 
of the nine HCC patients who underwent gastroscopy had complaints of peptic ulcer 
disease or gastroscopic view of peptic ulcer disease. Sequence analysis re-I vealed 
that the same two specic base pair di erences were also present in the 16S rDNA 
fragments from these gastric Helicobacter (Table 2). The Helicobacter status of the 
gastric samples correlated with the liver samples, i.e. all patients with positive gas-
tric samples also had positive liver samples while all patients with negative gastric 
samples also had negative liver samples. All 51 samples were positive in the beta-
globulin PCR, indicating that there were no false-negative PCRs due to inhibition 
of the samples. The ve control gastric biopsy samples (i.e. from patients with H. 
pylori-related gastric complaints and without HCC) were all positive for H. pylori in 
routine diagnostic culture. These ve gastric samples all tested positive in nested 
PCR. Sequence analysis from these samples gave identical sequences of the H. pylori 
reference strain (Table 2). 
Table II
16S rDNA sequence di erences of the detected Helicobacter spp. compared to the reference strain
Reference 92# 130#
Helicobacter pylori reference strain 26695 [19] A C
Liver samples HCC Present series G T
Liver samples colorectal metastases Present series G T
Ponzetto et al. [12] G T
Avenaud et al. [11] G T
Cultured Helicobacter from liver [14] G T
Gastric samples from control group Present series A C
Gastric samples from HCC patients Present series G T
# numbering according to 16S rrnA of H. pylori strain 26695 [19] 
G:Guanine, T:Thymine, A:Adenine, C:Cytosine
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DISCUSSION 
Although solid experimental evidence for a single causative agent of HCC is lack-
ing, there is a clear association of HCC with infections with hepatitis B virus (HBV) 
and hepatitis C virus (HCV), alcoholic liver disease, haemochromatosis, tyrosinaemia, 
and long-term use of oral contraceptives and anabolic steroids. This epidemiologi-
cal evidence has led to the hypothesis that cirrhosis resulting from any cause is the 
seedbed for HCC [20]. However, in a signicant proportion of patients with HCC in 
non-cirrhotic liver, no risk factor can be identied. 
In 1994 it was demonstrated that infection with Helicobacter hepaticus resulted in 
hepatitis and hepatic tumour induction in mice [5,6]. In 1997 a signicantly higher 
prevalence of immunoglobulin G (IgG) antibody against H. pylori in patients with 
liver cirrhosis than in controls (P < 0.0005) was reported [15]. Subsequent studies 
report an increased prevalence of Helicobacter DNA in the liver of patients with HCC, 
further supporting the notion that Helicobacter plays a role in the occurrence of HCC 
in humans [11–16]. As these studies are based mostly on the analysis of biopsy ma-
terials from cirrhotic livers, it is unclear whether the presence of Helicobacter species 
is the cause or merely the result of the cirrhosis. To address this issue, the presence 
of Helicobacter DNA in liver samples of patients with HCC in non-cirrhotic livers was 
examined. Matched controls were obtained from a group with virtual absence of 
any liver abnormalities, except for the presence of a tumour in a distinct location. 
The observed higher incidence of Helicobacter DNA in the HCC group supports the 
hypothesis of Helicobacter being a risk factor rather than an innocent bystander for 
HCC. 
In our study, two HCC patients were HCV-positive. Of these two patients, one was 
positive for Helicobacter DNA. The higher frequency of Helicobacter species in the 
liver of patients with HCC than in the liver of patients with colorectal metastasis is 
therefore unlikely to be the result of HCV infection or any other known risk factor. 
Recently, Coppola and colleagues [17] reported that they were unable to detect Heli-
cobacter DNA in the liver of 28 patients. From this they concluded that Helicobacter 
species are not associated with specic hepatobiliary disease and that the increased 
prevalence might have been due to the tumour process, which favours cholestasis, 
and not to a specic role of Helicobacter in the carcinogenic process. In our study 
group, all patients in the control group (colorectal liver metastases) had a liver tumour. 
Despite this, there was a signicantly higher frequency of Helicobacter species DNA in 
the non-cirrhotic liver of patients with HCC. The discrepancy between the data reported 
by Coppola and colleagues [17] and in our study may be explained by the less sensitive 
(non-nested) PCR approach used by them. If so, this indicates that only small amounts 
of bacterial DNA are present in the liver. This then poses the question: is there a true 
colonization of the liver or does it represent bacterial DNA from phagocytosed gastric 
Helicobacter that enter the liver via the macrophages of the portal blood ux? 
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The gastric samples we have obtained in patients with HCC correlated with the liver 
samples of these patients. Patients with positive gastric samples (with the same two 
mutations specic for the Helicobacter-specic PCR fragments found in the liver) also 
had positive liver samples, while patients with negative gastric samples had negative 
liver samples. Gastric Helicobacter may survive intestinal and bile acids and descend into 
the liver through the duodenum and common bile duct. The DNA sequences obtained 
from the liver and stomach specimens in our study were related most closely to that of 
H. pylori but always di ered at two base pair positions from the sequence of the H. pylori 
reference strain (Table 2). Interestingly, our sequence data are identical to the sequences 
of liver Helicobacter found in the studies by Avenaud and colleagues [11] and Ponzetto 
and colleagues [12] (Table 2). It is possible that a specic subspecies of Helicobacter, 
marked by the two typical mutations of the 16S rDNA, produces a specic factor that 
leads to the occurrence of HCC and thus may represent another extraintestinal manifes-
tation of H. pylori infection [21,22]. 
To answer the question whether there is a true colonization of the liver or only detectable 
bacterial DNA, culture is the ultimate test, as it proves the viability of the Helicobacter 
species in the liver samples. The inability to culture Helicobacter from the liver biopsy of 
HCC patients [11,13] suggests that the bacterial load in the liver of HCC patients is so low 
that it is insufcient for positive culturing. Alternatively, the positive hepatic PCR signals 
might represent Helicobacter DNA rather then true colonization of the liver. However, 
recently the rst successful culture of a Helicobacter species from a cirrhotic liver from a 
patient with Wilson’s disease has been reported [14]. This Helicobacter species presented 
the same two sequence di erences in the 16S rDNA as found in our study and others 
(Table 2). This result strongly supports the hypothesis of colonization. The fact that all 
patients in our series had received antibiotics before partial liver resection might be an-
other explanation for the inability to culture Helicobacter species. 
In conclusion, Helicobacter DNA was observed at a higher frequency in the non-cir-
rhotic liver of patients with HCC (P < 0.004). The same H. pylori subspecies was present 
in the stomach of patients with HCC. This suggests that gastric Helicobacter colonization 
may play a role in the induction of HCC, either directly via colonization of the liver or 
indirectly, e.g. via secretion of specic toxins by Helicobacter residing in the stomach. 
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Chapter IV
Fluorine-18 FDG imaging in hepatocellular 
carcinoma using positron coincidence 
detection and single photon emission 
computed tomography. 
Liver 2002;22:51-56
Local Ablation
RFA PEI TACE StRTx
Combination of modalities
RFA: Radio Frequency Ablation
PEI: Percutaneous Ethanol Injection
TACE: Trans Arterial Chemo Embolisation
StRTx: Stereotactic Radiotherapy
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ABSTRACT
Aim: We prospectively evaluated whether  uorine-18 deoxyglucose (18FDG) positron 
coincidence detection (PCD) or 18FDG single-photon emission computed tomogra-
phy (SPECT) provide additional bene ts to our conventional preoperative evaluation 
of lesion detection in patients suspected for hepatocellular carcinoma (HCC).
Methods: Thirteen consecutive patients with a suspected HCC underwent conven-
tional preoperative evaluation with ultrasonography (US), triple-phase helical com-
puted tomography (CT), superparamagnetic iron oxides (SPIO) enhanced magnetic 
resonance imaging (MRI) and serum α-fetoprotein (AFP) level. All thirteen patients 
had an 18FDG-PCD and SPECT. These results were evaluated to assess the value of 
18FDG-PCD and SPECT in addition to US, SPIO enhanced MRI and triple-phase helical 
CT.
Results: Ten of the thirteen (77%) patients had at least one histological con rmed 
HCC without extrahepatic abdominal spread. The tumours ranged in size from 1 to 
8 cm and the serum AFP ranged from 3 to 30000 ug/L. Of these ten patients, two 
patients had an increased tumour 18F-FDG uptake, (sensitivity of 20%); one patient 
with an AFP of 5ug/L and a tumour size of maximum 4.5 cm and one patient with an 
AFP of 249 ug/L and a tumour size of maximum 2 cm. In three patients with a benign 
liver mass, 18FDG imaging with either PCD or SPECT was negative. There was no false 
positive  nding.
Conclusions: We found a poor sensitivity of 18FDG-PCD and 18FDG-SPECT for the de-
tection of HCC. There were no clear relations between AFP or tumour size and FDG 
uptake. Therefore, we conclude that FDG imaging with PCD or SPECT has no value in 
the preoperative work-up for HCC in patients with cirrhosis.
18 FDG in HCC 37
Verhoef et al.
FDG Positron Coincidence Detection (PCD) and
single photon emission computed tomography
(SPECT) provide additional benefit to our conven-
tional preoperative evaluation of patients with a
suspected HCC.
Patients and methods
We prospectively studied 13 consecutive patients
with a suspected HCC (11 men and 2 women). The
patients ranged in age from 39 to 65years (mean
and median 54years). All 13 patients were seen in
the outpatient clinic and had a conventional pre-
operative evaluation with ultrasonography (US),
triple-phase helical CT, SPIO enhanced MRI and
serum a-fetoprotein (AFP). Finally, in all patients
we had histology of the suspected lesion to confirm
the diagnosis. Twelve patients had liver cirrhosis.
The etiology of the underlying liver disease was
chronic hepatitis B virus (HBV) infection in six pa-
tients, chronic hepatitis C virus (HCV) infection in
five patients and aª1antitrypsin deficiency in one
patient (Table1).
After the patients had their conventional pre-
operative evaluation, all patients had an FDG-
PCD directly followed by SPECT. A single ob-
server (RV) reviewed the images, being unaware of
the results of the conventional investigations. The
reading was based on visual interpretation. After
the reading of the FDG-PCD and SPECT studies,
the results were compared with the conventional
preoperative evaluation and the histology of the
resected specimen or ultrasound-guided needle
liver biopsy. FDG, CT, MRI and US were scored
as follows: Grade 0 – no lesion, Grade 1 – equivo-
cal, Grade 2 – lesion, but uncertain diagnosis,
Grade 3 – HCC (almost) certain. The whole work-
up was done within 3months. Surgery, if necessary
Table1. Summary of the results
Pt. Hist./size Cirrhosis AFP FDG-PCD SPECT CT MRI US Therapy
1 HCC/2cm HCV 47 2 – 3 3 3 OLT
2 HCC/4.5cm HCV 5 3 3 3 3 1 Laser/ethanol
3 HCC/2.5cm AT def 10 1 0 0 3 0 OLT
4 HCC/8cm HBV 3 1 1 2 3 2 Right hemihepatectomy
5 HCC/1cm HBV 400 0 0 0 3 0 Excision biopsy channel
6 Hemangioma/3cm HCV 18 1 1 2 2 2 Observation
7 HCC/1.8cm HBV 2060 0 0 3 3 2 OLT
8 HCC/5cm HCV 69 1 1 3 2 2 Ethanol
9 Focal lesion/1cm HBV 16 1 1 0 1 1 Observation
10 HCC/2cm HBV 30000 1 1 2 2 2 Segment resection
11 Hemangioma/5cm HCV 41 1 1 2 2 2 Observation
12 HCC/2cm HBV 249 3 3 3 3 3 Palliative
13 HCC/8cm No cirr. 609 0 0 3 3 3 Palliative
OLT: Orthotopic liver transplantation, AT def: aª1 antitrypsin deficiency, HBV: hepatitis B virus, HCV: hepatitis C virus, No cirr: no cirrhosis, cm: centimeter, AFP:
serum a-fetoprotein. Imaging modalities scored as follows: Grade 0 – no lesion, Grade 1 – equivocal, Grade 2 – lesion, but uncertain diagnosis, Grade 3 – HCC
(almost) certain.
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and possible, was done within 4weeks for partial
liver resection and not more than 4months for
orthotopic liver transplantation (OLT).
18FDG PCD
The patients fasted overnight, for at least 12h. Co-
incidence imaging of the abdominal region only
was started 45min after i.v. injection of 185 MBq
(5mCi) F-FDG (Prism 2000 XP, Marconi, Cleve-
land, OH, USA). Before injection, a normal blood
glucose level was found in all patients. The acqui-
sition was performed using axial filters, in list
mode, with 60 steps over 360æ, nominal 30s per
step. Decay correction was employed, yielding
longer acquisition times for later steps; the total
acquisition time was 37min The raw acquisition
data were rebinned to 180 views, in 128¿128 mat-
rices, using only photo peak pairs. An initial iter-
ative reconstruction with an ordered subset esti-
mation maximation (OSEM) algorithm defined the
outer contours of the patient. These were used for
calculating the attenuation correction during the
final reconstruction, assuming homogeneous at-
tenuation by tissues inside the body. The final re-
construction was done by a maximum likelihood
estimation maximation algorithm (ML-EM) with
20 iterations, followed by filtering using a 3D-Wi-
ener filter and reorientation in transverse, coronal
and sagittal slices.
Dual-isotope SPECT
After completion of PCD imaging, the patients re-
ceived an injection of 80 MBq 99mTc-colloid. Ten
minutes later, dual-isotope SPECT was performed
with a triple-head camera fitted with ultra-high en-
ergy collimators (Prism 3000 XP, Marconi, Cleve-
INTRODUCTION
There is a growing interest in the development of in vivo methods of assessing 
functi nal parameters and metabolism in normal and diseased tissues (1,2). Posit on 
emission tomography with  uorine-18-deoxyglucose (18FDG-PET) is one example of 
such a techniqu . PET is currently not widely available, mainly because of its high 
costs. Recently, alternative techniques for 8FDG imaging have become available: 
SPECT using special high-energy collimators (3) a d coincidence detection using 
adapted multi-head gamma cameras (4). These techniques are less costly than PET. 
However, their sensitivity is lower. To which extent gamma camera coincidence im-
ging c  be used in clinical circumstances is being investigated for ma y oncologi-
cal and cardiological applications (5).
Hepatoc llular carcinoma (HCC) is one of the most c mm  c ncers in men. Its 
world-wide annual incidence has been estimated to be 250.000 to 1 million (6) and 
more than 1 million deat  per yea  world-wide.(7) A number of imagi g modalities 
are used to detect HCC, but radionuclide scanning techniques currently play only a 
minor role in the diagno is of HCC (8,9,10,11).
In a pilot study we prospectively evaluated if 18FDG Positron Coincidence Detection 
(PCD) and single photon emission computed tomography (SPECT) provide addition-
al bene t to our conventional preoperative evaluation of patients with a suspected 
HCC. 
PATIENTS AND METHODS
We pro pectively studied thirteen consecutiv  pat ents with a suspected HCC (11 
men and 2 women). The patients ranged in age from 39 to 65 years (mean and 
median 54 year). All t irteen pati nt  were seen in the outpatient clinic and had a 
Table 1. Su mary of the results
OLT: Orthot pic liver transplantation, AT def: α
_1 antitrypsin de ciency, HBV: hepatitis B virus, HCV: hepatitis C virus, No cirr:  cirrhosis, 
cm: centimeter, AFP: serum α-fetoprotein. Imaging modalities scored as follows: Grade 0 – no lesion, Grade 1 – equivocal, Grade 2 – lesion, 
but uncertain diagnosis, Grade 3 – HCC (almost) certain.
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conventional preoperative evaluation with ultrasonography (US), triple phase heli-
cal CT, SPIO enhanced MRI and serum α-fetoprotein (AFP). Finally, in all patients we 
had histology of the suspected lesion to con rm the diagnosis. Twelve patients had 
liver cirrhosis. The aetiology of the underlying liver disease was chronic hepatitis B 
virus (HBV) infection in six patients, chronic hepatitis C virus (HCV) infection in  ve 
patients and α-1 antitrypsine de ciency in one patient (Table 1). 
After the patients had their conventional preoperative evaluation, all patients had an 
18FDG-PCD directly followed by SPECT. A single observer (RV) reviewed the images, 
being unaware of the results of the conventional investigations. The reading was 
based on visual interpretation. After the reading of the 18FDG-PCD and SPECT stud-
ies, the results were compared with the conventional preoperative evaluation and 
the histology of the resected specimen or ultrasound-guided needle liver biopsy. 
FDG, CT, MRI and US were scored as follows: Grade 0 – no lesion, Grade 1 – equivocal, 
Grade 2 – lesion, but uncertain diagnosis, Grade 3 – HCC (almost) certain. The whole 
work-up was done within 3 months. Surgery, if necessary and possible, was done 
within 4 weeks for partial liver resection and not more than 4 months for orthotopic 
liver transplantation (OLT).
18FDG PCD
The patients fasted overnight, for at least 12 hours. Coincidence imaging of the ab-
dominal region only was started 45 min. after i.v. injection of 185 MBq (5mCi) 18F-FDG 
(Prism 2000 XP, Marconi, Cleveland, OH). Before injection a normal blood glucose 
level was found in all patients. The acquisition was performed using axial  lters, in 
list mode, with 60 steps over 360°, nominal 30 sec. per step. Decay correction was 
employed, yielding longer acquisition times for later steps; the total acquisition time 
was 37 min. The raw acquisition data were rebinned to 180 views, in 128128 matri-
ces, using only photo peak pairs. An initial iterative reconstruction with an ordered 
subset estimation maximation (OSEM) algorithm de ned the outer contours of the 
patient. These were used for calculating the attenuation correction during the  nal 
reconstruction, assuming homogeneous attenuation by tissues inside the body. The 
 nal reconstruction was done by a maximum likelihood estimation maximation al-
gorithm (ML-EM) with 20 iterations, followed by  ltering using a 3D-Wiener  lter and 
reorientation in transverse, coronal and sagittal slices.
Table 2. Publications which formulated the value of static 18FDG imaging in patients with HCC concerning detection
Verhoef et al.
common tumors world-wide, with an incidence of
1–5 cases per 100000 citizens per year in Western
Europe and North America (8). In Western Eur-
ope, liver cirrhosis is present in up to 90% of pa-
tients with HCC (12,13). Cirrhosis is a process of
liver fibrosis that is characterized by architectural
distortion and the development of nodules ranging
from regenerative nodules to hepatocellular carci-
noma (14). That makes it difficult for ultrasono-
graphy and a variety of other imaging procedures
as CT and MRI, to detect HCC in a cirrhotic liver
(15).
Warburg et al. (16) and many others (17–19)
demonstrated that aerobic glycolysis was increased
in malignant tumors. Experimental studies demon-
strate that glycogenesis decreases and glycolysis in-
creases during carcinogenesis in the liver (20,21).
FDG, an analogue of glucose, enters the cell and
is phosphorylated by hexokinase. Because of the
relatively low level of glucose-6-phosphatase in
most malignant cells, FDG-6-phosphate is trapped
in the tumor tissue and leading to intracellular ac-
cumulation. The liver, and also muscle, intestine
and kidneys, are known to have increased activity
of glucose-6-phosphatase (22,23). This may result
in increased accumulations of FDG in HCC com-
pared to normal liver tissue, as confirmed by
others (2,24–37) PET using 18FDG is the most sen-
sitive technique for imaging and quantification of
glucose metabolism. Established and reimbursed
oncological applications for FDG-PET are well
known (38). Due to the high costs of PET it is
not widely available, and alternative less expensive
techniques for FDG imaging were developed. An
alternative to dedicated PET is coincidence im-
aging using an adapted hybrid gamma camera,
where the opposite camera heads and special elec-
tronics are used to detect coincident photon pairs.
The price of such cameras is typically less than one
million dollar, while a dedicated PET camera may
cost more than two million dollars. Gamma cam-
era based coincidence detection has the same spa-
tial resolution as PET, but the sensitivity is lower
(4). Therefore, small lesions �1.5cm in diameter
cannot be reliably detected with these systems,
while lesions smaller than 1cm may be detected by
ble2. Publications whic formulated th value of static 18FDG imaging in patients with HCC concerning detectio
Ref Author and year of publication No. of patients Sensitivity Aspect of study
30 Delbeke et al. 1998 23 70% Prospective
33 Rose et al. 1998 23 57% Retrospective
32 Trojan et al. 1999 14 50% Prospective
31 Khan et al. 2000 20 55% Retrospective
Present series 10 20% Prospective
REF: reference.
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PET. Nevertheless, due to the lower costs hybrid
coincidence gamma cameras are becoming wide-
spread (5).
A relatively simple approach is SPECT using a
normal gamma camera fitted with special high-en-
ergy collimators (3). An unique advantage of
SPECT is the ability to image in separate energy
windows simultaneously, thus enabling the dual-
isotope imaging of FDG and 99mTc-colloid. A cold
spot on the 99mTc-colloid image should coincide
with a hot spot on the corresponding FDG image,
thus theoretically enhancing the diagnostic accu-
racy.
FDG-PCD imaging is an established oncolog-
ical application in head and neck tumors (5) and
SPECT is of additional value in the detection of
cervical lymph node metastases of nasopharyngeal
carcinomas (39), mediastinal lymph node meta-
stases of non-small cell lung cancer (40) and eso-
phageal carcinoma (41). We evaluated the ad-
ditional benefit of FDG-PCD and dual-isotope
SPECT imaging in patients suspected for HCC. To
our knowledge, this has never been done before.
Therefor we compare our results with studies using
dedicated PET. We have used static imaging. Tori-
zuka et al. (24) and Okazumi et al. (25) proved the
advantage of dynamic imaging in characterization
of tumor and assessment of effect of treatment.
However, this dynamic imaging is not feasible with
our PCD system in a routine clinical setting. In an
other study of Torizuka et al. (29), all patients with
a HCC have had intervention therapy and after
this 19 of the 30 patients had an increased FDG
uptake, sensitivity of 63%, using static FDG im-
aging.
Only one prospective study was performed, Tro-
jan et al. (32), to evaluate the value of static FDG
imaging in patients with a histologically confirmed
HCC for detection of the lesion. Trojan et al. used
static FDG-PET in 14 consecutive patients with
HCC. The results were compared with US, CT, his-
tological grading, p53 protein expression and AFP.
Fifty percent of the patients had an increased tu-
mor FDG uptake. In three patients extrahepatic
spread was demonstrated by FDG PET. This study
also demonstrated that FDG imaging was highly
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DUAL-ISOTOPE SPECT
After completion of PCD imaging, the patients received an injection of 80 MBq 99mTc-
colloid. Ten min. later dual-isotope SPECT was performed with a triple-head camera 
 tted with ultra-high energy collimators (Prism 3000 XP, Marconi, Cleveland, OH). 
Acquisition was done in separate 511 keV (18F) and 140 keV (99m Tc) channels in 120 
views over 360 degrees using 64x64 matrices. The iterative reconstruction was done 
by an ML-EM algorithm with 20 iterations, followed by attenuation correction and 
 ltering with a low-pass  lter.
Reorientation in transverse, coronal and sagittal slices was done simultaneously for 
the 18F-FDG images and corresponding 99mTc-colloid images to enable exact com-
parison.
RESULTS
The results are summarised in table 1. Of the thirteen patients enrolled in this study, 
ten patients had a HCC, two patients had a hemangioma and one patient had a 
Fluorine-18 FDG imaging in hepatocellular carcinoma
land, OH, USA). Acquisition was done in separate
511 keV (F) and 140 keV (99m Tc) channels in 120
views over 360 degrees using 64¿64 matrices. The
iterative reconstruction was done by an ML-EM
algorithm with 20 iterations, followed by attenu-
ation correction and filtering with a low-pass filter.
Reorientation in transverse, coronal and sagittal
slices was done simultaneously for the 18F-FDG
images and corresponding 99mTc-colloid images to
nable ex ct compariso .
Results
The results are summarized in Table1. Of the 13
patients enrolled in this study, 10 patients had a
HCC, two patients had a hemangioma and one pa-
tient had a regenerating nodule. In two of the 10
patients with HCC, FDG with either PCD or
SPECT was positive (20%); patient 2 with an AFP
of 5mg/l and a tumor size of maximum 4.5cm (see
Fig.1 and 2) and patient 13 with an AFP of 249
mg/l and a tumor size of maximum 2cm. In three
patients without a HCC, FDG with either PCD or
Fig.1. FDG coincidence ECT image (transverse) of a patient with HCC (Left), with corresponding contrast-enhanced CT image
(Right). The tumor is indicated by arrows.
Fig.2. FDG and 99mTc-colloid dual-isotope SPECT images of the same patient as depicted in Fig.1. The simultaneous acquisition
and processing allows exact comparison. Note the cold defect in the liver with 99mTc-colloid corresponding to the hot tumor with
18FDG. The SPECT image has inferior sharpness and contrast compared with the coincidence ECT image (Fig.1).
53
SPECT was negative. This results in a sensitivity
of 20%. Histological examination in all 10 pa-
tients, six surgical resection specimens and four
core biopsies, confirmed the diagnosis of HCC.
The tumors ranged in size from 1 to 8cm with a
mean diameter of 3.6cm (median 2cm). For the
resected specimens, grading of HCC was per-
formed; five were moderately differentiated and
one was well differentiated. The serum AFP levels
of the pati nts with HCC ranged from 3 to 30000
mg/l, with a mean serum value of 3345mg/l (median
of 159mg/l). Of the three patients without HCC,
two patients had hemangiomas, histologically con-
firmed after ultrasound-guided needle liver biopsy.
In all three patients without HCC, we performed
an ultrasound and SPIO-enhanced MRI of the
liver after 1year of follow-up. Again, no tumor was
detected, thus confirming the benign diagnosis.
Discussion
Hepatocellular carcinoma is the most common pri-
mary hepatic maligna cy a d one of the most
Fig. 1. FDG coincidence ECT image (transverse) of a patient with HCC (Left), with corresponding contrast-enhanced CT image (Right). The tumor 
is indicated by arrows.
Fluorine-18 FDG imaging in hepatocellular carcinoma
land, OH, USA). Acquisition was done in separate
511 keV (F) and 140 keV (99m Tc) channe s in 120
views over 360 degrees using 64¿64 matrices. The
iterative reconstruction was done by an ML-EM
algorithm with 20 iterations, followed by attenu-
ation correction and filtering with a low-pass filter.
Reorientation in transverse, coronal and sagittal
slices was done simultaneously for the 18F-FDG
images and corresponding 99mTc-colloid images to
enable exact c mparison.
Results
The results are sum arized in Table1. Of the 13
patients enrolled in this study, 10 patients had a
HC , two patients had a hemangioma and one pa-
tient had a regenerating nodule. In two of the 10
patients with HC , FDG with either PCD or
SPECT was positive (20%); patient 2 with an AFP
of 5mg/l and a tumor size of maximum 4.5cm (see
Fig.1 and 2) and patient 13 with an AFP of 249
mg/l and a tumor size of maximum 2cm. In three
patients without a HC , FDG with either PCD or
Fig.1. FDG coincidence ECT image (transverse) of a patient with HCC (Left), with corresponding contrast-enhanced CT image
(Right). The tumor is indicated by arrows.
Fig.2. FDG and 99mTc-colloid dual-isotope SPECT images of the same patient as depicted in Fig.1. The simultaneous acquisition
and processing allows exact comparison. Note the cold defect in the liver with 99mTc-colloid corresponding to the hot tumor with
18FDG. The SPECT image has inferior sharpness and contrast compared with the coincidence ECT image (Fig.1).
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SPECT was negative. This results in a sensitivity
of 20%. Histological exami ation in all 10 pa-
tients, six surgical resection specimens and four
core biopsies, confirmed the diagnosis of HC .
The tumors ranged in size from 1 to 8cm with a
mean diameter of 3.6cm (median 2cm). For the
resected specimens, grading of HC was per-
formed; five were moderately differentiated and
one was well differentiated. The serum AFP levels
of the patients with HC ranged from 3 t 30000
g/l, with a mean serum value of 3345mg/l (median
of 159mg/l). Of the three patients without HC ,
two patients had hemangiomas, histologically con-
firmed after ultrasound-guided needle liver biopsy.
In all three patients without HC , we performed
an ultrasound and SPIO-enhanced MRI of the
liver after 1year of follow-up. Again, no tumor was
detected, thus confirming the benign diagnosis.
Discussion
Hepatocellular carcinoma is the most com on pri-
mary hepatic malignancy and one of the most
Fig. 2. FDG and 99mTc-colloid dual-isotope SPECT images of the same patient as depicted in Fig. 1. The simultaneous acquisition and processing 
allows exact comparison. Note the cold defect in the liver with 99mTc-colloid corresponding to the hot tumor with 18FDG. The SPECT image has 
inferior sharpness and contrast compared with the coincidence ECT image (Fig. 1).
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regenerating nodule. In two of the ten patients with HCC, FDG with either PCD or 
SPECT was positive (20%); Patient 2 with an AFP of 5ug/l and a tumour size of maxi-
mum 4.5 cm (see Figure 1 and 2) and Patient 13 with an AFP of 249 ug/l and a tumour 
size of maximum 2 cm. In three patients without a HCC , FDG with either PCD or 
SPECT was negative. This results in a sensitivity of 20%. Histological examination in 
all ten patients, six surgical resection specimen and four core biopsies, con rmed the 
diagnosis of HCC. The tumours ranged in size from 1 to 8 cm with a mean diameter 
of 3.6 cm (median 2 cm). Of the resected specimen, grading of HCC was performed; 
 ve were moderately di erentiated and one was well di erentiated. The serum AFP 
levels of the patients with a HCC ranged from 3 to 30.000 ug/L. with a mean se-
rum value of 3345 ug/l (median of 159 ug/L.). Of the three patients without a HCC, 
two patients had hemangiomas, histologically con rmed after ultrasound-guided 
needle liver biopsy. In all three patients without a HCC, we performed an ultrasound 
and SPIO enhanced MRI of the liver after one year follow-up. Again no tumour was 
detected, thus con rming the benign diagnosis.
DISCUSSION
Hepatocellular carcinoma is the most common primary hepatic malignancy and 
one of the most common tumours world-wide with an incidence of 1 to 5 cases 
per 100.000 citizens per year in Western Europe and North America (8). In Western 
Europe, liver cirrhosis is present up to 90% of the patients with HCC (12,13). Cirrhosis 
is a process of liver  brosis that is characterised by architectural distortion and the 
development of nodules ranging from regenerative nodules to hepatocellular carci-
noma (14). That makes it di  cult for ultrasonography and a variety of other imaging 
procedures as CT and MRI, to detect HCC in a cirrhotic liver (15). 
Warburg and Conti (16) and many others (17,18,19) demonstrated that aerobic gly-
colysis was increased in malignant tumours. Experimental studies demonstrate that 
glycogenesis decreases and glycolysis increases during carcinogenesis in the liver.
(20,21) FDG, an analogue of glucose, enters the cell and is phosphorylated by hexoki-
nase. Because of the relatively low level of glucose-6-phosphatase in most malignant 
cells, FDG-6-phosphate is trapped in the tumour tissue and leading to intracellular 
accumulation. The liver, and also muscle, intestine and kidneys, are known to have 
increased activity of glucose-6-phoshatase.(22,23) This may result in increased ac-
cumulations of FDG in HCC compared to normal liver tissue, as con rmed by others.
(2,24-37) PET using 18FDG is the most sensitive technique for imaging and quanti ca-
tion of glucose metabolism. Established and reimbursed oncological applications 
for 18FDG-PET are well known.(38) Due to the high costs of PET it is not widely avail-
able, and alternative less expensive techniques for 18FDG imaging were developed. 
An alternative to dedicated PET is coincidence imaging using an adapted hybrid 
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gamma camera, where the opposite camera heads and special electronics are used 
to detect coincident photon pairs. The price of such cameras is typically less than 
one million dollar, while a dedicated PET camera may cost more than two million 
dollars. Gamma camera based coincidence detection has the same spatial resolution 
as PET, but the sensitivity is lower.(4) Therefore, small lesions < 1.5cm in diameter 
cannot be reliably detected with these systems, while lesions smaller than 1cm may 
be detected by PET. Nevertheless, due to the lower costs hybrid coincidence gamma 
cameras are becoming widespread.(5)
A relatively simple approach is SPECT using a normal gamma camera  tted with spe-
cial high-energy collimators.(3) An unique advantage of SPECT is the ability to image 
in separate energy windows simultaneously, thus enabling the dual-isotope imag-
ing of 18FDG and 99mTc-colloid. A cold spot on the 99mTc-colloid image should coincide 
with a hot spot on the corresponding 18FDG image, thus theoretically enhancing the 
diagnostic accuracy. 
18FDG-PCD imaging is an established oncological application in head and neck tu-
mours (5) and SPECT is of additional value in the detection of cervical lymph node 
metastases of nasopharyngeal carcinomas (39), mediastinal lymph node metastases 
of non-small cell lung cancer (40) and oesophageal carcinoma (41). We evaluated 
the additional bene t of 18FDG-PCD and dual-isotope SPECT imaging in patients 
suspected for HCC. To our knowledge, this has never been done before. Therefor we 
compare our results with studies using dedicated PET. We have used static imaging. 
Torizuka et al. (24) and Okazumi et al (25) proved the advantage of dynamic imaging 
in characterisation of tumour and assessment of e ect of treatment. However, this 
dynamic imaging is not feasible with our PCD system in a routine clinical setting. In 
an other study of Torizuka et al. (29), all patients with a HCC have had intervention 
therapy and after this 19 of the 30 patients had an increased FDG uptake, sensitivity 
of 63%, using static FDG imaging.
Only one prospective study is performed, Trojan et al (32), to evaluate the value of 
static FDG imaging in patients with a histologically con rmed HCC for detection of 
the lesion. Trojan et al used static 18FDG-PET in 14 consecutive patients with HCC. 
The results were compared with US, CT, histological grading, p53 protein expres-
sion and AFP. Fifty percent of the patients had an increased tumour 18FDG uptake. 
In three patients extrahepatic spread was demonstrated by 18FDG PET. This study 
also demonstrated that 18FDG imaging was high sensitive for moderately or poorly 
di erentiated HCC (7of 8) and tumours > 5cm (5 of 5). Also patients with a markedly 
elevated AFP levels had a higher sensitivity. These results di er clearly with ours. We 
had a sensitivity of 20% (versus 50%) and there was no clear relation between AFP, 
tumour size or histologic grading. We had two patients (pts.4 and 13) with a size 
of 8 cm HCC (one of them moderately di erentiated), but there was no increased 
tumour 18FDG uptake. Neither had one of the patients (pts.5,7,10,13) with a mark-
edly raised serum AFP (≥ 400 ug/l.). One of the di erences between both studies 
Ch
ap
te
r I
V
42
was that we had HCC positive and negative patients. Another explanation might be 
the di erence in imaging technique, the use of PCD and SPECT in our study versus 
PET in other studies. It is known that coincidence detection with an adapted gamma 
camera has a lower sensitivity than PET. However, lesions that are larger than 1.5 cm 
in diameter should be visible with PCD, provided that they have signi cantly higher 
18FDG accumulation than the surrounding tissue. Therefore, another explanation of 
the low sensitivity in our study could be the high percentage of inhomogeneous 
background activity in cirrhotic livers, in our group 90% (9/10) of the patients with a 
HCC had a cirrhotic liver. When we compared the sensitivity with retrospective study 
results, we found two retrospective studies who also used static 18FDG-PET in detect-
ing HCC where the sensitivity was 57% (Rose et al.(33)) and 55%.(Khan et al.31)). In 
the study of Rose et al, 18FDG-PET was used selectively to determine the presence 
of extrahepatic disease in patients being considered for surgery, transplantation or 
hepatic regional therapy. One prospective study from Delbeke et al. (30) showed the 
value of PET scan using static imaging on benign versus malignant hepatic lesions. 
They concluded that PET technique using FDG imaging was useful to di erentiate 
malignant from benign lesions in the liver. In their study there were 23 patients with 
HCC, 16 patients had increased uptake values, a sensitivity of 70%. In this publication 
they described a sensitivity of 100% for livermetastases from adenocarcinoma and 
sarcoma primaries in 66 patients and cholangiocarcinomas in 8 patients. All benign 
hepatic lesions (n=23) had poor FDG uptake, except for 1 of 3 abscesses that had 
de nite uptake. All three patients with no malignancy in our study had a negative 
FDG imaging but there were eight false negative 18FDG-PCD scans. The results of the 
4 studies concerning static FDG imaging and HCC is summarised in table 2. Table 1 
shows us that MRI was the most sensitive imaging method to detect HCC or a benign 
lesion in our study. CT scanning missed two HCC (2.5cm and 1cm) and one regen-
erating nodule compared to the SPIO-enhanced MRI. This is in conformity with the 
literature where contrast-enhanced MR imaging is superior to CT for detecting and 
di erentiating focal lesions in a cirrhotic liver.(42,43,44,45) Promising is the use of 
contrast enhanced ultrasonography (46) but the data in the literature are too scarce 
to draw any de nite conclusions.
Conclusions
In this prospective study of 13 patients with or without a HCC, we evaluated if 18F-
FDG-PCD or SPECT provides an additional bene t in a preoperative evaluation. We 
found a poor sensitivity of FDG PCD and SPECT for the detection of HCC. There were 
no clear relations between AFP or tumour size and FDG uptake. We must conclude 
that FDG imaging with PCD has no value in the pre-operative work-up of patients 
suspected of hepatocellular carcinoma
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ABSTRACT
The clinical and morphological de nition of hepatocellular carcinoma (HCC), dyspla-
sia and adenoma su ers from a lack of biological understanding. This is especially 
important in the histomorphological diagnosis of nodular liver lesions in needle bi-
opsies. Therefore, we constructed a liver tissue micro-array (TMA) and evaluated 48 
HCC’s, 46 dysplasias, 8 adenomas, 20 cirrhotic specimens and 28 normal liver samples 
derived from 68 patients. Protein (over)expression of tumor suppressor genes p16, 
p53 and Rb1 was assessed by immunohistochemistry, the proliferative capacity was 
examined by immunostaining of Ki67. Further, DNA ploidy status (hyperdiploidy) 
was measured by  uorescent in situ hybridization (FISH) with a chromosome 1-spe-
ci c repetitive DNA probe. An abnormal chromosome 1 number, i.e. the percentage 
of hyperdiploid cells, was 11.0, 13.7, 16.1, 23.7 and 31.3 for normal liver samples, 
adenomas, cirrhosis, dysplasias and HCC’s, respectively. A signi cant di erence was 
found for HCC versus cirrhosis (P=0.024) or adenoma (P=0.033), a trend was seen 
for dysplasia versus cirrhosis (P=0.094). Immunohistochemical protein expression of 
p53 and Rb1, as well as Ki67 de ned proliferation, was clearly higher in HCC than in 
cirrhosis or dysplasia (all P<0.001). Proliferation was also higher in HCC than in ad-
enoma (P=0.025), whereas a trend was observed for Rb1 overexpression (P=0.063). 
These data suggest that in the liver cell dysplasia-carcinoma pathway changes in 
ploidy are followed by increased proliferation and cell biological perturbations 
involving p53 and Rb1. Adenomas can be distinguished from carcinomas, but not 
from dysplasias, based on ploidy and proliferation characteristics.
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INTRODUCTION
The global distribution of hepatocellular carcinoma (HCC) shows a high incidence 
in China, south-east Asia and Africa south of the Sahara, an intermediate incidence 
in southern Mediterranean countries, and a low incidence in north-western Europe, 
Australia and the USA (Bruix et al., 2004). Chronic (viral) liver disease ending in cir-
rhosis is an important contributing factor (Bruix et al., 2004; Feitelson et al., 2002). 
Over the past decade it became clear, that precursors of HCC can be found in the 
liver (Borzio et al., 1994; Mion et al., 1996; Riegler JL, 1996). Confusion is still existing 
about the exact de nition of these lesions. We will use the de nitions of the Working 
Party on Nodular Lesions in the Liver (1995). These aberrations can be found in non-
cirrhotic and cirrhotic livers, both with and without HCC. The diagnosis of nodular 
liver lesions is generally made by histopathology of needle biopsies. However, a 
correct classi cation of adenoma, liver cell dysplasia and (well di erentiated) HCC 
is often di  cult (Scheuer and Lefkowitch, 2000). Immunohistochemical methods 
might help in de ning parameters that aid in the histomorphological diagnosis of 
nodular liver lesions.
The genetics of liver cancer have been the subject of many studies (reviewed in: 
Feitelson et al., 2002; Van Dekken et al., 2003). However, little is known of genetic ab-
errations in preneoplastic liver lesions. Wong et al. (1999) used comparative genomic 
hybridization (CGH) to analyse 3 HBV-related “adenomatous hyperplasias” (cirrhotic/
dysplastic nodules), and detected gains of 1q and chromosome 20 in one. Wilkens 
et al. (2001) distinguished liver cell adenomas from HCC by CGH: all HCCs showed 
multiple alterations, whereas only 2 (out of 10) adenomas displayed few genomic 
changes. Likewise, no loss of heterozygosity (LOH) was detected in 6 adenomas 
(Ding et al., 1993). In a CGH study by Zondervan et al. (2000) dysplasias adjacent to 
HCC showed frequent losses on 4q, 16q and 17p, frequent gain was discriminated on 
17q. Polysomies of chromosomes 1, 7, 17 and 18 were found by in situ hybridization 
technology in large and small cell dysplasias (Terris et al., 1997). 
Likewise, there is ample data concerning genes involved in HCC, but the literature 
is sparse with respect to such investigations in liver cell dysplasia or cirrhosis. Loss 
of chromosome 17p, including the p53 gene locus, had already been described by 
classical karyotyping (Parada et al., 1998). Allelotyping investigations have revealed 
frequent LOH of 9p, 13q, and 17p implicating the involvement of p16, Rb1 and p53 
genes, respectively (Biden et al., 1997; Nagai et al., 1997; Okabe et al., 2000). Recur-
rent loss of these chromosomal regions on 9p, 13q and 17p was also discriminated 
by CGH (Marchio et al., 1997; Kusano et al., 1999; Zimonjic et al., 1999; Zondervan 
et al., 2000). A di use and strong immunolabeling with Ki67 of HCC was reported 
by Wu et al. (1999). In this study p53 protein overexpression was seen in approx. 
50% of carcinoma cells. In another report p53-positive HCC’s showed a signi cantly 
higher Ki67 score, although the p53 labeling index was relatively low (D’Errico et al., 
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1994). P53 staining patterns were found to be negative in liver cell dysplasia of large 
type, but positive in a small proportion of small cell dysplasia (Zhao et al., 1994). 
Cohen and DeRose (1994) discerned p53 positivity in half of the liver cancers, but in 
only one of thirty dysplasias in HBV patients. Mutant p53 protein expression was de-
scribed absent in adenoma, focal nodular hyperplasia and cirrhosis, but it increased 
in the successive pathological grades of HCC (Ojanguren et al., 1995). Likewise, Ki67 
was found to be low or absent in normal and cirrhotic tissues, but high in carcinomas 
(Grigioni et al., 1989). Immunohistochemistry data of p16 and Rb1 are essentially 
missing in the literature, although p16 alterations, including hypermethylation and 
deletion, were detected in 60% of HCC’s (Jin et al., 2000). Further, a signi cant cor-
relation between loss of Rb1 expression and Rb1 methylation was recently reported 
(Edamoto et al., 2003).
We created a liver tissue micro-array comprising a large series of nodular liver le-
sions. Cell biological markers, i.e. Ki67, p16, p53, Rb1 and ploidy were investigated 
by means of immunohistochemistry and in situ hybridization in order to address the 
following questions: 1] Is it possible to re ne the morphological criteria of nodular 
liver cell lesions during malignant progression from cirrhosis to carcinoma?, and 2] Is 
it possible to better discriminate liver cell adenomas from other nodular aberrations, 
i.e. carcinomas and liver cell dysplasias?
MATERIALS AND METHODS
Patient materials
We collected representative para  n blocks from neoplastic and non-neoplastic liver 
cell specimens. These tissues were selected based on the criteria of the International 
Working Party on the “Terminology of nodular hepatocellular lesions” (1995): 
1] Hepatocellular adenoma; a benign neoplasm composed of hepatocytes occurring 
in a liver that is otherwise histologically normal or nearly normal. 2] Dysplastic focus 
or nodule; a cluster or nodule of hepatocytes with dysplasia but without histologic 
criteria of malignancy. 3] Hepatocellular carcinoma (HCC); a malignant neoplasm 
composed of cells with hepatocellular di erentiation. HCC’s were graded using a 
standard grading system (Edmondson and Steiner, 1954). Staging was not included 
in our analysis, since di erent surgical procedures were applied.
The tissue micro-array (TMA) was constructed as described by Kononen et al. (1998). 
Samples from surgical resections of 68 patients (26 complete resections, 42 hemi-
hepatectomies) were selected for the TMA including 58 HCC’s, 2 dysplastic nodules 
(in cirrhosis without HCC) and 8 adenomas, plus adjacent dysplastic, cirrhotic and 
normal liver specimens. Of each patient 6 cylindric tissue cores were included in 
the TMA, e.g. 2 carcinoma, 2 dysplasia and 2 cirrhosis tissue cores, or, 3 carcinoma 
and 3 normal cores. A total of 150 liver tissue samples were available for analysis, 
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i.e. 48 HCC’s, 8 adenomas, 46 dysplasias, 20 cirrhotic specimens and 28 normal liver 
tissues cores. In addition, 4 tissue cores each of liver parenchyma derived from 10 
hemihepatectomies with metastases of colon carcinoma were included as normal 
liver controls.
Fluorescent in situ hybridization
FISH was performed on a 4-µm-thick tissue section of the TMA that was adhered 
to a aminoacetylsilane (AAS) coated slide (Starfrost, Berlin, Germany). The (peri)
centromeric DNA probe for chromosome 1 was labeled with Spectrum Green us-
ing a Nick Translation Reagent Kit (Vysis, Downers Grove IL, USA) according to the 
manufacturer’s directions. The FISH procedure was carried out basically as described 
before by us (Alers and Van Dekken; Van Dekken et al., 2003). Brie y, after appropri-
ate pepsin digestion, the section was heat-denatured for 2 min in 70% formamide 
in 2x SSC, and hybridized overnight at 37ºC with the denatured probe in a hybridiza-
tion mixture containing 2 ng/µl DNA probe, 500 ng/µl herring sperm DNA (Sigma, 
St. Louis MO, USA), 0.1% Tween-20, 10% dextran sulphate, and 60% formamide in 
2x SSC at pH 7.0. Then, a series of stringent washes followed to remove unbound 
probe, and the cells were counterstained with DAPI in antifade solution (Vectashield; 
Vector, Burlingame CA, USA). Two investigators scored a minimum of 50 interphase 
liver cell nuclei per tissue core for the centromere 1 probe on a computer screen. 
Images of each of the 2  uorochromes were collected using an epi uorescence mi-
croscope (Leica DM, Rijswijk, The Netherlands) equipped with appropriate excitation 
and emission  lter sets (Leica), and a cooled CCD camera (Photometrics, Tucson AZ, 
USA). The green and blue images were collected sequentially by changing the exci-
tation  lter using Smartcapture software (Vysis). The number of green  uorescent 
centromere 1 spots per nucleus was scored (0, 1, 2, 3, 4, >4 spots/nuclear slice), and 
the percentage of hyperdiploid cell nuclei was determined for further comparisons 
between tissue groups.
Immunohistochemistry
4µm thick consecutive tissue sections of the TMA were mounted on aminoacetyl-
silane (AAS) coated slides (Starfrost, Berlin, Germany), and immunostaining was 
performed using the UltraVision Large Volume Detection System Anti-Polyvalent, 
HRP (Labvision, Fremont, CA). After depara  nization microwave (700 W) pretreat-
ment was performed for 15 minutes using citrate bu er (10mM citric acid monohy-
drate, pH 6.0). The following antibodies, diluted in phosphate-bu ered saline/5% 
BSA, were used: p16 gene product, E6H4 (DAKO, Glostrup, Denmark; diluted 1/25); 
p53 protein, DO-7 (DAKO; diluted 1/100); retinoblastoma gene product, Rb1 (DAKO; 
diluted 1/25); Ki67 antigen, Mib-1 (Immunotech, Marseille, France; diluted 1/100). 
As a positive control a cytokeratin 8/18 antibody was used, as a negative control 
the primary antibody was omitted. Moderate or intense brown nuclear staining was 
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considered positive for p53, Rb1 or Ki67, whereas nuclear and/or cytoplasmic stain-
ing was evaluated for p16. Ten liver resection specimens from patients with colon 
cancer metastases, present on the TMA, served as nomal liver controls. No positively 
stained hepatocytes were observed for p16, p53 and Rb1 in these normal control 
cells (600-800 cells counted, i.e. 3-4 tissue cores), Ki67 revealed an occasional positive 
hepatocyte nucleus (mean 0.001, range 0-0.005). Subsequently, a cut-o  value of 1% 
was chosen. For practical reasons this cut-o  value was used for all immunostains. At 
least 50 cells were scored per tissue core by two independent investigators. Ki67: A 
percentage >1% positive cell nuclei was regarded as increased proliferation; 2-10% 
moderately (+), and >10% strongly (++) increased. For p16, p53 and Rb1 an identical 
scoring system was used: A percentage exceeding 1% of positive cells was regarded 
as protein overexpression of these tumor suppressor genes; 2-20% moderate (+), 
and >20% strong (++) overexpression. The + and ++ categories were arbitrarely de-
termined after a pre-screen of the TMA.
Patient Tumor Sex Age1 Virus Grade2 FISH (C#1)3 Ki674 p165 p535 Rb15
1 Adenoma m 37 - - + -
2 Adenoma f 21 6 ++ - - +
3 Adenoma f 30 8 - - - -
3 Normal 8 - - - -
4 Adenoma f 31 26 - - - -
4 Normal - - - -
5 Adenoma f 32 2 - - - -
5 Normal 6 - - - -
6 Adenoma f 15 28 - - + -
6 Normal - - - -
7 Adenoma f 21 - - - -
7 Normal - - - -
8 Adenoma f 32 12 - - - -
8 Normal 11 - - - -
9 Carcinoma m 59 HBV/HCV 1 22 + - - +
9 Dysplasia - - - -
9 Cirrhosis 18 - - - -
10 Carcinoma m 66 non-viral 3 40 + - + -
10 Dysplasia 14 - - - -
10 Cirrhosis 8 - - -
11 Carcinoma m 64 non-viral 2 50 + - ++ -
11 Dysplasia - + - -
11 Cirrhosis - + - -
Table 1. Clinical and experimental data
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Patient Tumor Sex Age1 Virus Grade2 FISH (C#1)3 Ki674 p165 p535 Rb15
12 Carcinoma m 74 non-viral 3 ++ - + -
12 Dysplasia - - + -
12 Normal - - + -
13 Carcinoma m 59 HBV 2 8 - - - -
13 Dysplasia - - - -
13 Cirrhosis - - - -
14 Carcinoma m 68 HCV 3 - - - -
14 Dysplasia 11 + - - -
15 Carcinoma m 45 HCV 2 40 + - - +
15 Dysplasia - - - -
15 Normal - - - -
16 Carcinoma f 70 HCV 2 64 - - +
16 Cirrhosis 8 - - +
17 Carcinoma f 52 HBV 2 24 + - - +
17 Dysplasia 18 + + - -
17 Normal 18 + + - -
18 Carcinoma m 63 non-viral 4 42 + - + -
18 Dysplasia 12 - + - -
18 Cirrhosis 12 - - - -
19 Carcinoma f 61 non-viral 2 56 + - - +
19 Dysplasia - - - -
19 Normal 8 - - - -
20 Carcinoma f 30 non-viral 1 2 - - - -
21 Carcinoma m 65 HBV 3 24 + - - -
21 Dysplasia - - - -
21 Cirrhosis - - -
22 Carcinoma m 46 non-viral 3 50 + - ++ +
22 Dysplasia 64 - - - -
22 Normal 14 - - - -
23 Carcinoma m 65 non-viral 2 14 - - + +
23 Dysplasia - - + -
23 Cirrhosis - - - -
24 Carcinoma m 69 non-viral 1 - - - -
24 Dysplasia - - - -
24 Cirrhosis - - - -
25 Carcinoma f 53 non-viral 1 12 - - + -
26 Carcinoma m 59 HBV 2 + - ++ -
26 Dysplasia 6 - + - -
27 Carcinoma f 43 non-viral 3 22 - - + -
27 Dysplasia - - - -
27 Normal 9 - - - -
28 Carcinoma m 72 non-viral 3 56 + - + +
29 Carcinoma m 48 HBV 2 24 - + + -
29 Dysplasia - - - -
29 Cirrhosis 28 - + - -
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Patient Tumor Sex Age1 Virus Grade2 FISH (C#1)3 Ki674 p165 p535 Rb15
30 Carcinoma m 63 HCV 2 66 + - - +
30 Dysplasia 20 - - - -
31 Carcinoma m 73 non-viral 3 40 ++ - + +
32 Carcinoma m 62 HBV 2 22 - - - -
32 Dysplasia - + - -
33 Carcinoma f 41 non-viral 4 16 ++ ++ ++ +
33 Normal 12 - - - -
34 Carcinoma f 43 non-viral 1 - + - -
34 Normal - - - -
35 Carcinoma m 66 HCV 2 12 - - - -
35 Dysplasia - - + -
35 Normal - - - -
36 Carcinoma f 45 non-viral 4 + + + +
36 Dysplasia 22 - - - -
36 Normal 8 - - - -
37 Carcinoma m 59 non-viral 2 26 - - - +
37 Dysplasia - - - -
37 Cirrhosis - - - -
38 Carcinoma f 22 HBV 2 + - + -
38 Dysplasia - - - -
38 Normal - - - -
39 Carcinoma f 56 HBV 2 - - - -
39 Dysplasia - - - -
40 Carcinoma f 56 non-viral 2 10 + - - +
40 Dysplasia - - - -
40 Normal - - - -
41 Carcinoma f 38 HBV 3 ++ ++ + +
41 Normal - - - -
42 Carcinoma f 70 non-viral 3 ++ + + -
42 Normal - - - -
43 Carcinoma f 46 HBV 3 16 - - - -
43 Normal 18 - - - -
44 Carcinoma f 65 HCV 2 10 - - + -
44 Dysplasia - - - -
44 Normal - - - -
45 Carcinoma m 43 HBV/HCV 3 12 - - - -
45 Dysplasia - - - -
45 Cirrhosis - - - -
46 Carcinoma m 53 HBV 2 16 - - - -
46 Dysplasia - - + -
47 Carcinoma m 72 HBV 2 ++ + + +
47 Dysplasia + - - +
47 Cirrhosis 21 - - - -
48 Carcinoma m 49 HCV 2 46 - - + -
48 Dysplasia 30 - + - -
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Patient Tumor Sex Age1 Virus Grade2 FISH (C#1)3 Ki674 p165 p535 Rb15
49 Carcinoma m 43 HBV 2 38 + + - +
49 Dysplasia - + - -
50 Carcinoma m 55 HBV 3 28 + ++ - +
50 Dysplasia 33 - - - -
50 Cirrhosis - - - -
51 Carcinoma m 66 HCV 2 64 + - + +
51 Normal 6 - - - -
52 Carcinoma m 59 non-viral 2 70 ++ - ++ ++
52 Dysplasia - - - -
52 Cirrhosis 12 - - + -
53 Carcinoma f 42 non-viral 4 - - - +
53 Normal - - - -
54 Carcinoma m 57 non-viral 2 - - + +
54 Dysplasia 25 - - - -
55 Carcinoma m 63 non-viral 4 ++ - + +
55 Dysplasia 17 - - - -
55 Normal - - - -
56 Carcinoma m 45 HCV 2 22 + - + +
56 Dysplasia - - - -
57 Dysplasia6 m 67 non-viral 25 - - - -
58 Dysplasia6 m 68 HCV - - - -
59 Dysplasia6 m 48 non-viral - - - -
60 Dysplasia6 m 64 non-viral 18 - - - -
60 Normal - - - -
61 Dysplasia6 f 23 HBV 28 - - - -
61 Normal 14 - - - -
62 Dysplasia7 m 42 HBV 22 - - - -
63 Dysplasia6 m 48 HCV - + - -
63 Cirrhosis - - - -
64 Dysplasia6 m 55 non-viral - - - -
64 Normal - - - -
65 Dysplasia6 m 51 non-viral - - - -
65 Cirrhosis 25 - - - -
66 Dysplasia7 f 49 non-viral 38 - - - -
66 Cirrhosis 17 - - - -
67 cirrhosis6 m 50 HBV 12 - - - -
68 cirrhosis6 m 66 HCV - - - -
1 Age at operation.
2 Histopathological grade according to Edmondson and Steiner (1954).
3 Percentage of hyperdiploid cells, i.e with abnormal chromosome 1 numbers.
4 Ki67 protein expression:  , +, and ++ represent p1%, 2–10% and 410% positive cells, respectively.
5 p16, p53 and Rb1 protein expression:  , +, and ++ refer to p1%, 2–20% and 420% positive cells.
6 HCC not available for evaluation.
7 Dysplasia only in surgical specimen, no HCC.
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Statistical evaluation
The Mann-Whitney-U test was used for comparisons between the specimen groups 
for the percentage of hyperdiploid cell nuclei (an abnormal chromosome 1 num-
ber). Fisher’s Exact Test was applied for comparisons of the immunostaining results 
between groups, as well as tumor grade in relation to FISH and immunostaining. 
P=0.05 (two-sided) was taken as the limit of signi cance. A P-value between 0.05 and 
0.10 was considered a statistical trend.
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FIGURE 1 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Images depicting morphological aspects, ploidy characteristics de ned by  uorescent in situ hybridization (FISH), and changes in cellular 
proliferation and tumor suppressor protein expression, as measured by immunohistochemistry (IHC). (A–E) H&E staining illustrating normal, 
cirrhotic, dysplastic, carcinomatous and adenomatous liver, respectively. (F–H) (patient 47): Ki67 IHC showing many positive nuclei, i.e. highly 
increased proliferation in the HCC (F), moderately increased proliferation in adjacent dysplasia (G), and no proliferating hepatocytes in neighboring 
cirrhosis (H). (I,J) (patient 33): p16; strong protein overexpression in carcinoma cells (I), no overexpression in adjacent normal liver tissue (J). (K) 
(patient 26): p53 illustrating immunoreactivity in many cancer cell nuclei. (L) (patient 6): p53; scattered positively staining nuclei in adenoma cells. 
(M,N) (patient 52): Rb1; frequent protein overexpression in cancer cell nuclei of HCC (M), adjacent cirrhosis is negative (N). (O) (patient 28): FISH 
revealing an abnormal chromosome 1 number in HCC (cells with 42 spots/nucleus). A 40  objective was used for (A–E), a 20  objective for (F–N), 
and a 63  objective for (O).
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RESULTS
We constructed a liver tissue micro-array (TMA) representing 68 surgical specimens. 
Evaluation was completed of 56 primary liver tumors, i.e. 48 HCC’s (31 male, 17 fe-
male; mean age 55.9 years, range 23-74) and 8 adenomas (1 male, 7 female; mean 
age 27.4, range 15-37). In addition, 2 dysplastic nodules in cirrhosis without HCC 
were included. Adjacent specimens comprised 44 dysplasias, 20 cirrhotic specimens 
and 28 normal liver samples. Both age and sex of the adenoma patients were signi -
cantly di erent from the HCC patients (P <0.001 and P=0.016, respectively). Twenty-
 ve of the investigated HCC’s were virus-associated, 23 were related to other causes; 
25 of the 48 investigated HCC’s developed in cirrhotic livers, 23 were not associated 
with cirrhosis.
The HCC and adenoma results are summarized in Table 1, illustrations are depicted 
in Figure 1. DNA ploidy was measured by  uorescent in situ hybridization (FISH) 
with a chromosome 1-speci c peri-centromeric DNA probe. An abnormal chromo-
some 1 number, i.e. the percentage of hyperdiploid cells, was 11.0 (range 6-18), 13.7 
(range 2-28), 16.1 (range 8-28), 23.7 (range 6-64) and 31.3 (range 2-70) for normal 
liver samples, adenomas, cirrhosis, dysplasias and HCC’s, respectively. Carcinomas 
and dysplasias were clearly di erent from normal liver tissues (P<0.001 and P=0.001, 
respectively), whereas this was not discerned for cirrhotic and adenomatous speci-
mens (Table 2). A signi cant di erence was found for HCC versus cirrhosis (P=0.024) 
or adenoma (P=0.033), a trend was seen for dysplasia versus cirrhosis (P=0.094; Table 
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normal 12 6 6 3 3
cirrhosis 16 6 14 5 5
dysplasia 24 7 17 9 2
carcinoma 31 57 19 52 50
adenoma 14 13 0 25 13
aneuploidy Ki-67 p16 p53 Rb1
Figure 2. Bar histograms (and table) depicting all investigated liver tissues in relation to aneuploidy and cell biological perturbations. All positive 
immunostaining results (+ and ++) are grouped for better visualization of the cell biological alterations. Note the clear di erence between HCC 
and the other liver tissues for cellular proliferation (Ki67) and tumor suppressors p53 and Rb1, but not p16. For hyperdiploidy the di erences are 
more complex (see Table 2).
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2). Protein (over)expression of tumor suppressor genes p16, p53 and Rb1 was as-
sessed by immunohistochemistry, the proliferative capacity was examined by im-
munostaining of Ki67. Immunohistochemical protein expression of p53 and Rb1, 
as well as Ki67 de ned proliferation, was clearly higher in HCC than in cirrhosis or 
dysplasia (all P<0.001). P16 protein expression appeared low in all investigated liver 
tissue groups. Proliferation was higher in HCC than in adenoma (P=0.025), whereas 
a trend was observed for Rb1 overexpression (P=0.063; Table 2). No di erences were 
observed between the normal, cirrhosis, dysplasia and adenoma groups for all in-
vestigated oncoprotein and proliferation markers. All of the data are schematically 
visualized in Figure 2. No statistical di erences were found between FISH and IHC 
TABLE 2. Statistical analysis of IHC (p16, p53, Rb1, Ki67) and FISH results.1,2
p53 normal cirrhosis dysplasia adenoma carcinoma
normal <0.001
cirrhosis <0.001
dysplasia <0.001
adenoma
carcinoma <0.001 <0.001 <0.001
Rb1 normal cirrhosis dysplasia adenoma carcinoma
normal <0.001
cirrhosis <0.001
dysplasia <0.001
adenoma 0.063
carcinoma <0.001 <0.001 <0.001 0.063
Ki67 normal cirrhosis dysplasia adenoma carcinoma
normal <0.001
cirrhosis <0.001
dysplasia <0.001
adenoma 0.025
carcinoma <0.001 <0.001 <0.001 0.025
FISH3 normal cirrhosis dysplasia adenoma carcinoma
normal <0.001 <0.001
cirrhosis 0.094 0.024
dysplasia <0.001 0.094
adenoma 0.033
carcinoma <0.001 0.024 0.033
1 No signi cant associations (no matrix) for p16.
2 Open box, not signi cant; signi cant, P value below 0.05; trend, P value between 0.05 and 0.10 (borderline signi cance).
3 Hyperdiploidy, i.e. an abnormal chromosome 1 number.
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results for tumor grade, viral and non-viral liver disease, and presence or absence of 
cirrhosis.
DISCUSSION
We used a tissue micro-array analysis comprising a total of 122 liver cell lesions and 
28 normal controls. The results suggest that in the cirrhosis-dysplasia-carcinoma 
pathway aneuploidy occurs in liver cell dysplasia, which is followed by increased 
proliferation and cell biological perturbations involving p53 and Rb1 in HCC. Ad-
enomas could be distinguished from carcinomas based on ploidy and proliferation 
characteristics, which could be of clinical utility. FISH with a chromosome-speci c 
repetitive DNA probe might be most promising in this respect, as the di erence in 
the mean percentage of hyperdiploid cells was large, i.e. 13.7 for adenomas and 31.3 
for HCC’s. This is in agreement with FISH and DNA  ow cytometry studies that found 
aneuploidy in carcinomas, but not in adenomas (Nasarek et al., 1995; Ruschenburg 
et al., 2000). In our series both frequency and degree of aneuploidy in dysplastic liver 
lesions was comparable to those found in HCC. This has also been detected by DNA 
cytometry (Thomas et al., 1992; Rubin et al., 1994). Discriminating adenoma from 
dysplasia appeared di  cult. Ki67 immunostaining pro les for benign neoplasms of 
the liver have been reported to show very low growth fractions, similar to those 
in normal or cirrhotic livers (Grigioni et al., 1989). Low percentages of p53-positive 
cells have also been described for cirrhotic, dysplastic and adenomatous liver le-
sions, when compared with carcinomas (Cohen and Derose, 1994; Ojanguren et al., 
1995). From these and our results we conclude that with oncoprotein and prolifera-
tion markers it is not possible to con dently discriminate adenomas from liver cell 
dysplasias.
We found few p16-positive cells in cirrhosis, dysplasia and HCC, whereas immu-
nostaining was basically absent in normal and adenomatous liver tissue. However, 
the p16 gene has been reported a major inactivation target in liver cancers (Jin et 
al., 2000). This phenomenon might be attributed to the immunohistochemical de-
tection of p16, which does not visualize genetic alterations, such as homozygous 
deletion or promotor hypermethylation (Narimatsu et al., 2004). Promotor hyper-
methylation of p16 with absence of deletions was described in liver cell adenomas 
(Tannapfel et al., 2002), which is in line with our results. High proliferation rates and 
frequent p53 protein overexpression were seen in HCC, which is in accordance to 
published data (Wu et al., 1999; Ojanguren et al., 1995). Both immunomarkers can 
be used to discriminate HCC from dysplasia, whereas Ki67 measurements can be 
helpful in separating liver cell adenoma from cancer. A correlation between loss of 
Rb1 mRNA expression and Rb1 methylation has been shown (Edamoto et al., 2003). 
However, immunostaining of Rb1 visualizes the phosphorylated protein, which is 
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overexpressed in a variety of tumor cell lines (Bartek et al., 1992). This was also seen 
in our series, where liver cell carcinoma could be easily distinguished from dysplasia, 
but more di  cult from adenoma.
The use of a tissue micro-array enabled us to screen a large number of liver cell le-
sions ranging from cirrhosis to cancer. From our data we conclude that it is unlikely 
that liver cell adenomas play a role in the pathway leading to liver cell carcinoma. 
Protein IHC with Ki67, p53 and Rb1 is capable to distinguish HCC from dysplasia and 
cirrhosis, whereas Ki67-de ned proliferation index and FISH-measured ploidy can be 
utilized to discriminate liver cell adenomas from carcinomas.
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ABSTRACT
Background: The results of partial liver resection of HCC in non-cirrhotic livers are 
not well known. Therefore a retrospective study was conducted. 
Methods: The medical records of 180 patients with HCC were reviewed. In 40 
patients (22%) HCC occurred in a non-cirrhotic liver. A detailed analysis of these 
patients was performed. The diagnosis HCC was based on imaging and/or percuta-
neous ultrasound-guided biopsy. A biopsy of the remaining liver and peroperative 
 ndings documented the absence of cirrhosis. 
Results: Twenty-two patients underwent partial liver resection. There was no sur-
gical mortality. The median tumour diameter in the operated patients was 10 cm. 
Survival rates for operated patients at one and  ve years were 96% and 68%, re-
spectively. Signi cant factors reducing survival were portal vein thrombosis, positive 
lymph nodes, microscopic vascular invasion and tumour recurrence. Tumour size at 
the initial moment of diagnosis was not of predictive value. After surgery with cura-
tive intent disease free interval at 1 and 5 years were respectively 86% and 56%. 
Conclusion: In selected patients without cirrhosis, HCC can be treated successfully 
by surgical resection, independent of the tumour diameter, with a 5-year survival 
rate of 68%.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancers in man. Its 
world-wide annual incidence has been estimated to be 250.000 to 1 million people 
(1) with more than 1 million deaths each year (2). In North America and several 
European countries, HCC is uncommon and the estimated death rate is less than 
5/100.000 inhabitants/year (3). Although many aspects of HCC have been studied in 
detail, less attention has been directed sofar to the presence or absence of cirrhosis 
in the underlying liver in relation to the prognosis for patients with this disease.(4,5) 
Several studies have described the histopathological characteristics of HCC in a non-
cirrhotic liver. Special attention was directed to the non-cirrhotic liver, the etiological 
factors and the clinical presentation.(6-15). However, the outcome of surgical resec-
tion of HCC in the non-cirrhotic liver has seldom been reported. We retrospectively 
analysed a group of 40 patients, with HCC in a non-cirrhotic liver, seen at our institu-
tion.
PATIENTS AND METHODS
Between January 1987 and July 2000, 180 patients with HCC were seen in the Eras-
mus Medical Centre, a tertiary referral center in the Netherlands. The medical charts 
of these 180 patients with HCC were analysed in retrospect. Cirrhosis was absent in 
samples of non-tumorous liver of 40 patients. These patients were selected for this 
study. In this non-cirrhotic HCC group the mean age was 56 years +/- 17 years (range 
17-90 years). Males (n=22) and females (n=18) gender was more or less equally dis-
tributed, with a male-to-female ratio of 1.2 : 1. Male patients had a mean age of 59 
years +/- 15 years, female patients a mean age of 52 years +/- 18 years. Thirteen pa-
tients had one or more markers for hepatitis B or C infection (33%); twelve patients 
were infected with Hepatitis B Virus (30%), one with a Hepatitis C Virus (3%) and two 
both (5%).
One pathologist (PEZ) reviewed all biopsies and resected specimen. All liver biop-
sies/resected specimen were evaluated according to the Knodell index (16). Sixteen 
patients (40%) had slight or moderate  brosis, in one patient (3%) haemochromato-
sis and in 5 patients (13%) moderate steatosis was seen. Histopathological examina-
tion of the tumour is described in Table 1. Tumour di erentiation was less in 7%, 
moderate in 48% and well-di erentiated in 26%. In 19% of cases di erentiation was 
not evaluated. In 40% of cases, vascular invasion was found, in 40% of cases vascular 
invasion was not found; it was not determined in 20% of cases.
Characteristics of the operations are displayed in Table 2. Twenty-two of the 40 pa-
tients (resection rate of 55%) were operated on. All resections had a tumour free 
margin. All resections were undertaken with the intent to cure. There was no opera-
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tive mortality. No (neo) adjuvant therapy was given in the operated patients. Eigh-
teen patients were not operated on. Six patients had multiple tumours in the right 
and left side of the liver. Two patients had a large tumour that had ruptured into the 
abdominal cavity and were therefore considered irresectable (at that time). Two pa-
tients had a poor cardiac function, 8 patients had vascular ingrowth and/or positive 
lymph nodes, demonstrated by CT and /or percutaneous punction.
Operative mortality was de ned as intraoperative death and death during hospital 
stay postoperatively. Actuarial survival was calculated from the date of diagnosis. 
Survival and survival without recurrence were analysed according to the Kaplan-
Meier survival method. Continuous data will be shown as the median (range). The 
Log-rank test and Cox regression test were used to analyse prognostic factors ac-
cording to survival and recurrence. The Cox-time dependent regression model was 
Table 1 Characteristics of the study population. 
Operated Not operated Total Group
22 18 40
Male 13 9 22 
Female 9 9 18 
Age (mean in years, range) 56 (23-77) 56 (17-90) 56 (17-90)
Race
     Caucasian 17 12 29 
     Black 1 1 2 
     Eastern 3 4 7 
     Hindu 1 1 2 
Tumour   (mean in cm, range) 10 (1,5-18) 9 (1,5-21) 10 (1,5-21)
Hep B/C infection 7 6 13
AFP (mean in µg/L, range) 6198 (1-128720) 62848 (1-810000) 30050 (1-810000)
Positive lymph nodes 1 5 6 
V. porta thrombosis 1 10 11 
Solitary tumour 18 9 27 
Tumour location in liver
     Left  half 10 2 12 
     Right half 11 10 21 
     Left and Right sides 1 6 7 
Core biopsy tumour 17 16 33 
Histopathological examination
     Trabecular type 5 8 13 
     Acinar type 4 2 6 
     Fibrolamellar type 2 1 3 
     Mixed Type 11 2 13 
     Unknown 0 5 5 
Pts : Patients
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used to analyse recurrence as a prognostic factor for survival. Calculations were per-
formed on a personal computer using SPSS for Windows 95. Signi cance is de ned 
as P < 0.05.
RESULTS
In Table 1 the characteristics of the patients of the operated and non-operated 
groups are described. Elevated levels (> 30 µg/L) of serum α fetoprotein (AFP) were 
found for 23 patients (55%). AFP levels were available on all patients.
 The last patient included in this analysis was operated in July 2000. Follow-up was 
completed prospectively as to September 2003. One patient moved to China and 
therefore lost to follow-up. Cumulative survival for the non-operated group after 1 
and 5 years was 24% and 6% respectively with a median survival time of 7 months, 
by Kaplan Meier method. Cumulative survival for the operated patients after 1 and 
5 years was 96% and 68% respectively with a median survival of 79 months ( gure 
1). After operation the disease free interval after 1 and 5 years was 86% and 56% re-
spectively. Ten of the 22 (45%) patients who were operated on developed recurrence 
of HCC during follow-up. An overview of the patients with recurrence is presented in
table 3. Three patients developed 4 extrahepatic metastases and were operated (Pt 
1, 5, 9). These (highly selected) patients are still alive 17 months, 59 months and 62 
months after metastasectomy. Pt number 1 (table 3) developed a second recurrence 
(intra-abdominal) after 58 months. This was operated and patient is still alive, 84 
Good Outcomes after Resection of HCC in
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Table 3. Overview of patients with recurrent HCC after partial liver resection
Patient Type of resection Recurrence site Recurrence
months
Treatment Status Survival
months
1 hemihepatectomy subcutaneous seeding 22 surgical resection alive 84 
2 hemihepatectomy intrahepatic 39 local ablation ali e 69 
3 segmental resection intrahepatic 7 hemihepatectomy dead 78 
4 segmental resection intrahepatic 11 none dead 18 
5 hemihepatectomy subcutaneous seeding 25 surgical res ctio  alive 84 
6 hemihepatectomy intra-abdominal/bones 8 none dead 9 
7 segmental resection intrahepatic 15 none dead 18 
8 hemihepatectomy lung/intrahepatic 36 none alive 50 
9 segmental resection intra-abdominal 29 surgical resection alive 46 
10 segmental resection intrahepatic 13 none dead 23
lymph nodes and tumour recurrence were significant
prognostic factors for survival (p ! 0.05). Not significant
factors were, among many others, tumour size, age, sex,
race, viral status, more than one primary tumour, serum
AFP or peroperative blood loss. Significant prognostic
factors for tumour recurrence in the operated group were
portal vein thrombosis and positive lymph nodes (p !
0.05). Tumour size, age, sex, race, viral status, number of
primary tumours, vascular invasion, serum AFP and
peroperative blood loss were not found to be significant
factors.
Discussion
In this study, we evaluated the outcome of surgical
treatment and characteristics of patients with HCC with-
out liver cirrhosis. The absence of underlying cirrhosis is
found in approximately 5–40% of patients with HCC in
Western countries [6, 7, 9, 17, 18]. Because the absence of
cirrhosis leads to late presentation in the course of the dis-
ease, larger tumours are more likely to be seen in a patient
with a non-cirrhotic than a cirrhotic liver. At our institute,
the size of the tumour was never a contraindication for
operation as such. Despite the large resections encoun-
tered, there was no post-operative liver failure. This may
be explained by the gradual growth of the large tumours
which induces functional adaptation of the contralateral
lobe.
In this study, we had a relatively high percentage of
percutaneous biopsies of the tumour (83%) pre-operative-
ly. As a rule, it was performed in the hospital where the
patients were first seen. Our policy is not to perform a
percutaneous biopsy of the tumour because of the risk of
Fig. 1. Long-term survival after partial liver resection (Kaplan-Meier
curve). The number of patients alive at follow-up (months) was as
follows: 21 (12), 16 (24), 15 (36), 11 (48), 10 (60), 6 (72), 4 (84) and 1
(96).
subcutaneous seeding [19]. In this study, 2 of the 35
patients (6%) that underwent percutaneous tumour biop-
sies developed subcutaneous tumour seeding related to
the biopsies during follow-up. We advocate a percuta-
neous biopsy of the ‘normal’ liver to exclude cirrhosis. We
perform a biopsy of the lesion when characteristics ob-
tained by imaging do not support a diagnosis and further
management remains unclear.
The prognosis for patients with HCC in a non-cirrhotic
liver is not as clearly described as that for patients with
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months after  rst resection. An example of a patient with a hemihepatectomy who 
did not su er a recurrence in her 5 years of follow-up is seen in  gure 2.
For the whole group of patients (n=40), operation, vascular invasion and portal vein 
thrombosis were highly signi cant (p<0.0001) prognostic factors for survival. The 
presence of more than one tumour nodule or positive lymph nodes had also a poorer 
survival (p<0.05). Not signi cant were tumour size, age, sex, race, viral status, serum 
AFP and pre operative serum haemoglobin levels. In the operated group of patients 
(n=22), portal vein thrombosis, microscopic vascular invasion, positive lymph nodes 
and tumour recurrence were signi cant prognostic factors for survival (p<0.05). Not 
signi cant factors were, among many others, tumour size, age, sex, race, viral status, 
more than one primary tumour, serum AFP or per operative bloodloss. Signi cant 
prognostic factors for tumour recurrence in the operated group were portal vein 
thrombosis and positive lymph nodes (p<0.05). Tumour size, age, sex, race, viral sta-
tus, number of primary tumours, vascular invasion, serum AFP and per operative 
bloodloss were not found to be signi cant factors. 
DISCUSSION
In this study we evaluated the outcome of surgical treatment and presentation of 
patients with HCC without liver-cirrhosis. Absence of underlying cirrhosis is found in 
approximately 5-40% of patients with HCC in Western countries. (6,7,9,17,18) Because 
the absence of cirrhosis leads to late presentation in the course of the disease, larger 
tumours are more likely to be seen in a patient with a non-cirrhotic than a cirrhotic 
liver. At our institute the size of the tumour was never a contraindication for opera-
tion as such. Despite the large resections encountered, there was no postoperative 
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Table 2. Operation characteristics
(22 patients) Operation performed
4 segment resections
9 right lobectomies
7 left lobectomies
2 extended left lobectomies
Hospital stay
Mean: 20 days
Median: 16 days
Range: 3–72 days
Complications and treatment
Liver related
3 patients with ascites diuretics, no drainage
2 patients with a biloma 1 patient had ERCP with stent,
both had percutaneous drainage
Not liver related
1 patient with fascial dehiscence (burst abdomen) re-operation
3 patients with pneumonia antibiotics
2 patients with urinary tract infection antibiotics
1 patient with Horner syndrome because of v. jugularis catheter injury
cardiac function, 8 patients had vascular ingrowth and/or positive
lymph nodes, demonstrated by CT and/or percutaneous punction.
Statistical Analysis
Operative mortality was defined as intraoperative death and
death during hospital stay post-operatively. Actuarial survival was
calculated from the date of diagnosis. Survival and survival without
recurrence were analysed according to the Kaplan-Meier survival
method. Continuous data will be shown as the median (range). The
log-rank test and Cox regression test were used to analyse prognostic
factors according to survival and recurrence. The Cox time-depen-
dent regression model was used to analyse recurrence as a prognostic
factor for survival. Calculations were performed on a personal
computer using SPSS for Windows 95. Significance was defined as
p ! 0.05.
Results
Patient Characteristics
The characteristics of patients from the operated and
non-operated groups are described in table 1. Elevated
levels (130 Ìg/l) of serum ·-fetoprotein (AFP) were found
in 23 patients (55%). AFP levels were present in all
patients.
Follow-Up
The last patient included in this analysis was operated
in July 2000. Follow-up was completed prospectively as to
September 2003. One patient moved to China and was
therefore lost to follow-up. Cumulative survival for the
non-op rated group after 1 and 5 years was 24 and 6%,
respectively, with a median survival time of 7 months, by
Kaplan-Meier method. Cumulative survival for the oper-
ated atients aft r 1 and 5 years was 96 and 68%, respec-
tively, with a median survival of 79 months (fig. 1). After
operation, the disease-free interval after 1 and 5 years was
86 and 56%, respectively. Ten of the 22 (45%) patients
who were operated on developed recurrence of HCC dur-
ing follow-up. An overview of the patients with recurrence
is presented in table 3. Three patients developed 4 extra-
hepatic metastases and were operated on (patients 1, 5, 9).
These (highly selected) patients are still alive 17, 59 and
62 months after metastasectomy. Patient number 1 (ta-
ble 3) developed a second (intra-abdominal) recurrence
after 58 months. This was operated and the patient is still
alive, 84 months after first resection. An example of a
patient with a hemih patectomy who did n t suffer a
recurrence in her 5 years of follow-up is seen in figure 2.
Prognostic Factors
For the whole group of patients (n = 40), operation,
vascular invasion and portal vein thrombosis were highly
significant (p ! 0.0001) prognostic factors for survival.
The presence of more than one tumour nodule or positive
lymph nodes also meant poorer survival (p ! 0.05). Not
significant were tumour size, age, sex, race, viral status,
serum AFP and pre-operative serum haemoglobin levels.
In the operated group of patients (n = 22), portal vein
thrombosis, microscopic vascular invasion, positive
Table 2. Operation characteristics (22 patients)
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liver failure. This may be explained by the gradual growth of the large tumours which 
induces functional adaptation of the contralateral lobe. 
In this study we had a relatively high percentage of percutaneous biopsies of the 
tumour (83%) pre-operatively. As a rule it was performed in the hospital where the 
patients were  rst seen. Our policy is not to perform a percutaneous biopsy of the 
tumour because of the risk of subcutaneous seeding.(19) In this study, 2 of the 35 
Table 3. Overview of patients with recurrence HCC after partial liver resection
Type of resection Recurrence-site Recurrence  Treatment Status Survival
Pt 1 Hemi hepatectomy Subcutaneous seeding 22 months Surgical resection Alive 84 months
Pt 2 Hemi hepatectomy Intra-hepatic 39 months Local Ablation Alive 69 months
Pt 3 Segmental resection Intra-hepatic 7 months Hemihepatectomy Dead 78 months
Pt 4 Segmental resection Intra-hepatic 11 months None Dead 18 months
Pt 5 Hemi hepatectomy Subcutaneous seeding 25 months Surgical resection Alive 84 months
Pt 6 Hemi hepatectomy Intra-abdominal/ Bones 8 months None Dead 9 months
Pt 7 Segmental resection Intra-hepatic 15 months None Dead 18 months
Pt 8 Hemi hepatectomy Lung/Intra-hepatic 36 months None Alive 50 months
Pt 9 Segmental resection Intra-abdominal 29 months Surgical resection Alive 46 months
Pt 10 Segmental resection Intra-hepatic 13 months None Dead 23 months
384 Dig Surg 2004;21:380–386 Verhoef/de Man/Zondervan/Eijkemans/
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Fig. 2. An example of a patient with hemihepatectomy who did not suffer a recurrence in her 5 years of follow-up.
1 = Liver; 2 = stomach; 3 = spleen; 4 = aorta; 5 = inferior vena cava; 6 = HCC. a Before hemihepatectomy. b Five years
after the resection.
Table 4. Long-term survival of HCC resections in a non-cirrhotic
liver
Reference Patients Year of
publication
Five-year
survival
rate, %
Smalley et al. [22] 29 1988 25
Adson [33] 45 1988 35
Iwatsuki and Starzl [34] 55 1988 25
Ringe et al. [35] 86 1991 45
Iwatsuki et al. [28] 59 1991 44
Bismuth et al. [20] 68 1995 40
Fong et al. [4] 54 1999 42
Nagasue et al. [21] 100 2001 50
Present series 22 68
HCC in a cirrhotic liver. Only a few data are available.
The 5-year survival rates range from 25 to 50% (table 4).
Bismuth et al. [20] and Nagasue et al. [21] reported a sur-
vival rate of 26 and 47%, respectively, at 10 years. Naga-
sue et al. [21] reported a significant rise in intrahepatic
recurrences in patients with hepatitis C virus infection.
We found no differences regarding survival or recurrences
between the patient groups with or without hepatitis C
virus infection. We did not support this finding probably
because of the small numbers in our study (n = 3).
Considering the usually large size of these tumours, in
the present series a median and mean of 10 cm, these
results appear better than those reported for HCC in the
cirrhotic liver [5, 20]. A trend of an increasing 5-year sur-
vival rate for HCC in a non-cirrhotic liver was found. If
we look at table 4, the first 3 studies reported a 5-year sur-
vival rate of 25–35%. The last 3 studies had a 5-year sur-
vival rate of 42–68%. The improved outcomes might be
related to a better patient selection.
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patients (6%) that underwent percutaneous tumour biopsies developed subcutane-
ous tumour seeding during follow-up, related to the biopsies. We advocate a per-
cutaneous biopsy of the “normal” liver to exclude cirrhosis. We perform a biopsy of 
the lesion when characteristics obtained by imaging do not support a diagnosis and 
further management remains unclear.
The prognosis for patients with HCC in a non-cirrhotic liver is not as clearly described 
as that for patients with HCC in a cirrhotic liver. Only a few data are available. The 
5-year survival rates range from 25% to 50% (Table 4). Bismuth et al. (20) and Na-
gasue et al. (21) reported a survival rate of 26% and 47%, respectively at 10 years. 
Nagasue et al. (21) reported a signi cant rise in intrahepatic recurrences in patients 
with hepatitis C virus infection. We found no di erences in the patient group having 
hepatitis C virus infection or not regarding survival or recurrences. Probably because 
of the small numbers our study (n=3) we did not support this  nding. 
Considering the usually large size of these tumours, in the present series a median 
and mean of 10 cm, these results appear better than those reported for HCC in the 
cirrhotic liver. (5,20) A trend of an increasing 5-year survival rate for HCC in a non-
cirrhotic liver was found. If we look at Table 4, the  rst three studies reported a 5-year 
survival rate of 25% to 35%. The last three studies had a 5-year survival rate of 42% to 
68%. The improved outcomes might be related to a better patient selection.
Literature is in favor of surgical treatment if intra-hepatic recurrence has developed. 
(20-23) The role of surgery for extrahepatic recurrence of HCC is not well established. 
Extrahepatic recurrence occurs in about 30% of the patients (24). Literature on 
the subject of survival after treatment of extrahepatic recurrence is limited. To our 
knowledge, there are four studies reporting resection of extrahepatic recurrence in 
patients with HCC (24-27). Although small number of patients (8 - 14 patients), these 
studies report that long term survival can be achieved. In our study, three patients 
are still alive 17, 59 and 62 months after extra-hepatic metastasectomy. Therefore, 
we conclude that in this very selected patient group, resection must be considered. 
Long term survival can be achieved if radical resection can be performed.
Table 4. Long-term survival of HCC resections in a non-cirrhotic liver
Reference No. of patients Year of publication 5-year survival rate
Smalley et al. (22) 29 1988 25%
Adson et al. (33) 45 1988 35%
Iwatsuki et al. (34) 55 1988 25%
Ringe et al. (35) 86 1991 45%
Iwatsuki et al. (28) 59 1991 44%
Bismuth et al. (20) 68 1995 40%
Fong et al. (4) 54 1999 42%
Nagasue et al. (21) 100 2001 50%
Present series 22 68%
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Attempts to improve the treatment of hepatocellular carcinoma in non cirrhotics 
by performing total hepatectomy and liver transplantation have failed. The rates of 
post-transplant 5-year survival were 26% reported by Iwatsuki et al.(28). Pichlmayr et 
al.(29) and Houben/McCall (30) con rmed that patients should not be o ered OLT for 
HCC (they speci ed it for the non  brolamellar HCC) in a non-cirrhotic liver. Neuhaus 
et al.(31) reported that liver transplantation is also not appropriate for  brolamellar 
carcinoma in the non-cirrhotic liver. 
Three patients had a ruptured HCC in our series. This is not a contraindication for 
resection. Chiappa et al.(32) conclude, because of their own experience combined 
with a literature review of 755 cases of ruptured HCC, that surgical resection is asso-
ciated with long-term survival. When conservative management was chosen, there 
were no long-term survivors.
In Conclusion: According to our experiences as well as current literature it appears 
that partial liver resection is the gold standard for treatment of HCC in the non-cir-
rhotic liver. We will emphasize that tumour size did not in uence outcome. Patients 
without metastases, positive lymph nodes and portal vein thrombosis had a 5 year 
survival rate after resection, independent of clinical and biochemical characteristics, 
of 68% in our series.
Ch
ap
te
r V
I
70
References
 Simonetti RG, Camma C, Fiorello F, 1. et al. Hepatocellular carcinoma. A worldwide problem and the 
major risk factors. Dig Dis Sci 1991;36:962-72.
 Rutsgi VK. Epidemiology of hepatocellular carcinoma. Ann Int Med 1988;108:390-91.2. 
 Ramsey WH, Wu GY. Hepatocellular carcinoma: Update on diagnosis and treatment. Dig Dis 3. 
1995;13:81-91.
 Fong Y, Sun RL, Jarnagin W, 4. et al. An analysis of 412 cases of hepatocellular carcinoma at a western 
center. Ann Surg 1999;229:790-800.
 Bilimoria MM, Lauwers GY, Dohery DA, 5. et al. Underlying liver disease, not tumor factors, predicts 
long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001;136:528-33.
 Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and non cirrhotic livers. 6. 
A clinico-histopathologic study of 804 North American patients. Am J Clin Path 1996;105:65-75.
 Trevisani F, D´Intimo PE, Caraceni P, 7. et al. Etiologic factors and clinical presentation of hepato-
cellular carcinoma: di erences between cirrhotic and noncirrhotic Italian patients. Cancer 
1995;75:2220-32.
 Bralet MP, Regimbeau JM, Pineau P, 8. et al. Hepatocellular carcinoma occurring in non brotic 
liver:Epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200-04.
 Van Roey G, Fevery J, Van Steenbergen W. Hepatocellular carcinoma in Belgium: clinical and viro-9. 
logical characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol 
Hepatol 2000;12(1):61-66.
 Okuda K, Nakshima T, Kojiro M, 10. et al. Hepatocellular carcinoma without cirrhosis in Japanese pa-
tients. Gastroenterology 1989;97:140-46.
 Grando-Lemaire, Guettier C, Chevret S, 11. et al, for the Groupe d´Etude et de traitement du carcinome 
hepatocellulaire. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors 
and histopathology of the non-tumorous liver. J Hepatol 1999;31:508-13.
 Blanc JF, De Ledinghen V, Bernard PH, 12. et al. Increased incidence of HFE C282Y mutations in pa-
tients with iron overload and hepatovcellular carcinoma developed in non-cirrhotic liver.J Hepatol 
2000;32:805-11.
 Britto MRC, Thomas LA, Balaratnam N, 13. et al. Hepatocellular carcinoma arising in non-cirrhotic liver 
in genetic haemochromatosis. Scand J Gastroenterol 2000;35:889-93.
 Kondo M, Yamamoto H, Nagano H, 14. et al. Increased expression of COX-2 in nontumor liver tissue is 
associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Can-
cer Res 1999;5:4005-12.
 Turlin B, Juguet F, Moirand R, 15. et al. Increased liver iron stores in patients with hepatocarcinoma 
developed on non-cirrhotic liver. Hepatology 1995;22:446-50.
 Knodell RG, Ishak KG, Black WC, 16. et al. Formulation and application of a numerical scoring 
system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatol-
ogy1981;1:431-35.
 Kubicka S, Rudolph KL, Hanke M, 17. et al. Hepatocellular carcinoma in Germany:a retrospective epi-
demiological study from a low-endemic area. Liver 2000;20:312-18.
 Bosch FX. Global epidemiology of hepatocellular carcinoma. In:Liver Cancer. Okuda K, Tabor E (edi-18. 
tors). New York: Churchill Livingstone;1997:13-28.
 Schotman SN, De Man RA, Stoker J, 19. et al. Subcutaneous seeding of hepatocellular carcinoma after 
percutaneous needle core biopsy. Gut 1999;45(4):626-27.
 Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic 20. 
liver: experience with 68 liver resections. World J Surg 1995;19:35-41.
 Nagasue N, Ono T, Yamanoi A, 21. et al. Prognostic factors and survival after hepatic resection for 
hepatocellular carcinoma without cirrhosis. Br J Surg 2001;88:515-22.
 Smalley SR, Moertel CG, Hilton JF, 22. et al. Hepatoma in the noncirrhotic liver. Cancer 
1988;62:1414-24.
 Zhou XD, Tang ZY, Yu YQ, 23. et al. Hepatocellular carcinoma: some aspects to improve long term sur-
vival. J Surg Oncol 1989;41:256-62.
 Farges O, Regimbeau JM, Belghiti J. Aggressive management of recurrence following surgical re-24. 
section of hepatocellular carcinoma. Hepatogastroenterology 1998;45 Suppl 3:1275-80.
HCC in the non-cirrhotic liver 71
 Poon RT, Fan ST, O’Suilleabhain CB, Wong J. Aggressive management of patients with extrahepatic 25. 
and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional 
therapy. J Am Coll Surg 2002;195(3):311-8.
 Arii S, Monden K, Niwano M, Furutani M, Mori A, Mizumoto M, et al. Results of surgical treatment 26. 
for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric 
carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat 
Surg 1998;5(1):86-92.
 Lo CM, Lai EC, Fan ST, Choi TK, Wong J. Resection for extrahepatic recurrence of hepatocellular 27. 
carcinoma. Br J Surg 1994;81(7):1019-21.
 Iwatsuki S, Starzl TE, Sheahan DG, 28. et al. Hepatic resection versus transplantation for hepatocellular 
carcinoma. Ann Surg 1991;214:221-28.
 Pichlmayr R, Weimann A, Oldhafer KJ, 29. et al. Role of liver transplantation in the treatment of unre-
sectable liver cancer. World J Surg 1995;19:807-13.
 Houben KW, McCall JL.Liver transplantation for hepatocellular carcinoma in patients without un-30. 
derlying liver disease: a systematic review. Liver Transplantation and Surgery 1999;5:91-95.
 Neuhaus P, Jonas S, Bechstein WO. Hepatoma of the liver, resection or transplantation ? 31. 
Langenbeck´s Arch Surg 2000;385:171-78.
 Chiappa A, Zbar A, Audisio RA, 32. et al. Emergency liver resection for ruptured hepatocellular carci-
noma complicating cirrhosis. Hepatogastroenterology 1999;46:1145-50.
 Adson MA. Primary hepatocellular cancers:Western experience. In Surgery of the Liver and Biliary 33. 
Tract (2nd ed.), Blumgart LH editor. Edinburgh, Churchill Livingstone 1988:1153-65.
 Iwatsuki S, Starzl TE. Personal experience with 411 hepatic resections. Ann Surg 1988;208:421-34.34. 
 Ringe B, Pichlmayr R, Wittekind C, 35. et al. Surgical treatment of HCC:experience with liver resection 
and transplantation in 198 patients. World J Surg 1991;15:270-85.
 

Chapter VII
Interstitial laser coagulation with 
temporary hepatic artery occlusion for 
patients with cirrhosis and irresectable 
hepatocellular carcinoma
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ABSTRACT
Background: To determine the degree of local control of hepatocellular carcinoma 
(HCC) in patients with cirrhotic liver disease when treated with ultrasound guided
interstitial laser coagulation (ILC) with temporary hepatic artery occlusion.
Methods: Twenty-four HCC tumours in 16 patients were treated. Follow-up exami-
nation was by CT or MRI every 3 months. 
Results: Nineteen out of 24 tumours showed complete necrosis immediately after 
treatment. In these 19 lesions, there was no tumour recurrence during follow-up 
(mean 14 months, median 12 months). No e ect on liver function was observed after 
one week and there was no mortality. In 13 of 16 patients, new HCC foci developed 
at other sites.
Conclusion: Percutaneous ILC combined with temporary hepatic artery occlusion 
during a single session is e ective local treatment for HCC nodules < 5cm. However, 
new HCC lesions develop in the majority of patients and this underscores the need 
for adjuvant therapy or repeated treatment in these patients.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common cancers in men. Its 
world-wide annual incidence has been estimated to be 250.000 to 1 million 1 and 
more than 1 million death per year occur world-wide 2. In North America and several 
European countries, HCC is uncommon and the estimated death rate is less than 
5/100.000/year 3. In the Netherlands the incidence rates for liver cancer are among 
the lowest in the world 4. However, its incidence increases in low-endemic areas, 
as has been reported for the United Kingdom 5, France 6 and the United States 7. 
Surgery is the gold standard as a treatment for HCC, but a partial hepatectomy is 
only an option in up to 40% of patients 8. Several other treatment modalities have 
been developed 9, one of which is percutaneous interstitial laser coagulation (ILC). 
A few studies have reported that this procedure is virtually free of signi cant side-
e ects and an e ective treatment for patients with a nonresectable HCC 10-12. Further 
re nement is needed to achieve elimination of viable tumour cells at the tumour 
host interface. To enhance the e  ciency of ILC, experimental studies in a pig model 
found that if the blood ow to the liver was temporarily interrupted the coagulated 
area was larger than without occlusion13.
Based on these  ndings a prospective clinical study was initiated to assess the e ec-
tiveness of long-term local control after treatment with ILC with temporary hepatic 
arterial occlusion, in cirrhotic patients with HCC. 
PATIENTS AND METHODS
Patient characteristics
None of the patients could have surgical resection because of anatomical restric-
tions (after previous surgery) or medical co-morbidity. The inclusion criteria for 
treatment with ILC were comparable with the surgical criteria. Patients with extra 
hepatic disease, more than 3 nodules or a diameter larger than 5 cm were excluded. 
To undertake a percutaneous approach the tumours had to be visible on ultrasound 
and triple phase CT-scan. All patients had underlying histologically documented 
liver cirrhosis. Underlying liver cirrhosis or portal hypertension was accepted if there 
was no ascites and Thromboplastin Time was at least 20%, International Normalised 
Ratio: < 2. 
Treatment Technique
Three patients (= 5 lesions) were treated at laparotomy. The surgeon decided during 
operation that a resection was not possible. One patient was scheduled for a neph-
rectomy because of a Grawitz tumour and a hemihepatectomy because of HCC but 
because of the complicated nephrectomy, the surgeon selected for an ablation. The 
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remaining 13 patients (=19 lesions) were treated percutaneously. The patients were 
admitted to our hospital, one day before the procedure. They received low-molecular 
heparin 2500 IE subcutaneously. ILC was performed under general anaesthesia, and 
Heparin 5000 IE was administered intravenously. This was reversed with Protamine 
after the procedure. A single dose of 1500 mg Cefuroxim was given intravenously 
just prior the intervention. Analgesics were provided on request. ILC was performed 
using a neodymium-yttrium-aluminiumgranate laserlight (=1064nm;Laserscope; 
Santa Clara, Calif.,U.S). The power of the laserlight (6-20 W) and the time of expo-
sure (6-12 min) were determined before the procedure and were tumour-diameter-
dependent. In the experimental phase of this procedure on animals and resected 
liver specimen a reference table was constructed which combined the length of the 
 bertip, number of Watts and exposure time. One  ber (Cardiofocus), was enclosed 
in a transparent catheter and inserted into the tumour (3mm diameter; Powerap-
plicator; Somatex, Berlin, Germany). This catheter was irrigated with sterile saline 
to prevent carbonisation of the tip. The laser ber tip was placed centrally in the 
tumour, under ultrasound guidance. The femoral artery was punctured in the groin 
and an occlusion-balloon-catheter was placed in the common hepatic artery by the 
radiologist. Just prior to laser application the intra-arterial balloon was in ated to 
occlude the arterial  ow.
Follow-up
The safety of treatment with ILC was assessed at day 1 of clinical observation and 
monitored by routine laboratory tests, as previously reported 14. The e ectiveness 
in terms of local control was evaluated by means of triphasic, contrast-enhanced CT, 
 24 hours after the procedure and post-treatment follow-up was performed with 
triphasic, contrast-enhanced CT or MRI, every 3 months. The volume of the contrast-
enhanced tumour was compared with the volume on the CT before the intervention 
15,16. The part of tumour that had no contrast (compared with the  rst CT) was de ned 
as the avascular zone. This was classi ed according the group of Amin 15,16: Grade 1 
was 100% avascularity of the tumour (complete response), Grade 2: more than 50% 
avascularity and grade 3: less than 50% avascularity (Figure 1). The protocol was ap-
proved by the human study committee of the Erasmus Medical Centre
Table 1.  Characteristics of the study population undergoing ILC
Number 16 patients
Gender 15 male / 1 female
Age (median/range) in years 64 (50 – 70)
Child-Pugh Classi cations 10 Child-Pugh A
6 Child-Pugh B
No of Nodules 24
Size (median/range) in cm. 3.2 (2 - 6)
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RESULTS
Between May 1998 and January 2001, 16 patients were treated (see table 1). All but 
2 of the 24 lesions were smaller than 5 cm. All tumours had one treatment session, 
and in four patients two lesions were treated in one session. 
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a nodule diameter larger than 5 cm were excluded.
To undertake a percutaneous approach the tumours
had to be visible on ultrasonography and triple-phase
computed tomography (CT). All patients had underlying
histologically documented liver cirrhosis. Underlying liver
cirrhosis or portal hypertension was accepted if there was
no ascites and the thromboplastin time was at least 20 per
cent, with an international normalized ratio of less than 2.
Treatment
Three patients (five lesions) were treated at laparotomy.
The surgeon decided during operation that a resection was
not possible. One patient was scheduled for a simultaneous
nephrectomy (for aGrawitz tumour) and hemihepatectomy
(for HCC) but, because of the complicated nephrectomy,
the surgeon opted for hepatic ablation. The remaining
13 patients (19 lesions) were treated percutaneously.
The patients were admitted 1 day before the procedure.
They received low molecular weight heparin 2500
units subcutaneously. ILC was performed under general
anaesthesia, and heparin 5000 units was administered
intravenously. This was reversed with protamine after
the procedure. A single dose of cefuroxime 1500 mg
was given intravenously just before the intervention.
Analgesics were provided on request. ILC was performed
using a neodymium yttrium–aluminium–garnet laser
(wavelength 1064 nm; Laserscope, Santa Clara, California,
USA). The power of the laser (6–20 W) and the
exposure time (6–12 min) were determined before the
procedure and were dependent on the tumour diameter.
From previous experiments on animals and resected
liver specimens, a reference table was constructed
which combined the length of the fibre tip, power
and exposure time. One fibre (Cardiofocus
TM
; West-
Yarmouth, Massachusetts, USA) was enclosed in a
transparent catheter and inserted into the tumour (3 mm
diameter, Powerapplicator; Somatex, Berlin, Germany).
This catheter was irrigated with sterile saline to prevent
carbonization of the tip. The laser fibre tip was placed
centrally in the tumour, under ultrasonographic guidance.
The femoral artery was punctured in the groin and a
balloon catheter was placed in the common hepatic artery
by the radiologist. Just before application of the laser the
intra-arterial balloon was inflated to occlude the arterial
flow.
Follow-up
The safety of treatment with ILC was assessed on day 1 of
clinical observation and monitored by routine laboratory
tests, as reported previously14. The effectiveness in terms
of local control was evaluated by means of triphasic
contrast-enhanced CT, carried out 24 h before and after
the procedure. Follow-up was performed with triphasic
contrast-enhanced CT or magnetic resonance imaging
(MRI) every 3 months. The volume of the contrast-
enhanced tumour was compared with the volumemeasured
by CT before the intervention15,16. The part of tumour
that had no contrast (compared with the first scan) was
defined as the avascular zone. This was classified according
to Amin et al.15,16: grade I, 100 per cent avascularity of
the tumour (complete response); grade II, more than
50 per cent avascularity; and grade III, less than 50
per cent avascularity (Fig. 1). The protocol was approved
by the human study committee of the Erasmus Medical
Centre.
a  Grade I b  Grade II c  Grade III
Fig. 1 Typical computed tomograms of tumours according to Amin grade. a Grade I, 100 per cent avascularity; b grade II, more than
50 per cent avascularity; c grade III, less than 50 per cent avascularity (arrows show the induced coagulative necrosis)
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Fig. 1 Typical computed tomograms of tumours according to Amin grade. a Grade I, 100 per cent avascularity; b grade II, more than 50 per cent 
avascularity; c grade III, less than 50 per cent avascularity (arrows show the induced coagulative necrosis)
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Results
Between May 1998 and January 2001, 16 patients were
treated (Table 1). All but two of the 24 lesions were smaller
than 5 cm. All tumours had one treatment session, and in
four patients two lesions were treated in one session.
Table 1 Characteristics of the study population undergoing
interstitial laser coagulation
No. of patients 16
Sex ratio (M : F) 15 : 1
Age (years)* 64 (50–70)
Child–Pugh class
A 10
B 6
No. of nodules 24
Size (cm)* 3·2 (2–6)
*Values are median (range).
Complications
Pain at the puncture side was the most common
complication. No patient developed derangement of liver
function after ILC. Two patients experienced moderate
fever (38◦C) without a focus, which resolved within 2 days
without specific treatment.One patient had referred pain to
the right shoulder.One patient developed a pleural effusion
that required percutaneous drainage, which prolonged the
hospital stay. After 18 months this patient developed a
new HCC and was again treated successfully by ILC but
without complication.
Initial tumour response
Post-t eatment CT showed complete necrosis of the
t mour (grade I) in 19 of 24 nodules (Fig. 2). In three
tumours the treatment had no effect. In one of these
a  Before ILC b  Before ILC
c  24 h after ILC d  24 h after ILC
Fig. 2 Computed tomograms of two nodules of hepatocellular carcinoma in one patient. a and c Images obtained before interstitial laser
coagulation (ILC) with temporary hepatic artery occlusion. b and dNodules in a and c respectively 24 h after ILC with temporary
hepatic artery occlusion
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Fig. 2 Computed tomograms of two nodules of hepatocellular carcinoma in one patient. a and c Images obtained before interstitial laser 
coagulation (ILC) with temporary hepatic artery occlusion. b and d Nodules in a and c respectively 24 h after ILC with temporary hepatic artery 
occlusion
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Complications
Pain at the puncture side was the most common complication. No patient devel-
oped derangement of liver function after ILC. Two patients developed moderate 
fever (38 0C) without a focus. The temperature fell to normal within two days without 
speci c treatment. One patient had referred pain to his right shoulder. One patient 
developed a pleural e usion and this complication required percutaneous drainage, 
requiring prolonged hospital stay. After 18 months this patient developed a new 
HCC and he was again successfully treated by ILC without complication.
Initial tumour response 
Post-treatment CT showed a complete necrosis of the tumour (grade 1) in 19 out of 
24 nodules. An example of this is shown in Figure 2. In three tumours there was no 
e ect. In one session there was a false positioning of the tip of the ILC and in one 
session with two lesions the catheter broke because of a defect in the system and 
the session was halted after 5 minutes. The  rst patient mentioned was successfully 
treated by a second ILC session. The patient with two lesions refused another ILC ses-
sion and was therefore treated by percutaneous ethanol injection. On an intention 
to treat basis, excluding the invalid performed sessions, complete necrosis occurred 
in 19 out of 21 nodules. Two patients with two nodules > 5 cm. had a grade 2 e ect 
(>50% necrosis). Table 1 shows the e ect of ILC in relation to the diameter of the 
tumour. 
Long term control
In the 19 nodules with complete necrosis on CT scanning, no tumour recurrence 
was identi ed on follow-up CT scan/MRI or hepatectomy specimen (n=2) with a 
follow-up of 3 to 46 months and a mean of 14 months (median of 12 months). Eight 
patients died during follow-up and two patients underwent total hepatectomy and 
orthotopic liver transplantation. Thirteen patients developed new nodules and/or 
extrahepatic disease. Figure 3 shows the tumour free survival for patients who had 
Table 2.
Tumour diameter compared with initial e ectiveness 
(as measured 24 hours after ILC)
Tumour
Diameter
Amin-grade*
I II III
Total
< 3 cm 8 0 1 9 
3-4 cm 7 0 2 9 
> 4 cm 4 2 0 6 
Total 19 2 3 24 
*Amin gradation: Grade I : 100% avascularity, Grade II : >50% avascularity, 
Grade III : <50% avascularity (Figure 4 shows examples of Amin I-III).
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patients the coagulator tip was incorrectly positioned, and
in one patientwith two lesions the catheter broke because of
a defect in the system and the sessionwas halted after 5 min.
The former patient was treated successfully at a second ILC
session. The other patient refused further ILC treatment
and underwent percutaneous ethanol injection. On an
intention-to-treat basis, excluding the afore-mentioned
failed sessions, complete necrosis occurred in 19 of 21
nodules. Two patients, each with a lesion larger than 5 cm,
had a grade II effect (more than 50 per cent necrosis).
Table 2 Tumour diameter compared with initial effectiveness
measured 24 h after interstitial laser coagulation
Tumour
Amin grade*
diameter (cm) I II III Total
<3 8 0 1 9
3–4 7 0 2 9
>4 4 2 0 6
Total 19 2 3 24
*Amin grades: grade I, 100 per cent avascularity; grade II, more than
50 per cent avascularity; grade III, less than 50 per cent avascularity.
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Fig. 4 Kaplan–Meier survival curve for all patients treated with
interstitial laser coagulation
Table 2 shows the effect of ILC in relation to the diameter
of the tumour.
Long-term control
Among the 19 nodules with complete necrosis on CT,
no tumour recurrence was identified on follow-up CT or
MRI, or by examination of the hepatectomy specimen
(n = 2) after 3–46 months (mean 14 months, median
12 months). Eight patients died during follow-up and two
patients underwent total hepatectomy and orthotopic liver
transplantation. Thirteen patients developed new nodules
and/or extrahepatic disease. Fig. 3 shows the tumour-free
survival for patients who had complete necrosis after
treatment and Fig. 4 shows the overall survival of all
patients after ILC treatment.
Discussion
Because of the disadvantages of percutaneous ethanol
injection, alternative forms of percutaneous treatment
have been developed. Radiofrequency ablation and ILC
are the most widely used; both thermal methods induce
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patients the coagulator tip was incorrectly positioned, and
in one patientwith two lesions the catheter broke because of
a defect in the system and the sessionwas halted after 5 min.
The former patient was treated successfully at a second ILC
session. The other patient refused further ILC treatment
and underwent percutaneous ethanol injection. On an
intention-to-treat basis, excluding the afore-mentioned
failed sessions, complete necrosis occurred in 19 of 21
nodules. Two patients, each with a lesion larger than 5 cm,
had a grade II effect (more than 50 per cent necrosis).
Table 2 Tumour diameter compared with initial effectiveness
measured 24 h after interstitial laser coagulation
Tumour
Amin grade*
diameter (cm) I II III Total
<3 8 0 1 9
3–4 7 0 2 9
>4 4 2 0 6
Total 19 2 3 24
*Amin grades: grade I, 100 per cent avascularity; grade II, more than
50 per cent avascularity; grade III, less than 50 per cent avascularity.
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Among the 19 nodules with complete necrosis on CT,
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MRI, or by examination of the hepatectomy specimen
(n = 2) after 3–46 months (mean 14 months, median
12 months). Eight patients died during follow-up and two
patients underwent total hepatectomy and orthotopic liver
transplantation. Thirteen patients developed new nodules
and/or extrahepatic disease. Fig. 3 shows the tumour-free
survival for patients who had complete necrosis after
treatment and Fig. 4 shows the overall survival of all
patients after ILC treatment.
Discussion
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complete necrosis after treatment. Figure 4 shows the overall survival of all patients, 
after ILC treatment. 
DISCUSSION
Because of the disadvantages of percutaneous ethanol injection alternative forms 
of percutaneous treatment have been developed, with RF and ILC being the most 
widely used. Both thermal methods induce a reproducible volume of necrosis 17-19. 
RF has the disadvantage that it needs relatively large bore needles (14-17 G in diam-
eter) and these are less handy than the  ne needles that can be used for ILC (21-22 
G in diameter), as previous described by Giorgio et al.11. Also, RF needles are more 
expensive than ILC needles 11. Another advantage of ILC is that ILC is MRI compatible, 
so real time monitoring is possible. 
ILC has mainly been described to treat patients with liver metastases from ad-
enocarcinoma and HCC 10,11,15. Because almost all patients with HCC treated with a 
percutaneous ablation method have underlying liver cirrhosis, these groups must 
be separated in the evaluation ILC (or any other percutaneous ablation method). 
Because it has been suggested that tumour necrosis is facilitated by the surrounding 
cirrhotic tissue, resulting in larger ablations than would be expected 20. In addition, 
the residual capacity of the liver after percutaneous ablation may di er between 
cirrhotic patients and those with an otherwise normal liver. 
Three previous studies described the treatment of HCC by ILC but none used tem-
porary hepatic arterial occlusion. Cristophi and Muralidharan 12 described 8 patients 
with 18 lesions of HCC, with a size range of 3 – 7 cm. They had a 72% control of 
tumour size during follow-up. Vogl et al 10 in their large series of 1914 lesions in 676 
patients, included 16 patients with HCC lesions smaller than 5 cm. The results of 
the treated HCC lesions are not separately described in the article but in the whole 
group there was no local recurrence of tumour. Giorgio et al 11 published the largest 
series of 77 patients with 104 HCC nodules with a diameter range of 1-6.6 cm., mean 
3.2 cm. During follow-up (mean 4.5 months) one recurrence occurred and in no case 
was intra-hepatic recurrence in di erent segments observed. Good local control 
of the tumour after ILC was also seen in the present series but in almost all cases 
new intra-hepatic recurrences occurred. An explanation for this striking di erence 
is the relatively short follow-up, and the aetiology of the liver disease with multiple 
dysplastic nodules. Another explanation might be that post-treatment follow-up of 
patients was performed with US of the liver. The present study routinely used triple 
phase CT scans and dynamic contrast-enhanced MRI in these patients. Catalano et al 
21 found that at least half the HCC recurred after percutaneous ablation therapy, de-
spite initial imaging and biopsy proven evidence of successful ablation 21-23. Others 
reported even higher recurrence rates of 81% 24 and 96% 25. Because of the probably 
ILC in HCC 81
inferior quality of US as an imaging method after ablation the present local control 
e ect after ILC with temporary arterial occlusion can not be compared with the re-
sults of the group Giorgio et al. 11 without temporary arterial occlusion. 
The problem of subcutaneous seeding after diagnostic puncture of the liver in pa-
tients with HCC has been described 26. Llovet et al 27 described neoplastic seeding 
in 12.5% patients with HCC after percutaneous RF ablation with cooled-tip needle. 
However, Livraghi 28 described in a series of 330 patients with 605 HCC lesions, only 
0.6% neoplastic seeding. In the present study no patient had subcutaneous seeding. 
It is although reasonable to assume that a single session with one  ber minimizes the 
risk of complications (needle tract tumours and bleeding). The present data suggest 
that if temporary arterial occlusion was applied, a single session with one  ber was 
su  cient for tumours up to 5 cm. The major factor limiting the size of the thermal 
injury produced by ILC is hepatic perfusion. Various previous studies have shown 
preservation of viable cells surrounding larger vessels after ILC. The cells probably 
survive as the result of the cooling e ect provided by the blood  ow 29-31. In experi-
mental studies 13,32 hepatic in ow substantially reduces the size of lesion produced 
by ILC. In patients with severe liver cirrhosis, there is almost no portal circulation, and 
there may be even a retrograde  ow 33. 
Vogl et al10 have published the largest group of patients treated with ILC and found 
the same percentage of complications. Pleural e usion was observed in 8% and in 
33% of the patients they observed a temperature up to 38.4 0C. Pleural e usion can 
be a complication of the heating of normal structures adjacent to the tumour, in this 
case the pleural layers. 
A single session of ILC with temporary hepatic artery occlusion results in good local 
control of small HCC nodules (< 5cm.) in patients with cirrhotic liver disease. How-
ever, the development of new liver lesions in 81% of patients stresses the need for 
adjuvant therapy or repeated sessions in these patients. 
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ABSTRACT
Background: The aims of this study were to assess the technical e ectiveness of 
radiofrequency (RF) ablation in patients with primary or secondary hepatic malig-
nancies, and to determine survival and complication rates.
Methods: This was a retrospective analysis of prospectively collected data of patients 
treated with RF-ablation and controlled for recurrence every 3 months by contrast 
enhanced computed tomography, or magnetic resonance imaging. The outcome is 
compared with a comprehensive review of data published in recent literature.
Results: Forty-seven patients underwent 50 RF-sessions for the ablation of 73 tu-
mors. Local tumor progression was observed in 11 patients (23%). A tumor sized 
larger than 30 mm, a tumor load larger than 14 cm3, and a percutaneous approach 
were associated with a faster time to local tumor progression. At the end of a mean 
(± SD) follow-up period of 11.4 ± 7.5 months, 39 patients (83%) were alive, including 
eight patients with recurrent disease. The overall cumulative survival rates at 12 and 
24 months were 87% and 70%, respectively. 
Conclusion: In our center, RF-ablation can be safely performed to achieve adequate 
local control and survival rates. Time to local tumor progression was signi cantly 
related to initial size of the tumor and tumor load.
RFA in livertumors 87
INTRODUCTION
Colorectal cancer (CRC) is a major cause of cancer related death in Europe. The cu-
mulative lifetime risk in the Western world is approximately 5%, the incidence rate 
is 50/100,000. Nearly 50% of patients with colorectal carcinoma either have liver 
metastases at presentation (15-25%) or will subsequently develop them (20%)1, 2. 
Without any treatment, the median survival after the detection of liver metastases 
is less than a year, depending on the extent of the disease at the time of diagnosis3, 
4. In contrast, resection of liver metastases from colorectal origin is associated with 
a 5-year survival rate of 30-50%, depending on the extent of liver involvement and 
provided that all disease can be removed safely4. Unfortunately, only 10-25% of the 
patients with colorectal liver metastases are amenable for liver resection, either be-
cause of tumor location, comorbidity or insu  cient hepatic reserve5, 6.
Hepatocellular carcinoma (HCC) is the  fth most common cancer in the world and 
the third most common cause of cancer mortality1. In North America and in several 
European countries as well as in the Netherlands, HCC is uncommon with an inci-
dence rate of less than 5/100,000 and a mortality rate of less than 5/100,0001, 2. An 
increase of the incidence in low-endemic areas has been reported for the United 
Kingdom, France and The United States7-9. In contrast, Verhoef et al recently did not 
 nd any rising trend for the Netherlands10. In the last 10 years screening programs 
have resulted in a relative increase in the number of resectable cases, and the ab-
solute number of resectable cases has increased as well. Surgical resection is the 
golden standard of therapy and appears to be the only e ective way, aside from liver
transplantation, to alter survival. However, due to advanced or decompensated liver 
cirrhosis, co-morbidity and multifocality of the tumors, only 10-37% of the patients 
with HCC are considered to be candidates for surgical resection11, 12.
Thus, in approximately 80% of both patients with CRC and HCC, a partial liver re-
section is not possible and interest in other treatment modalities is growing. In our 
center, several locoregional treatment modalities have been studied, including iso-
lated liver perfusion13, interstitial laser coagulation14, and radiofrequency ablation 
(RF-ablation). RF-ablation has several potential advantages over the other therapies, 
o ering more comfort, less morbidity and severity due to its potential for minimal 
invasive application. Other advantages are reduced hospital stays (1-2 days), re-
duced costs, and the possibility of repeated treatment. To evaluate the outcome of 
RF-ablation in the treatment of primary and secondary hepatic malignancies at our 
department, we reviewed our records.
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PATIENTS AND METHODS
We performed a retrospective analysis of data collected prospectively at the Eras-
mus MC - University Medical Center Rotterdam, The Netherlands, a tertiary refer-
ral hospital experienced in the  eld of interventional radiology. From July 2002 to 
December 2005 radiofrequency ablation was used to treat a total of 73 tumors in 47 
consecutive patients with a primary or secondary hepatic malignancy. Assignment 
to RF-ablation and choice of treatment approach was determined by our institu-
tion’s weekly multidisciplinary liver meeting, including the opinion of the interven-
tion radiologist, the surgeon, the oncologist and the hepatologist. In our center RF-
ablation was performed percutaneously, or as part of an open surgical procedure. 
A percutaneous approach was used whenever possible, but when the tumor was 
poorly visualised on US, or when the tumor was located in the high dome of the 
liver or near the liver capsule where percutaneous treatment could produce thermal 
injury to an adjacent visceral organ, ablation was performed via laparotomy. Also, 
some patients underwent a combined surgical hepatic resection and RF-ablation to 
treat multiple and bilobar disease.
All patients treated with RF-ablation were deemed to have unresectable hepatic 
disease based on tumor multifocality, the presence of advanced stage of cirrhosis 
with inadequate functional parenchymal reserve, high surgical risk, or surgical re-
fusal. Tumors should be detectable by (intra-operative) ultrasound (US) and contrast 
enhanced spiral computed tomography (CT) or magnetic resonance imaging (MRI), 
and informed consent from the patient should be obtained. Patients were excluded 
if they had extrahepatic disease, uncontrollable ascites, tumor invasion of or a posi-
tion too close to larger vessels or bile ducts, a life expectancy below six months, 
Child-Pugh C liver cirrhosis, a thromboplastin time below 40%, or a blood platelet 
count less than 50,000/µL. Baseline evaluation included a history and physical ex-
amination, serum laboratory tests, and imaging with US and contrast enhanced CT 
or MRI.
Technique
RF-ablation was performed primarily by an interventional radiologist under general 
anaesthetics. A 17-gauge internally cooled single or cluster RF electrode (Radionics, 
Burlington, Massachusetts, USA) was introduced into the hepatic malignancies by 
ultrasound guidance. The RF electrodes were attached to a 480-kHz RF generator 
(Radionics Cool-tipTM RF system, Burlington, Massachusetts, USA) capable of produc-
ing 200 W of power. During the procedure the applied current, power output, and 
tissue impedance were monitored constantly. After RF exposure, the cooling system 
was stopped to measure the local tissue temperature with the electrode tip. When 
temperature exceeded 60 ˚C, the ablation was considered adequate. At the end of 
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the procedure, the generator was reactivated as the RF-electrode was withdrawn to 
ablate the needle track and prevent tumor seeding. 
Follow-up
Within 24 hours, a contrast enhanced CT was performed to assess any possible com-
plications which might necessitate longer hospitalisation. The e ectiveness in terms 
of local control was evaluated by means of triphasic contrast enhanced CT, carried 
out 6 weeks after the RF-procedure. Follow-up included imaging with contrast 
enhanced CT, or MRI when the treated lesions were not easily detected, as well as 
monitoring of the tumor-speci c tumor markers α-fetoprotein (AFP) or carcinoem-
bryonic antigen (CEA), every three months. 
De nitions and statistical analysis
To assess the treatment e ectiveness local tumor progression was scored, compris-
ing both incompletely ablated tumor tissue (local failure) as well as progression of 
initially completely ablated tumors con rmed by contrast-enhanced CT or MRI. The 
local failures where included to avoid bias, because of the impossibility to di erenti-
ate between incompletely ablated tumor tissue that continued to grow, and new tu-
mor foci growing at the original ablated site. Tumor size was scored in 3 dimensions 
to calculate an estimate of the tumor volume by using the equation for an ellipsoid 
(volume = 4/3pi (x/2) (y/2) (z/2)). The 30 mm cut-o  point for tumor size corresponds 
to a 14 cm3 limit for tumor load per patient. Tumor load was de ned as the sum of 
tumor volume per patient.
Time to  rst local tumor progression or time to death for each patient was modelled 
with a Kaplan-Meier survival analysis15. To avoid bias, the date of last imaging was 
used as the cut-o  point for censoring patients. When a patient received radiothera-
py at the initial ablation site, or chemotherapy in addition to an earlier ablation pro-
cedure, we considered the patient censored. Censoring was assumed independent 
to patient prognosis. If a patient had more than one tumor, only the largest tumor 
in diameter was included in the analysis so that each patient contributes only one 
observation to the data, and the sample size did not become incorrectly in ated due 
to repeated measurements within patients. If an ablated tumor showed local tumor 
progression, all of patients’ other tumors were considered censored in this measure 
at that time. 
Distribution of survival time and time to local tumor progression or death were ana-
lyzed in relation to the di erent variables collected. Univariate tests (Log Rank) were 
used to test for di erences in these distributions by any single factor. The factors 
that solely appeared to have a signi cant impact were selected for entrance into 
a Cox proportional hazards model in order to analyze their e ect on survival while 
adjusting for each other16. A backward elimination procedure was used for further 
covariate selection in the Cox proportional hazards model.
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Student’s t-test was used to perform pair wise comparisons between continuous 
variables. Categorical variables were tested using Fisher’s Exact Test, or Pearson Chi-
square test. Signi cance was determined at the 95% con dence interval (95% CI, P < 
0.05). All data were collected in a computerized Microsoft Excel® database (Microsoft 
Inc., Redmond, Washington, USA). The analysis was performed using SPSS® (version 
11.5) for Windows (SPSS Inc., Chicago, Illinois, USA) statistical software. 
Review
To compare our data with the state of the art, a review was performed by searches 
in PubMed using the search terms “radiofrequency ablation”, “colorectal liver metas-
tases”, “hepatocellular carcinoma”, and “liver cancer”. Reviews, letters, case reports, 
editorials, and articles not written in English were excluded. Because research and 
improvements on RF-ablation are rapidly evolving, we excluded papers published 
before January 2000 to make a fair comparison. Manual cross-referencing was done 
based on the bibliography of studies identi ed in the original searches. Papers were 
excluded if they were duplicate publications or involved the treatment of 24 patients 
or fewer.
RESULTS 
Patient and tumor characteristics
Between July 2002 and October 2005, 47 consecutive patients underwent abla-
tion for 73 primary and secondary hepatic malignancies. Of these, 30 (64%) were 
men and 17 (36%) were women, with a mean (± SD) age of 60.7 ± 12.0 years (range, 
32.8-81.2 years). Hepatocellular carcinoma was diagnosed in 22 patients and col-
orectal liver metastases in 21 patients, of whom 17 received chemotherapy prior to 
the RF treatment (90% were responder). Four patients were diagnosed with either a 
gastrinoma, medullar thyroid carcinoma, carcinoid cancer or adrenal cell carcinoma. 
Fifty ablations were performed via 27 ultrasound-guided percutaneous procedures 
and 23 intra-operative procedures. Fifteen of them were treated in combination 
with simultaneous partial liver resection, cholecystectomy to prevent gallbladder 
damage, or both. Three patients underwent a sequential ablation for either remnant 
tumor tissue (2) or intra-hepatic progressive liver disease (1).
Of the 73 treated tumors, 31 (42%) were HCC and 32 (44%) were metastases from 
malignancies of the colon and rectum. Other metastatic tumors included four adre-
nal cell carcinomas, three gastrinomas, two medullar thyroid carcinomas, and one 
carcinoid tumor. RF-ablation was used to treat an average of 1.6 tumors per patient 
(range, 1-4) with a mean (± SD) size of 22 mm ± 12 mm (range, 6-80 mm). The average 
(± SD) hospital stay was 1.3 ± 0.8 days (median, 1day; range, 0-4 days) for patients 
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treated percutaneously, and 12.4 ± 9.1 days (median, 11days; range, 5-36 days) for 
patients treated in combination with resection. 
Local tumor progression
Post-treatment contrast enhanced spiral CT at 6 weeks showed complete ablation 
in 44 of 47 patients (94%) and in 70 of 73 tumors (96%). In 2 of 3 patients with re-
sidual viable tumor tissue a sequential ablation was performed, showing complete 
response on post-treatment imaging. 
During a mean (± SD) follow-up period of 11.4 ± 7.5 months (range, 4-35 months), 
11 of 47 patients (23%) developed local tumor progression con rmed by contrast-
enhanced CT or MRI. Demographics of patients in which local control was achieved, 
or who developed a local tumor progression, are shown in Table 1. Mean (± SD) actu-
arial survival time until local tumor progression was 26 ± 2.3 months (95% CI: 22-31 
months). The median time until local tumor progression occurred was not measur-
able with the Kaplan-Meier method due to the small number of events observed. 
However, the Kaplan-Meier estimated local tumor progression rate at 6 months 
for all patients was 24%. Only one local tumor progression was observed after six 
months (10 months). Time to local tumor progression, strati ed by tumor histology 
showed no signi cant di erences (Fig. 1).
When tumor size was treated as a continuous variable, Cox regression showed that 
time to local tumor progression was signi cantly related to size of the tumor with a 
hazard ratio (HR) of 1.071 and a 95% CI of 1.024-1.120 (P = 0.002). Strati ed by HCC 
and metastatic tumors, Cox regression showed a signi cant relation between time to 
local tumor progression and tumor size with a hazard ratio (HR) of 1.065 and a 95% CI 
of 1.016-1.116 (P = 0.009). Having a tumor sized larger than 30 mm was signi cantly 
was achieved or who developed a local tumor pro-
gression are shown in Table 1. Mean (6 SD) actuar-
ial survival time until local tumor progression was 26
6 2.3 months (95% CI, 22–31 months). The median
time until local tumor progression occurred was not
measurable with the Kaplan-Meier method due to
the small number of events observed. However,
the Kaplan-Meier estimated local tumor progression
rate at 6 months for all patients was 24%. Only one
local tumor progression was observed after 6 months
(10 months). Time to local tumor progression strat-
ified by tumor histology showed no significant
differences (Fig. 1).
When tumor size was treated as a continuous
variable, Cox regression showed that time to local
tumor progression was significantly related to size
of the tumor, with a hazard ratio (HR) of 1.071
and a 95% CI of 1.024–1.120 (P 5 0.002). Stratified
by HCC and metastatic tumors, Cox regression
showed a significant relationship between time to lo-
cal tumor progression and tumor size, with a HR of
1.065 and a 95% CI of 1.016–1.116 (P 5 0.009).
Having a tumor sized larger than 30 mm was signif-
icantly associated (P 5 0.0284) with a faster time to
local tumor progression, with a HR of 3.831 and
a 95% CI of 1.153–12.736. Survival curves for pa-
tients until local tumor progression occurred, strat-
ified by tumor diameter, are shown in Fig. 2. Both
curves are statistically significant from each other,
with a log-rank statistic of 5.53 (1 df ) and a P value
of 0.0187.
Tumor load per patient was also significantly re-
lated to local tumor progression, with a HR of 1.040
and a 95%CI of 1.012–1.069 (P5 0.0052). Again, af-
ter stratification by HCC and metastatic tumors, Cox
regression showed a significant relationship between
tumor load per patient and local tumor progression,
with a HR of 1.040 and a 95% CI of 1.012–1.069
(P 5 0.0052). Patients with a tumor load larger than
14 cm3 significantly developed (P5 0.0459) an earlier
local tumor progression, with a HR of 3.366 and
a 95% CI of 1.022–11.079. The survival curves that
are not shown were significantly different, with a
log-rank statistic of 4.49 (1 df ) and a P value of 0.0341.
Increasing AFP and CEA levels during follow-up
were significantly associated with local tumor pro-
gression in patients with HCC (OR 15.000; P 5
0.023) and CRC (OR 13.333; P 5 0.047), respec-
tively (Table 2). Tumor markers were obtained in
all patients diagnosed with HCC; however, in three
patients with CRC, the CEA level was not measured
at baseline. None of these three patients developed
a local recurrence.
Survival
At the end of follow-up, six patients (13%) had
died of progressive disease and 41 patients (87%)
Table 1. Comparison of demographics and baseline characteristics of patients with or without
local tumor progression
Local control
(n 5 36)
Local tumor
progression (n 5 11) P value
Age in years (mean 6 SD) 59.5 6 12.9 64.5 6 7.9 0.133* (NS)
Sex ratio (male:female) 24:14 6:3 0.486* (NS)
Number of tumors 62 11
Number of tumors per patient (mean 6 SD) 1.6 6 1.0 1.5 6 1.2 0.753* (NS)
Tumor histology of patients (tumors) 0.495† (NS)
HCC 16 (25) 6 (6)
CRC 16 (27) 5 (5)
Other 4 (10) 0 (0)
RF approach 0.036‡
Percutaneous 15 9
Open 21 2
Index tumor size in mm (mean 6 SD) 20 6 9.1 32 6 19 0.001*
Mean (6 SD) tumor volume in cm3 8.2 6 11 26 6 43 0.029*
Index AFP count in mg/L (mean 6 SD) 433 6 830 2112 6 3452 0.084* (NS)
Index CEA count in mg/L (mean 6 SD) 27.4 6 39.3 10.7 6 10.5 0.181* (NS)
AFP 5 a-fetoprotein; CEA 5 carcinoembryonic antigen; NS 5 not significant.
*Student’s t-test.
†Pearson chi-square test.
‡Fisher’s exact test.
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Table 1. Comparison of demographics and baseline characteristics of patients with or without local tumor progression
P 5 a-fetoprotein; CEA 5 carcinoembryonic ant ge ; NS 5 not signi cant.
*Student’s t-test.
†Pearson chi-square test.
‡Fisher’s exact test.
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were alive, including eight patients in which local tu-
mor progression was observed. Mean (6 SD) actuar-
ial survival time until death was 286 2.8months, with
a 95% CI of 23–34 months, and is shown in Fig. 3.
Again, the median time was not yet reached. The
overall cumulative survival rates at 12 and 24 months
were 87%and 70%, respectively. Fig. 3 also shows the
overall survival stratified by tumor histology. Differ-
ences in survival were not statistically significant,
with a P value of 0.0831 (log-rank 5 3.00, 1 df ).
Fig. 1. Time to local tumor progression by number of patients, stratified by tumor histology.
Fig. 2. Time to local tumor progression by number of patients, stratified by tumor diameter.
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Figur  2 Time to local tumor progression by num er of patients, strati ed by tumor diameter
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a 95% CI of 23–34 months, and is shown in Fig. 3.
Again, the median time was not yet reached. The
overall cumulative survival rates at 12 and 24 months
were 87%and 70%, respectively. Fig. 3 also shows the
overall survival stratified by tumor histology. Differ-
ences in survival were not statistically significant,
with a P value of 0.0831 (log-rank 5 3.00, 1 df ).
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associated (P = 0.0284) with a faster time to local tumor progression with a HR of 
3.831 and a 95% CI of 1.153-12.736. Survival curves for patients until local tumor 
progression occurred strati ed by tumor diameter are shown in Fig 2. Both curves 
di er statistically signi cant from each other with a Log Rank statistic of 5.53 (1 df ) 
and a P-value of 0.0187.
Tumor load per patient was also signi cantly related to local tumor progression with 
a HR of 1.040 and a 95% CI of 1.012-1.069 (P = 0.0052). Again, after strati cation by 
HCC and metastatic tumors, Cox regression showed a signi cant relation between 
tumor load per patient and local tumor progression with a HR of 1.040 and a 95% CI 
of 1.012-1.069 (P = 0.0052). Patients with a tumor load larger than 14 cm3 signi cantly 
developed (P = 0.0459) an earlier local tumor progression with a HR of 3.366 and a 
Complications
In six patients (13%), a minor complication oc-
curred, requiring no intervention or extension of
hospital stay. Three patients developed some ascites,
and in three other patients a small intrahepatic he-
matoma was found at the postintervention spiral
CT. No major complications were observed, nor
was any mortality related to the RF procedure.
DISCUSSION
Reports in the literature on the use of RF ablation
are increasing. Although many favorable reports
have encouraged the use of RF by both surgeons
and radiologists, we do not advocate RF ablation as
an alternative but rather as an adjunct to hepatic
resection, which remains the golden standard for
the treatment of hepatic malignancies. In our study,
RF ablation was used as an adjunct to resection in 15
procedures. Eight patients were abl ted during lapa-
ro omy, and percutaneous RF ablation was the pri-
mary procedure in the remaining patients, who
were poor candidates for surgery. It is essential
that the technique of RF ablation should be opti-
mized before proper comparison with surgical resec-
tion can be initiated. One of the main issues to be
addressed is the completeness of ablation, which
was the primary endpoint in our study.
We observed a patient-based local tumor progres-
sion rate of 23% and a tumor-based local tumor pro-
gression rate of 15%. Compared with studies in
patients with both primary and secondary hepatic ma-
lignancies in prior literature, our results showed a few
Table 2. Correlation between increasing tumor markers and onset of local recurrence
Local tumor progression
No. Yes Odds Ratio P value 95% CI
HCC AFP decreased 12 1 (ref) 0.023* 1.325–169.870
AFP increased 4 5 15.000
CRC CEA decreased 10 1 (ref) 0.047* 1.048–169.557
CEA increased 3 4 13.333
Total Marker decreased 23 2 (ref) 0.001* 2.569–85.107
Marker increased 7 9 14.786
Ref [ reference.
*Fisher’s exact test.
Fig. 3. Overall survival by number of patients, stratified by tumor histology.
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Figure 3 Time to local tumor progression by number of patients, strati ed by tumor histology
Complications
In six patients (13%), a minor complication oc-
curred, requiring no intervention or extension of
hospital stay. Three patients developed some ascites,
and in three other patients a small intrahepatic he-
matoma was found at the postintervention spiral
CT. No major complications were observed, nor
was any mortality related to the RF procedure.
DISCUSSION
Reports in the literature on the use of RF ablation
are increasing. Although many favorable reports
have encouraged the use of RF by both surgeons
and radiologists, we do not advocate RF ablation as
an alternative but rather as an adjunct to hepatic
resection, which remains the golden standard for
the treatment of hepatic malignancies. In our study,
RF ablation was used as an adjunct to resection in 15
procedures. Eight patients were ablated during lapa-
rotomy, and percutaneous RF ablation was the pri-
mary procedure in the remaining patients, who
were poor candidates for surgery. It is essential
that the technique of RF ablation should be opti-
mized before proper comparison with surgical resec-
tion can be initiated. One of the main issues to be
addressed is the completeness of ablation, which
was the primary endpoint in our study.
We observed a patient-based local tumor progres-
sion rate of 23% and a tumor-based local tumor pro-
gression rate of 15%. Compared with studies in
patients with both primary and secondary hepatic ma-
lignancies in prior literature, our results showed a few
Table 2. Correlation betwe n increasing tumor markers and onset of local recurrence
Local tumor progression
No. Yes Odds Ratio P value 95% CI
HCC AFP decreased 12 1 (ref) 0.023* 1.325–169.870
AFP increased 4 5 15.000
CRC CEA decreased 10 1 (ref) 0.047* 1.048–169.557
CEA increased 3 4 13.333
Total Marker decreased 23 2 (ref) 0.001* 2.569–85.107
Marker increased 7 9 14.786
Ref [ reference.
*Fisher’s exact test.
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Table 3 Results of studies using RF as a treatment modality for hepatocellular carcinoma.
Hepatocellular carcinoma (HCC)
origin
approach
tum       
[pts]
tumor size
(in mm)
follow-up 
time 
(in months)
local tumor 
progression
survival 
rates
complications
Livraghi38
Radiology
2000
Italy
HCC
perc: all
126    
[114]
mean: 
1.1
range: 
1-3
mean: 54
range: 31-95
mean: 10.2
range: 5-30
pts: -
tum: 66 (52)
1 yr: -
2 yr: -
3 yr: -
minor: 5 (4.4)
major: 2 (1.8)
death: 1 (0.9)
total: 8 (7.0)
Curley28
Ann Surg
2000
Italy & USA
HCC
perc: 76
lap: 31
open: 3
149    
[110]
mean: 
1.4
range: 
1-4
perc: 
  mean: 28±8
open:
  
mean:46±17
median: 19
range: -
pts: 4 (3.6)
tum: -
1 yr: -
2 yr: -
3 yr: -
minor: 7 (6.4)
major: 7 (6.4)
death: 0 (0)
total: 14 (13)
Buscarini27
Eur Radiol
2001
Italy
HCC
perc: all
101      
[88]
mean: 
1.1
range: 
1-3
All ≤35
mean: 34
range: 2-73
pts: 12 (14)
tum: -
1 yr: 89
3 yr: 62
5 yr: 33
median: 
48mo
minor: 14 (16)
major: 2 (2.3)
death: 0 (0)
total: 16 (18)
Guglielmi37
Hepatogastroenterol
2003
Italy
HCC
perc: all
65        
[53]
mean: 
1.2
range: -
mean: 40±13
range: 10-70
mean: 18
range: 8-41
pts: -
tum: 4 (6.2)
1 yr: 87
2 yr: 63
3 yr: 45
minor: 11 (21)
major: 0 (0)
death: 0 (0)
total: 11 (21)
Harrison30
J Am Coll Surg
2003
USA
HCC
perc: 46
open: 4
54        
[50]
mean: 
1.1
range: 
1-2
median: 35
range: 
10-120
median: 16
range: 1-28
pts: 18 (36)
tum: -
1 yr: -
2 yr: -
3 yr: -
minor: -
major: -
death: -
total: -
Giovannini29
J Gastrointest Surg
2003
France
HCC
perc: all
71        
[56]
mean: 
1.3
range: 
1-3
mean: 41
range: 8-60
mean: 20
range: 6-36
pts: 8 (14)
tum: -
1 yr: 96
2 yr: 94
3 yr: 94
mean: 36mo
minor: 2 (3.6)
major: -
death: -
total: 2 (3.6)
Choi36
Radiology
2004
Korea
HCC
perc: all
53        
[45]
mean: 
1.2
range: 
1-2
mean: 21
range: 8-40
mean: 23
range: 10-40
pts: -
tum: 11 (21)
1 yr: 82
2 yr: 72
3 yr: 54
minor: -
major: -
death: -
total: -
Lam31
Br J Surg
2004
China
HCC
perc: 18
open/lap: 33
70        
[51]
mean: 
1.4
range: -
<30: 25 pts
30-50: 17 pts
>50: 9 pts
mean: -
range: -
pts: 18 (35)
tum: - 
1 yr: 73
1½  yr: 61
2 yr: -
minor: -
major: -
death: 1 (2.0)
total: -
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95% CI of 1.022-11.079. The survival curves which are not shown were signi cantly 
di erent with a Log Rank statistic of 4.49 (1 df ) and a P-value of 0.0341.
Increasing AFP and CEA levels during follow-up were signi cantly associated with 
local tumor progression in patients with HCC (OR 15.000, P = 0.023) and CRC (OR 
13.333, P = 0.047), respectively (Table 2). Tumor markers were obtained in all patients 
Hepatocellular carcinoma (HCC)
origin
approach
tum       
[pts]
tumor size
(in mm)
follow-up 
time 
(in months)
local tumor 
progression
survival 
rates
complications
Vivarelli33
Ann Surg Oncol
2004
Italy
HCC
perc: all
-           
[79]
mean: -
range: -
≤30: 22 pts
>30: 57 pts
mean: 
15.6±11.7
range: -
pts: 12 (15)
tum: - 
1 yr: 78
2 yr: -
3 yr: 33
minor: -
major: -
death: 0 (0)
total: - 
Xu39
Clin Radiol
2004
China
HCC
perc: 43
microwave:    
  54
190       
[97]
mean: 2
range: 
1-5
mean: 25±12
range: 9-88
mean: 27.4
range: 2-53
pts: -
tum: 18 (9.5)
1 yr: 76
2 yr: 59
3 yr: 50
mean: 32mo
minor/major: 
9 (9.0)
death: 1 (1.0)
total: 10 (10)
Lin35
Gastroenterology
2004
Taiwan
HCC
perc: all
69         
[52]
mean: 
1.3
range: 
1-3
mean: 29±8
range: 10-40
mean: 
24.5±11.3
range: -
pts: 7 (14)
tum: 8 (12)
1 yr: 90
2 yr: 82
3 yr: 74
minor/major: 
4 (7.7)
death: 0 (0)
total: 4 (7.7)
Tateishi32 §
Cancer 
2005
Japan
HCC
perc: 
2140   
[664]
mean: 
3.2
range: -
mean: 26
range: 8-97
median: 
27.6
range: 
2.0-61
2.4% at a 
median 
follow-up of 
19 months 
1 yr: 95
2 yr: 86
3 yr: 78
4 yr: 67
5 yr: 54
minor: 17 (2.6)
major: 40 (6.0)
death: 0 (0)
total: 57 (8.6)
Lencioni34
Radiology
2005
Italy
HCC
perc: all
240     
[187]
mean: 
1.3
range: 
1-3
mean: 28±7
range: 15-50
mean: 
24±21
range: 3-78
pts: 38 (20)
tum: 41 (17)
1 yr: 97
2 yr: 89
3 yr: 71
4 yr: 57
5 yr: 48
median: 57 
minor: 9 (4.8)
major: 3 (1.6)
death: 0 (0)
total: 12 (6.4)
De Meijer
Current study
2005
The Netherlands
HCC
perc: 15
open: 7 
31        
[22]
mean: 
1.4
range: 
1-4
mean: 31±16
range: 14-80
mean: 
10±9.5
range: 2-35
pts: 6 (27)
tum: 6 (19)
1 yr: 79
2 yr: -
3 yr: -
minor: 3 (14)
major: 0 (0)
death: 0 (0)
total: 3 (14)
- = not given   /   tum = tumor(s)   /   pts = patient(s)   /   yr = year(s)   /   mo = month(s)
perc = percutaneous   /   open = intra-operative   /   lap = laparoscopic   /   microwave = microwave ablation 
Numbers in parentheses refer to percentages.
§  for the analysis of local recurrence and survival rates, only patients who received RF-ablation as the initial treatment for HCC where included. 
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Table 4 Results of studies using RF as a treatment modality for colorectal liver metastases.
Colorectal carcinoma liver metastases (CRC)
origin
approach
tum       
[pts]
tumor size
(in mm)
follow-up 
time 
(in months)
local tumor 
progression
survival 
rates
Complications
Solbiati43
Radiology
2001
Italy
CRC
perc: all
chemo: 84
179     
[117]
mean: 
1.5
range: 
1-4
mean: 
28±12
range: 6-96
mean: -
range: 6-52
pts: 64 (55)
tum: 70 (39) 
1 yr: 93
2 yr: 69
3 yr: 46
median: 
36mo
minor: 1 (0.9)
major: 1 (0.9)
death: 0 (0)
total: 2 (1.7)
Cheng47
Surg Endosc
2003
USA
CRC:
lap: all
chemo: 15
-            
[20]
mean: 
2.1±1.2
range: -
≤40: 14 pts
>40: 6 pts
mean: 
11.5±7.8
range: 1-38
pts: -
tum: -
1 yr: -
2 yr: -
3 yr: -
mean: 
25±3.4
minor: -
major: 0 (0)
death: 0 (0)
total: 0 (0)
Livraghi42
Cancer
2003
Italy
CRC
perc: all
chemo: 70
134       
[88]
mean: 
1.5
range: 
1-3
mean: 21
range: 6-40
median: 28
range: -
pts: 35 (40)
tum: 49 (37)
1 yr: -
2 yr: -
3 yr: -
minor: 2 (2.3)
major: 1 (1.1)
death: 0 (0)
total 3 (3.4)
Oshowo46
Br J Surg
2003
UK
CRC
perc: all
chemo: 
22
25         
[25]
mean: 1
range: -
mean: 30
range: 
10-100
median: 37
range: 9-67
pts: -
tum: -
1 yr: -
2 yr: -
3 yr: 53
median: 
37mo
minor: 0 (0)
major: 1 (4.0)
death: 0 (0)
total: 1 (4.0)
Abdalla40
Ann Surg
2004
USA
CRC:
open: all
chemo: -
110     
[578]
mean: 
1.9
range: 
1-8
median: 25
range: -
median: 21
range: 4-112
pts: 5 (8.8)
tum: -
1 yr: 92
2 yr: 60
3 yr: 37
4 yr: 22
median: 
25mo
minor: -
major: -
death: -
total: -
Gillams41
Eur Radiol
2004
UK
CRC
perc: all
chemo: 
134
-          
[167]
mean: 
4.1
range: 
1-27
mean: 39
range: 
10-120
mean: 17
range: 0-89
pts: 72 (43)
tum: -
1 yr: 71
3 yr: 21
5 yr: 14
median: 
22mo
minor: 22 (13)
major: 14 (8.4)
death: 0 (0)
total: 36 (22)
White44
Dig Surg
2004
UK
CRC
perc: all
chemo: 15
56         
[30]
mean: 
1.9
range: -
median: 30
range: 8-70
median: 17
range: 3-37
pts: -
tum: 22 (39)
1 yr: 75
2 yr: 45
3 yr: -
median: 
22mo
minor: 2 (6.7)
major: 1 (3.3)
death: 0 (0)
total: 3 (10)
De Meijer
Current study
2005
The 
Netherlands
CRC
perc: 7
open: 14
chemo: 
12 
32        
[21]
mean: 
1.5
range: 
1-4
mean: 
20±6.9
range: 
6-35
mean: 
8.3±4.4
range: 2-18
pts: 5 (24)
tum: 5 (16)
1 yr: 95
2 yr: -
3 yr: -
minor: 0 (0)
major: 0 (0)
death: 0 (0)
total: 0 (0)
- = not given   /   tum = tumor(s)   /   pts = patient(s)   /   yr = year(s)   /   mo = month(s)
perc = percutaneous   /   open = intra-operative   /   lap = laparoscopic   /   chemo = prior chemotherapy
Numbers in parentheses refer to percentages.
RFA in livertumors 97
Table 5 Results of studies using RF as a treatment modality for both hepatocellular carcinoma and liver metastases.
Mixed tumor origin
origin:
hcc   crc   
oth
approach:
tum       
[pts]
tumor 
size
(in mm)
follow-up 
time
(in months)
local tumor 
progression
survival 
rates
complications
De Baere18 ¥
AJR
2000
France
   0        
-         -   
perc: 33
lap: 0
open: 21
100      
[54]
mean: 
1.9
range: -
mean: 
21±11
range: 
5-42
mean: 13.7
range: 4-23
pts: 9 (16)
tum: 9 (9.0)
1 yr: -
2 yr: -
3 yr: -
minor: 4 (7.4)
major: 3 (5.6)
death: 0 (0)
total: 7 (13)
Siperstein21
Ann Surg 
Oncol
2000
USA
  4      18      
20
lap: all
181      
[43]
mean: 
4.2 
range: 
1-14
mean 
volume:  
  8.7±1.1 
cm3
size 
range: 
  10-100
mean: 13.9
range: 5-38
pts: 12 (29)
tum: 22 (12)
1 yr: -
2 yr: -
3 yr: -
minor: 0 (0)
major: 0 (0)
death: 0 (0)
total: 0 (0)
Wood24
Ann Surg 
Oncol
2000
USA
11      37      
36
perc: 18
lap: 27
open: 39
231      
[84]
mean: 
2.8
range: -
median: 
20
range: 
3-90
median: 9
range: 1-27
pts: 15 (18)
tum: -
1 yr: -
2 yr: -
3 yr: -
minor: 4 (4.8)
major: 3 (3.6)
death: 1 (1.2)
total: 8 (9.5)
Bowles25
Arch Surg
2001
Hawaii
 25      39    
12
perc: 44
lap: 6
open: 26
328      
[76]
mean: 
4.3
range: 
1-14
median: 
30
range: 
10-180
mean: 15
range: -
pts: -
tum: 30 (9.1)
1 yr: 80
2 yr: 50
3 yr: -
minor: 10 (13)
major: 7 (9.2)
death: 1 (1.3)
total: 18 (24)
Wong23
Am J Surg
2001
USA
  2       31        
7
perc: 1
open: 39
122      
[40]
mean: 
3.1 
range: 
1-10
mean: -
range: -
median: 9.5
range: -
pts: 6 (15)
tum: -
1 yr: -
2 yr: -
3 yr: -
median: 
9.5
minor/major: 
8 (20)
death: 0 (0)
total: 8 (20)
Kosari26
J Gastrointest 
Surg
2002
USA
12      18      
15
perc: -
lap: -
open: -
143      
[45]
mean: 
3.2
range: -
mean: 20
range: -
median: 
19.5
range: 6-34
pts: -
tum: 11 (7.7)
1 yr: -
2 yr: -
3 yr: -
minor: 3 (6.7) 
major: 8 (18)
death: 1 (2.2)
total: 12 (27)
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Table 5 Results of studies using RF as a treatment modality for both hepatocellular carcinoma and liver metastases.
Mixed tumor origin
origin:
hcc   crc   
oth
approach:
tum       
[pts]
tumor 
size
(in mm)
follow-up 
time
(in months)
local tumor 
progression
survival 
rates
complications
Jiang19
World J 
Gastroent
2002
China   
21     12       
3
perc: 20
open: 16
48        
[36]
mean: 
1.3
range: -
mean: 25
range: 
5-90
mean: 10
range: 1-24
pts: 6 (17)
tum: -
1 yr: -
2 yr: -
3 yr: -
minor: 3 (8.3)
major: 1 (2.8)
death: 0 (0)
total: 4 (11)
Bleicher17
Ann Surg 
Oncol
2003
USA
21     59        
73
perc: -
lap: -
open: -
447    
[153]
mean: 
2.9
range: 
1-13
mean: 
29±16
range: 
5-135
mean: 11
range: -
pts: 32 (21)
tum: 52 (12)
1 yr: -
2 yr: -
3 yr: -
minor/major: 
36 (24)
death: 0 (0)
total: 36 (24)
Pawlik20
Ann Surg 
Oncol
2003
USA
  5    124     
43
open: all
350    
[172]
mean: 
2.0
range: -
mean: 18
range: 
3-55
median: 
21.3
range: -
pts: 8 (4.7)
tum: 8 (2.3)
1 yr: -
2 yr: -
3 yr: -
median: 
45.5
minor: 0 (0)
major: 1 (0.6)
death: 0 (0)
total: 1 (0.6)
Curley48
Ann Surg
2004
USA & Italy
206   258   
144
perc: 226
open: 382
1225  
[608] 
mean: 
2.0
range: 
1-12
mean: 27
range: 
4-120
mean: -
range: -
pts: -
tum: -
1 yr: -
2 yr: -
3 yr: -
minor/major: 
58 (9.5)
death: 3 (0.5)
total: 61 (10)
Tepel22
Eur J Surg 
Oncol
2004
Germany
   4      18       
4
open: all
56        
[26]
mean: 
2.5
range: -
mean: 
39±26
range: -
mean: 
14.6±9.2
range: 2-36
pts: 3 (12)
tum: -
1 yr: 79
2 yr: -
3 yr: -
median: 
18
minor: 0 (0)
major: 7 (27)
death: 0 (0)
total: 7 (27)
De Meijer
Current study
2005
The 
Netherlands
31       32        
10
perc: 24
open: 23
73        
[47]
mean: 
1.6
range: 
1-4
mean: 
22±12
range: 
6-80
mean: 
11.5±7.5
range: 4-35
pts: 11 (23)
tum: 11 (15)
1 yr: 87
2 yr: 70
3 yr: -
mean: 
28±2.8 
minor: 6 (13)
major: 0 (0)
death: 0 (0)
total: 6 (13)
- = not given   /   tum = tumor(s)   /   pts = patient(s)   /   yr = year(s)   /   mo = month(s)
perc or p. = percutaneous   /   open or o. = intra-operative   /   lap = laparoscopic
Numbers in parentheses refer to percentages.
¥  only those patients included in the analysis with a follow-up of at least four months
RFA in livertumors 99
diagnosed with HCC, however, in three patients with CRC the CEA level was not mea-
sured at base line. None of these three patients developed a local recurrence.
Survival
At the end of follow-up, six patients (13%) had died of progressive disease and 41 
patients (87%) were alive, including eight patients in which local tumor progression 
was observed. Mean (± SD) actuarial survival time until death was 28 ± 2.8 months 
with a 95% CI of 23-34 months and is shown in Fig. 3. Again, the median time was not 
yet reached. The overall cumulative survival rates at 12 and 24 months were 87% and 
70%, respectively. Fig. 3 also shows the overall survival strati ed by tumor histology. 
Di erences in survival were not statistically signi cant with a P-value of 0.0831 (Log 
Rank = 3.00, 1 df ).
Complications
In six patients (13%) a minor complication occurred, requiring no intervention or 
extension of hospital stay. Three patients developed some ascites, and in three other 
patients a small intrahepatic hematoma was found at the post-intervention spiral-
CT. No major complications observed were observed, nor any mortality related to 
the RF-procedure.
DISCUSSION/CONCLUSION
Reports in literature on the use of RF-ablation are increasing. Although many favour-
able reports have encouraged the use of RF by both surgeons and radiologists, we do 
not advocate RF-ablation as an alternative, but rather as an adjunct to hepatic resec-
tion, which remains the golden standard for the treatment of hepatic malignancies. 
In our study, RF-ablation was used as an adjunct to resection in  fteen procedures. 
Eight patients were ablated during laparotomy, and percutaneous RF-ablation was 
the primary procedure in the remaining patients, who were poor candidates for sur-
gery. It is essential that the technique of RF-ablation should be optimized before 
proper comparison with surgical resection can be initiated. One of the main issues 
to be addressed is the completeness of ablation, which was the primary endpoint in 
our study.
We observed a patient-based local tumor progression rate of 23% and a tumor-
based local tumor progression rate of 15%. Compared with studies in patients with 
both primary and secondary hepatic malignancies in prior literature, our results showed 
a little more recurrences than the reported patient-based local tumor progression rates 
of 4.7-21%17-24, and also more than the tumor-based local tumor progression rates of 
2.3-12%17, 18, 20, 21, 25, 26 (Table 5). Compared with more homogeneous patient popula-
tions, we observe similar local tumor progression rates of 2.4-36%27-35 patient-based 
and 6.2-52%34-39 tumor-based for HCC (Table 3), and local tumor progression rates of 
8.8-55%40-43 patient-based and 37-39%42-44 tumor-based for CRC (Table 4), respectively. 
We realise that it is di  cult to compare studies on RF-ablation due to di erences in pa-
tient selection, adjuvant treatment and approach. Nevertheless, this comparison raises 
the question whether it is justi ed to apply a treatment modality with these local tumor 
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progression rates to all patients. Given our results, we feel that RF should be used with 
caution for tumors larger than 30 mm in diameter. When applied, extra care should be 
taken to increase the local technical success. As local tumor progression usually occurs 
at the radial margins of the ablated tumor, it’s essential to have a reliable monitoring of 
the ablation, especially when overlapping ablations are required to encompass both the 
tumor and an ablation margin. Currently, the main problem in monitoring is the absence 
of reliable real-time peroperative imaging techniques. This is also well illustrated by the 
statistical signi cantly higher local failure rate in patients treated percutaneously com-
pared to patients who were treated intra-operative, because the latter bene tted by the 
availability of more accurate intra-operative US (Table 1).
A way to achieve adequate local control is the method presented by Tateishi et al in pa-
tients diagnosed with a HCC32. They inserted the RF electrode under real-time ultrasound 
guidance and performed a dynamic CT scan directly at the end of the session to evaluate 
the ablation e ect. When the result was judged as incomplete, additional sessions were 
performed until complete ablation was achieved. They also performed transcatheter 
arterial embolisation at least 7 days prior to the RF treatment to occlude the arterial  ow. 
This combination resulted in a very low local tumor progression rate of 2.4% during a 
median follow-up of 19 months, indicating that adequate local control can be achieved.
With respect to the follow-up of patients treated with RF ablation, we found a statistically 
signi cant relation between the elevation of tumor markers and the onset of a local tu-
mor progression. Although there are novel biomarkers coming up, and more advanced 
markers already in use, monitoring the tumor markers AFP and CEA still play a signi cant 
role besides routinely scanning for local, intrahepatic, or extrahepatic recurrences.45, 46
At the end of follow-up, six patients had died of progressive disease including three 
patients in which local tumor progression was observed. The  rst patient had a history 
of hepatitis C and liver transplantation, in which the virus recurred. The second patient 
died of progression of chronic obstructive pulmonary disease, and the third patient died 
of pulmonary metastases. Thus, in all three patients local tumor progression did not di-
rectly in uenced survival.
In our study we observed 1 and 2-year survival rates of 87% and 70%, respectively. 
Although there was no signi cant di erence in overall survival between patients with 
a primary or secondary hepatic malignancy, it appears that Figure 3 shows a ttbetter 
survival in patients with a hepatic metastasis. This  nding may relate with the strict selec-
tion of patients with metastatic cancer who are candidate for RF-ablation in our center.
As either local recurrence or death could both count as an event, the problem of depen-
dent competing risks might arise. However, since all cases of local tumor progression 
occurred within six months and only one patient died before that time, the assumption 
was made that in our study dependency of competing risks did not play a role of signi -
cance, and that for the end point local tumor progression the patient who died could be 
properly considered censored at time of death. Also, when a patient was treated with 
chemotherapy (or radiotherapy) in addition to an earlier ablation procedure, we consid-
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ered the patient censored at the date of last imaging to remain the ability to investigate 
the initial therapeutic e  cacy of RFA. This possibly have lead to an underestimation of 
the survival analysis.
Because studies which include both patients with a primary or secondary hepatic ma-
lignancy rarely publish survival rates (Table 5), we can only compare our results with 
an earlier study by Bowles et al25 showing similar 1 and 2-year survival rates of 80% and 
50%, respectively. Although our study population was relatively small and the data was 
retrospectively collected, our  ndings are consistent with the literature. Considering all 
studies in Table 3, 4 and 5, 1 and 2-year survival rates ranged from 71-97%22, 25, 27, 29, 31-37, 
39-41, 43, 44, and 45-94%25, 29, 32, 34-37, 39, 40, 43, 44, 47, for primary and secondary hepatic malignan-
cies, respectively. Three and 5-year survival rates ranged from 21-94%27, 29, 32-37, 39-41, 43, 48, 
and 14-54%27, 32, 34, 41. 
Cox regression showed no signi cant relation between tumor diameter, tumor histol-
ogy, and overall survival. 
Although RF has many advantages in the treatment of liver tumors, it has disadvantages 
and complications as well, ranging from 0-27%17-29, 32, 34, 35, 37-39, 41-44, 48-50. A large system-
atic review of 1931 patients treated with RF-ablation from 1995 to 2002 by Mulier et 
al51 showed that major complications occurred in 7.1% of all patients. The most com-
mon complications were impairment of hepatic function, haemorrhage, infection and 
biliary damage. The most severe complication is treatment related death, occurring in 
0-2.2%17-28, 31-33, 37-39, 41-44, 48-50. Mulier et al51 published a death rate of 0.7%. 
We recorded any adverse event related to the procedure. Major complications were de-
 ned as events that might lead to substantial morbidity, disability or mortality, or result 
in hospital admission or substantially lengthened hospital stay52. All other complications 
were considered minor. Our study showed no major complications. Only six minor com-
plications (three small intrahepatic hematomas, and in three patients some ascites) were 
observed, requiring no intervention. 
Radiofrequency ablation techniques have continued to evolve since the current study 
was conducted. Our results relate to currently available techniques and it is likely that 
with the development of new tumor ablation techniques, real-time imaging and new 
probes, even better results might be obtained. Current evidence suggests that in small 
tumors, RF can be performed with adequate local control and with few complica-
tions. Larger series and randomised clinical trials with other techniques and treatment 
algorithms are necessary to determine the exact role of radiofrequency ablation as a 
treatment modality for primary and secondary hepatic malignancies. Until then, proper 
selection of patients for RF treatment in experienced hepatobiliary centres with a multi-
disciplinary team should be advocated.
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Chapter IX
Resection of extrahepatic Hepatocellular 
Carcinoma metastasis can result in long 
term survival
Acta Chir Belg 2005;105(5):533-6
Local Ablation
RFA PEI TACE StRTx
Combination of modalities
RFA: Radio Frequency Ablation
PEI: Percutaneous Ethanol Injection
TACE: Trans Arterial Chemo Embolisation
StRTx: Stereotactic Radiotherapy
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ABSTRACT
Hepatocellular carcinoma (HCC) is one of the most common primary cancers in the 
world and the third most common cause of cancer mortality world-wide. Surgery is 
the gold standard in the treatment of patients with HCC. The prognosis is mainly de-
termined by the underlying liver disease and recurrent rates. In the Western World, 
up to 30% of the patients with HCC have a non-cirrhotic liver. The main prognostic 
factor in this special group of patients are the recurrences. Most recurrences are in-
trahepatic, however, 30% of the recurrences are extrahepatic. The role of resection in 
case of intrahepatic recurrences is widely accepted, particularly in the non-cirrhotic 
liver. The role of resection in extrahepatic HCC recurrences is not well established 
and unknown among many physicians. We present two patients with HCC in a non-
cirrhotic liver with extrahepatic recurrences and long term survival after resection. 
The corresponding literature support an aggressive approach in case of extrahepatic 
HCC recurrence in selected cases: Resectable metastasis, Preserved liver function, 
Absence of intracranial metastasis and Control of the primary tumour. Further re-
search is warranted because of the limited number of reports and the absence of 
randomised trials.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common primary cancers in the 
world (1) and the third most common cause of cancer mortality world-wide (2). In the 
Western World it is less common with e.g. incidence rates for males of 1.6/100.000/
year and for females 0.3/100.000/year in the Netherlands (3). The treatment of choice 
is partial liver resection. The improved preoperative diagnostic modalities, which 
detect HCC at an earlier stage (4), result in a better selection of patients. Still a high 
number of recurrences after partial hepatic resection are found (5, 6, 7). While the 
majority of recurrences occur intrahepatic (5, 8, 9), extrahepatic recurrences are also 
seen (6). The preferred treatment of intrahepatic recurrences is repeat hepatectomy, 
which may o er long term survival (8, 10). When resection of an intrahepatic recur-
rence is not possible, local ablation methods and transarterial chemoembolization 
(TACE) have been applied successfully (11). The role of surgery for extrahepatic re-
currence of HCC is not well established. We present two patients who have been 
treated surgically at our institution for extrahepatic recurrence of HCC and reviewed 
the corresponding literature. 
CASE REPORTS
Patient no 1
A 74-year-old male was analysed at our hospital for a liver tumour found by coinci-
dence. Magnetic resonance Imaging (MRI) showed a large lesion in segment 6 of the 
liver, suspect for HCC. There was no cirrhosis and no infection with Hepatitis B Virus 
(HBV) or Hepatitis C Virus (HCV). The alpha-fetoprotein (AFP) level was 206 µg. A re-
section of segment 6 and 7 and a partial resection of the diaphragm was performed 
in March 2000. Histology showed a HCC with a diameter of 9 cm with clear margins 
without in ltration of the diaphragm. The liver tissue was  brotic, no cirrhotic tis-
sue was found and microscopic vascular invasion was seen. During follow-up a MRI 
scan 14 months postoperatively showed a lesion in Gerota’s fascia on the right side 
(Figure 1). This lesion was not seen on the MRI pre-operatively. AFP was 3 µg/l. A re-
section of the lesion was performed 15 months after the  rst resection and histology 
con rmed the diagnosis metastatic Hepatocellular carcinoma. To date, 44 months 
after resection of the extrahepatic metastasis and 59 months after partial liver resec-
tion the patient is still alive and well, and no new recurrence has been found.
Patient no 2
A 39-year-old woman with a medical history of HBV and no cirrhosis or HCV, was ad-
mitted to our hospital for pain in the right upper quadrant of the abdomen. The AFP 
level was 23020 µg/l. Analysis showed an HCC, con rmed by biopsy, for which a right 
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hemihepatectomy was performed in October 1996. Histology showed an HCC with 
a diameter of 9.5 cm with central necrosis. No microscopic vascular invasion was 
found. After partial liver resection, AFP values returned to normal. After 11 months 
of follow-up, there was an increase of AFP to 560 µg/l. MRI revealed a possible me-
tastasis in the thoracic wall, at the location of the biopsy. The lesion was excised and 
histology con rmed the diagnosis of a metastasis of HCC. After the excision the AFP 
level decreased to normal values. Sixty months after primary resection, a second rise 
of the AFP was found (10701 µg/l). A lesion in the lower abdomen was found on CT. 
A tumour, localised behind the right side of the uterus, was resected and the diag-
nosis HCC metastasis was con rmed by histology. To date, 101 months after partial 
liver resection and 41 months after resection of the intra-abdominal recurrence, the 
patient is still alive and well.
2 C. Verhoef et al.
Patient no 2
A 39-year old woman with a medical history of HBV
and no cirrhosis or HCV, was admitted to our hospital
f r pain in the right upper quadrant of the abdomen. The
AFP level was 23020 µg/l. Analysis showed an HCC,
confirmed by biopsy, for which a right hemihepatecto-
my was performed in October 1996. Histology showed
an HCC with a diameter of 9.5 cm with central necrosis.
No microscopic vascular invasion was found. After par-
tial liver resection, AFP values returned to normal. After
11 months of follow-up, there was an increase of AFP to
560 µg/l. MRI revealed a possible metastasis in the
thoracic wall, at the location of the biopsy. The lesion
was excised and histology confirmed the diagnosis of a
metastasis of HCC. After the excision the AFP level
decreased to normal values. Sixty months after primary
resection, a second rise of the AFP was found
(10701 µg/l). A lesion in the lower abdomen was found
on CT. A tumour, localized behind the right side of the
uterus, was resected and the diagnosis HCC metastasis
was confirmed by histology. Today, 101 months after
partial liver resection and 41 months after resection of
the intra-abdominal recurrence, the patient is still alive
and well.
Discussion
Most of the literature about HCC is coming from the
Eastern part of the World, where over 90% of the HCC
patients have an underlying liver cirrhosis. This is sub-
stantially lower in the Western World, with up to 30% of
HCC occur in a non-cirrhotic liver (12). The prognosis
for this special group of patients is not as clearly
described as that for patients with HCC in a cirrhotic
liver. There are recent reports that describ  the results of
surgery in HCC patients without underlying liver cirrho-
sis (12-15). Usually these patients present with large
tumours (median size between 8 and 10 cm are
described) and 5-year survival rates have been reported
between 42 and 68% after partial liver resection. These
Fig. 1
A. T2 weighted image of May 2001. The lesion (_) is visible ;
B. Arterial phase, May 2001. The adrenal gland shows
enhancement, as do the spleen and aorta, this is characteristic
for the arterial phase. The lesion also shows enhancement. A
combination of high signal intensity on T2 and intense arterial
enhancement is typical for recurrent HCC in this patient ;
C. Late phase : the lesion decreases in enhancement.
Furthermore artefacts of the operationclips of the primary
operation are visible (_).
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Fig. 1
A. T2 weighted image of May 2001. The lesion (_) is visible ; 
B. Arterial phase, May 2001. Th  adrenal gland shows enh nc ment, 
as do the spleen and aorta, this is characteristic for the arterial 
phase. The lesion also shows enhancement. A combination of high 
signal intensity on T2 and intense arterial enhancement is typical for 
recu rent HCC in this patient ; 
C. Late phase : the lesion decreases in enhancement. Furthermore 
artefacts of the operationclips of the primary operation are visible 
(_).
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DISCUSSION
Most of the literature about HCC is coming from in the Eastern part of the World, 
where over 90% of the HCC patients have underlying liver cirrhosis. This is substan-
tially lower in the Western World with up to 30% of HCC occur in a non-cirrhotic liver 
(12). The prognosis for this special group of patients is not as clearly described as 
that for patients with HCC in a cirrhotic liver. There are recent reports that describe 
the results of surgery in HCC patients without underlying liver cirrhosis (12 - 15). Usu-
ally these patients present with large tumours (median size between 8 and 10 cm are 
described) and 5-year survival rates have been reported between 42 and 68% after 
partial liver resection. These results appear to be better than those reported for HCC 
in the cirrhotic liver with comparable size. De novo tumor or local recurrence of HCC 
is the predominant cause of death following resection of HCC. Although much e ort 
has been done to reduce the recurrence rates of HCC after partial liver resection, 
there are no (neo) adjuvant therapies of proven bene t (16). Microvascular in ltra-
tion is one of the main prognostic factors. In HCC associated with cirrhosis, tumor 
size has a clear relationship with microvascular in ltration. This correlation is not 
well established in the non-cirrhotic group (13). We will emphasize that large tu-
mour size of HCC in non-cirrhotic liver is not a drawback for an aggressive approach. 
Intrahepatic recurrence of HCC without treatment results in poor survival. Farges et 
al reported a 1-, 3-, and 5 year survival of patients with intrahepatic metastases of 
respectively 20%, 4% and 0% (10). When a patient with intrahepatic recurrence of 
HCC is eligible for surgery these survival rates are respectively 75%, 46% and 30%. 
These numbers harbour a bias, because the patients were not randomised. What 
these numbers do display, is the fact that long term survival can be achieved after 
resection of intrahepatic HCC recurrences. If surgery is not possible in case of intra-
hepatic recurrences, nonsurgical procedures such as percutaneous ablation thera-
pies and transcatheter arterial chemoembolization (TACE) are widely employed (11). 
In case of underlying liver cirrhosis, only a small portion of the patients are eligible. 
Author N° of patients Location of extra-hepatic metastases Survival
LO et al. (25) 12 Abdominal wall, Lung, Omentum, Peritoneum Median survival : 19.7 months
FARGES et al. (10) 14 Bone, cerebral, pulmonary and abdominal wall Median survival : 8 months
LAM et al. (26) 9 Pulmonary Median survival : 42 months
ARII et al. (7) 8 Lung, Omentum, bone, spleen 5-year survival : 37.5 %
SHUTO et al. (27) 4 Adrenal 10, 20, 25 and 63 months survival
POON et al. (5) 10 Lung, diaphragm, lymphnode, abdominal wall, adrenal gland Median survival : 44 months
MOMOI et al. (28) 13 Adrenal 5-year survival : 34 %
CHANG et al. (29) 25* Intracranial Median survival : 4 months*
GWAK et al. (30) 4 Pulmonary 29, 43, 54 and 72 months survival
Table 1 Survival of patients with extrahepatic metastases of HHC treated with surgery according to the literature
* 8 patients underwent excision, 1 patient radiosurgery, 16 patients radiotherapy.
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Because of the preserved liver function of patients with HCC in a non-cirrhotic liver, 
intrahepatic recurrence can be treated by TACE, local ablation or even resection. 
Therefore, this group of patients (HCC in a non-cirrhotic liver) might be the group 
of patients who may bene t the most from an aggressive management regarding 
extra-hepatic recurrences. Extrahepatic recurrence occurs in 30% of the patients 
(10). It has been reported that systemic chemotherapy for extrahepatic metastasis of 
HCC has unsatisfactory survival outcomes (17,18). Resection of isolated extrahepatic 
HCC metastasis has been advocated to obtain a possibility of long-term survival. The 
literature is scarce about this issue, possibly because extrahepatic disease is often 
considered to be a contraindication for any further treatment. Table 1 depicts nine 
studies reporting resection of extrahepatic recurrence in patients with HCC. This
table shows that long-term survival can be achieved in selected cases. If we sum-
marize the results of these studies, patients who may bene t from surgical resection 
are the patients with resectable extrahepatic metastasis, no intracranial metastasis 
and a compensated liver function. The primary hepatic tumor must be radical re-
sected or must be under control. Partial pulmonary resections, spleen resections and 
adrenal resections (if necessary in combination with partial vena cava resections) 
have been described. Therefore, even when a vital organ is involved by a metastasis, 
long-term survival can be achieved by resection. In case of an AFP producing HCC, 
the sensitivity of screening with AFP has a high sensitivity (19) for the detection of 
recurrent HCC. An increasing level of circulating AFP may indicate the recurrence of 
HCC, though elavated levels of AFP can also be the result of an active hepatitis (20). 
If there is a suspicion of extrahepatic disease, subsequent extensive imaging should 
be done (CT thorax, MRI abdomen). The role of PET-scan in identifying intra-hepatic 
HCC is limited (21,22). Some reports displayed an additional role PET in identifying 
extrahepatic metastases (23, 24). However, the role of PET in metastatic HCC needs 
further validation.
When extrahepatic recurrence of HCC is found in patients without liver cirrhosis, the 
patient may be candidate for resection. Our two cases demonstrate that long-term 
survival can be achieved in patients with resection of an extrahepatic recurrence. 
The patients are alive, 59 and 101 months after the hepatic resection, 44 and 41 
months after resection of the extrahepatic metastasis without recurrent disease. 
After reviewing the literature, surgery can be indicated for patients with extrahe-
patic recurrence of HCC if there is a preserved liver function, absence of intracranial 
metastasis and if complete tumor removal can be expected.
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Identi cation of somatostatin receptors 
subtypes in human hepatocellular 
carcinomas: a clinical study.
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ABSTRACT 
Background: The evidence on the e  cacy of somatostatin analogues in the treat-
ment of hepatocellular carcinoma (HCC) in humans is con icting. Somatostatin re-
ceptors (SS-Rs) have been demonstrated in a variety of human tumors. At least 5 
di erent human subtypes (SS-R subtype 1 – 5) have been cloned. All subtypes bind 
human somatostatin with high a  nity, while somatostatin analogues bind with high 
a  nity to SS-R subtype 2 (sst2)
Aim of the study: We investigated the sst2 expression in HCC and examined whether 
HCC’s expressing sst2 are a distinct subgroup at the cell biological, clinical or patho-
logical level.
Patients and Methods: We constructed a tissue micro-array and tested 45 human 
HCC’s for sst2 expression and genetic alterations. The proliferative capacity of the 
tumours was determined with Ki67 immunostaining and the DNA ploidy status was 
measured by  uorescent in situ hybridization (FISH) with a chromosome 1-speci c 
repetitive DNA probe. Expression of tumour suppressor genes (p16, p53 and Rb1) 
was measured by immunohistochemistry.
Results: Of 45 tumours, sst2 expression was detected in 30 tumours (67%). Age, 
gender, α-fetoprotein levels, tumour size, tumour grade and underlying liver disease 
of the sst2 positive tumours were not signi cantly di erent from the sst2 negative 
tumours. No correlation existed between sst2 expression and the immunopro les of 
the tumor suppressor genes, aneuploidy or proliferation. 
Conclusion: In 67% of the patients with HCC, sst2 could be detected in the tumour. 
No clinical or pathological characteristics were speci c for sst2 positive tumours and 
these are not a distinct subgroup at the genetic level. Clinical studies with soma-
tostatin analogues should be limited to those patients expressing sst2 in their liver 
tumour.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and  fth 
most common cancer in the world. Recent reports suggest an increase of the inci-
dence of HCC in the Western World, however, this may re ect a referral bias (1,2). Only 
a minority of patients can be treated by partial liver resection, liver transplantation 
or local treatment (radiofrequency, percutaneous ethanol injection, trans arterial 
chemo embolization). Because HCC is not sensitive to systemic chemotherapy (3), 
other therapies are tried. Results of studies investigating the e ect of somatostatin 
analogues on HCC in humans are con icting (4-8). Somatostatin receptors (SS-Rs) 
have been demonstrated in a variety of human tumors. At least 5 di erent human 
subtypes (SS-R subtype 1 – 5) have been cloned. All subtypes bind human soma-
tostatin with high a  nity, while somatostatin analogues bind with high a  nity to 
SS-R subtype 2 (sst2). Literature data on the expression of SS-Rs in HCC are scarce. 
There is no study published, investigating whether HCC tumours expressing SS-Rs 
are a distinct subgroup at the genetic level. To investigate the SS-Rs in HCC and to 
test whether speci c genetic alterations are associated with SS-Rs-positive or SS-Rs-
negative HCC’s, we examined protein (over) expression of tumour suppressor genes 
(p16, p53 and Rb1) by immunohistochemistry. Further, the proliferative capacity was 
examined by immunostaining of Ki67 and DNA ploidy status (aneuploidy) was mea-
sured by  uorescent in situ hybridization (FISH) with a chromosome 1-speci c repeti-
tive DNA probe. Our results will indicate the existence of SS-Rs in human HCC and 
we will describe whether there is a correlation between SS-Rs expression and clinical 
and pathological characteristics, or alterations of investigated proto-oncogenes.
MATERIAL AND METHODS
Patient material
Tissue of surgically resected tumours of patients with HCC were analysed in this 
study. The diagnosis was formulated according to the guidelines issued by the World 
Health Organisation (9). We collected representative para  n blocks from neoplastic 
liver cell specimens. HCC’s were graded using a standard grading system (10). 
Tumour samples from surgical resections of 58 Patients with HCC were selected for 
the tissue micro-array (TMA). Of each resection specimen 0.6 mm tissue cylinders 
were punched out of the tissue blocks, and brought into the array block with regular 
spacing between the cylindrical biopsies. From each patient, 2 tissue cores were in-
cluded in the TMA. A standard H&E stained histological section of the TMA was made 
for quality control. In 10 cases no adequate carcinoma tissue cores were available for 
analysis due to absence or inadequate numbers of tumor cells. In three cases, SS-Rs 
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could not be determined by technical errors. A total of 90 liver tissue samples were 
available for analysis, i.e. 45 HCC’s.
Fluorescent in situ hybridization
FISH was performed on a 4-µm-thick tissue section of the TMA that was adhered 
to a aminoacetylsilane (AAS) coated slide (Starfrost, Berlin, Germany). The (peri)
centromeric DNA probe for chromosome 1 was labeled with Spectrum Green us-
ing a Nick Translation Reagent Kit (Vysis, Downers Grove IL, USA) according to the 
manufacturer’s directions. The FISH procedure was carried out basically as described 
before by us (11,12). Brie y, after appropriate pepsin digestion, sections were heat-
denatured for 2 min in 70% formamide in 2x SSC, and hybridized overnight at 37ºC 
with the denatured probes in a hybridization mixture containing 2 ng/µl DNA probe, 
500 ng/µl herring sperm DNA (Sigma, St. Louis MO, USA), 0.1% Tween-20, 10% dex-
tran sulphate, and 60% formamide in 2x SSC at pH 7.0. Then, a series of stringent 
washes followed to remove unbound probe. Finally, the section was counterstained 
with DAPI in antifade solution (Vectashield; Vector, Burlingame CA, USA). The FISH 
results were analyzed on a computer screen. Images of each of the 2  uorochromes 
were collected using an epi uorescence microscope (Leica DM, Rijswijk, The Neth-
erlands) equipped with appropriate excitation and emission  lter sets (Leica), and 
a cooled CCD camera (Photometrics, Tucson AZ, USA). The green and blue images 
were collected sequentially by changing the excitation  lter using CW4000 FISH 
software (Leica). Two investigators scored a minimum of 50 interphase cell nuclei 
per tissue core, and the number of green  uorescent centromere 1 spots per nucleus 
was scored (0, 1, 2, 3, 4, >4 spots/nuclear slice). Then, the percentage of hyperdiploid 
cell nuclei was determined.
Immunohistochemistry p16, p53, Rb1 and Ki67 antigen
The immunohistochemistry was carried out as described before by us (13). Basi-
cally, 4µm consecutive tissue sections of the TMA were mounted on aminoacetylsi-
lane (AAS) coated slides (Starfrost, Berlin, Germany), and immunostaining was per-
formed using the UltraVision Large Volume Detection System Anti-Polyvalent, HRP 
(Labvision, Fremont, CA). After deparaffinization microwave (700 W) pretreatment 
was performed for 15 minutes using citrate buffer (10mM citric acid monohydrate, 
pH 6.0). The p16 gene product was evaluated using antibody E6H4 (DAKO, Glostrup, 
Denmark), diluted 1/25 in phosphate-buffered saline/5% BSA. To assess overexpres-
sion of the p53 protein, the primary antibody DO-7, recognizing both wild type and 
mutant p53, (DAKO) was used, diluted 1/50 in phosphate-buffered saline/5% BSA. 
The Retinoblastoma gene product was evaluated with clone Rb1 (DAKO), diluted 
1/25 in phosphate-buffered saline/5% BSA. This antibody reacts with cell the cycle-
related phosphorylated form of Rb protein. To estimate proliferation rate primary 
labelling of the Ki67 antigen was performed with antibody Mib-1 (Immunotech, 
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Marseille, France), diluted 1/100 in phosphate buffered saline/5% BSA. As a positive 
control a cytokeratin 8/18 antibody was used, as a negative control the primary 
antibody was omitted. At least 50 cells were scored by two independent investi-
gators. Ki67: A percentage >1% was regarded as increased proliferation. For p16, 
p53 and Rb1 an identical scoring system was used: A percentage exceeding 1% of 
positive cells was regarded as protein overexpression of these tumor suppressor 
genes. The cut-off value of 1% was based on immunostaining profiles of normal 
liver controls.
Somatostatin receptor immunohistochemistry
Five µm sections of the TMA were mounted on aminoacetylsilane (AAS) coated 
slides (Starfrost, Berlin, Germany). This was depara nized, dehydrated, exposed to 
microwave heating (in citric acid bu er, 10 min. at 100 0C), rinsed in tap water and 
phosphate bu ered saline (PBS) and incubated for 15 min. in normal goat serum 
(1:10 dilution in PBS + 5% bovine serum albumin (BSA). Thereafter, the cells were 
incubated overnight at 4 0C with antibody against sst2. The antibodies were used at a 
dilution of 1:1000 in PBS + 5% BSA. A standard streptavidin-biotinylated-peroxidase 
complex (ABC) kit (Biogenix, San Ramon, CA, USA) was used according to the manu-
facturers to visualise the bound antibodies. In our laboratory we tested the deter-
mination of ssr subtypes with immunohistochemistry followed by a determination 
with PCR as the gold standard. The most reliable subtype determination was sst2 and 
sst3 (100% score). The other subtypes are not reproducible. Because ssr2 is the most 
clinical signi cant, we tested this subtype.
Statistical evaluation
The Mann-Whitney-U test was used for comparisons between the specimen groups 
for the percentage of hyperdiploid cell nuclei (aneuploidy). It was further used to 
evaluate the clinical parameter age and tumour size. Fisher’s Exact Test was applied 
 TABLE I Clinical and pathological data from 45 patients with HCC
sst2 + sst2 - TOTAL di erence
Total number of patients 30 (67%) 15 (33%) 45 (100%)
Age (years) 59 (23 – 74) 53 (39-74) 57 (23-74) NS
Male 19 (63%) 9 (60%) 28 (62%) NS
Female 11 (37%) 6 (40%) 17 (38%)
Diameter Tumour (cm) 5 (1-16) 4 (2-12) 5 (1-16) NS
Grade I or II Tumour 19 (63%) 9 (60%) 28 (62%) NS
Grade III Tumour 11 (37%) 6 (40%) 17 (38%)
Underlying liver cirrhosis 20 (67%) 9 (60%) 29 (64%) NS
Without liver cirrhosis 10 (33%) 6 (40%) 16 (36%)
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for comparisons of the immunostaining results between groups, as well as tumor 
grade in relation to FISH and immunostaining. Also the parameter gender was evalu-
ated using this test. P=0.05 (two-sided) was taken as the limit of signi cance. A P-
value between 0.05 and 0.10 was considered a statistical trend.
RESULTS
Somatostatin receptor 2 expression was assessed by immunohistochemistry. In our 
series of 45 tumours, ssr2 expression was detected in 30 tumours (67%). Patient and 
tumour characteristics compared with ssr2 status of the tumour are summarized in
table I. Twenty-eight men and 17 women were investigated with a median age of 
57 years (23-74) and a median tumour size of 5 cm (1-16). Twenty-nine patients had 
underlying liver cirrhosis. Age, gender, tumour size, tumour grade and underlying 
liver disease of the ssr2 + tumours were not signi cantly di erent from the ssr2 – 
tumours.
Protein (over) expression of tumour suppressor genes (p16, p53 and Rb1) was 
examined by immunohistochemistry. The proliferative capacity was examined by 
immunostaining of Ki67 and DNA ploidy status (aneuploidy) was measured by 
 uorescent in situ hybridization (FISH) with a chromosome 1-speci c repetitive 
DNA probe. The results are shown in Table II.
Aneuploidy, i.e. the percentage of hyperdiploid cells, was 33 (range 8-70) in the ssr2
+ tumours versus 19 (range 10-66) in the ssr2 – tumours (NS). No di erences were 
observed between the ssr2 – and + tumours for p53, p16, Rb1 oncoprotein or prolif-
eration markers. 
TABLE II. Genetic alterations in 45 HCC’s in relation to sst2 expression
sst2 + sst2 - TOTAL di erence
Number of patients 30 (67%) 15 (33%) 45
P16 + 6 (20%) 2 (13%) 8 (18%) NS
P16 - 24 (80%) 13 (87%) 37 (82%)
P53 + 15 (50%) 8 (53%) 23 (51%) NS
P53 - 15 (50%) 7 (47%) 22 (49%)
Rb1 + 15 (50%) 8 (53%) 23 (51%) NS
Rb 1 - 15 (50%) 7 (47%) 22 (49%)
Ki67 + 17 (57%) 9 (60%) 26 (58%) NS
Ki 67 - 13 (43%) 6 (40%) 19 (42%)
Aneuploidy 33 (8-70) 19 (10-66) 28 (8 – 70) NS
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 DISCUSSION
In pre-clinical studies Somatostatin analogues (SS) inhibit the growth of a wide 
variety of tumours in vivo and in vitro (14-16). The published studies regarding the 
e  cacy of SS on survival in patients with HCC are con icting. Some studies did not 
display an improve in survival in patients with unresectable HCC’s (4-6) while others 
found a signi cant survival bene t (7,8,17). The placebo controlled randomized trials 
did not show signi cant bene t of SS on patient survival (4,18). 
There is no explanation for these contradictory results. If you analyse the number of 
studies regarding the e  cacy of SS in the treatment of HCC, it is striking that studies 
investigating the somatostatin receptor in human HCC are limited. The variations in 
receptor expression may explain di erences in clinical e  cacy. To our knowledge, 3 
studies described the expression of tumour ssr in patients with HCC (Table III). The 
studies of Blaker et al (19) and Reubi et al. (20) studied the correlation between ssr 
and tumour characteristics. Our study con rmed their results that there is no cor-
relation between tumour stage, tumour di erentiation and underlying liver disease. 
Moreover, there was no correlation between ssr and age or gender. Therefor it is not 
possible to predict the existence of ssr in human HCC based on available clinical 
parameters. If the expression of ssr in HCC plays a role in the outcome regarding SS 
treatment in patients with HCC, it is not possible to stratify the patients based on 
clinical characteristics. 
It is known that there are 5 subtypes of ssr. All ssr’s (1-5) have been implicated in 
antiproliferative signalling (21). Our study investigated the ssr-2 and not the other 
subtypes ssr 1, 3-5. There is a di erence in binding a  nity between analogues of 
SS and the ssr subtypes. Octreotide, an often used SS analogue, has a high binding 
a  nity with ssr-2 compared to the other ssr subtypes. The absence or presence of 
ssr-2 subtype in HCC might be the cause of the divergent biological responses in 
trials with octreotide in patients with advanced HCC. This is one of the reasons we 
tested ssr-2 in human HCC. Most important decisive factor to test ssr-2 is the fact 
that we examined the determination of ssr subtypes with immunohistochemistry 
followed by a determination with PCR as the gold standard. The most reliable sub-
type determination was ssr-2 and ssr-3 (100% score). Testing for the other subtypes 
is in our hands not reproducible. Because of the high a  nity with SS analogues, we 
TABLE III. Somatostatin receptors in patients with HCC
No of pts SSR2 + (tumor) Method
Reubi et al 59 41%* Autoradiography
Bläker et al. 56 41% Immunohistochemistry
Reynaert et al. 6 67% Immunohistochemistry 
Erasmus MC 45 67% Immunohistochemistry
*: all ssr subtypes (1-5)
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determined that ssr-2 is the most clinical signi cant subtype. In our series, 67% of the 
HCC’s expressed ssr-2, what is exact the same percentage ssr-2 found in the study of 
Reynaert et al. (22) and higher than the 41% Blaeker et al. (19) found. Because of the 
higher binding a  nity of ssr-2 to SS analogues compared to the other ssr subtypes 
and the variable ssr-2 expression in HCC found in our study and others, clinical trials 
evaluating the treatment of SS analogues in patients with HCC, should take these 
 ndings into account.
Somatostatin receptors may play a role in the progression of cancers. Binding studies 
suggested that ssr´s were preferentially expressed in well di erentiated compared 
to less di erentiated tumors (23,24). In other words, ssr´s may play a role in the dif-
ferentiation in some cancers. Loss of ssr expression in tumour cells would confer 
a proliferative advantage to those cells and their progeny. In regard of this point 
genes of the ssr´s can be regarded as tumour suppressor genes. This suggestion is 
supported by the observation that a point mutation in ssr-2 gene results in a prolif-
erative advantage in small cell lung cancer cells in vitro (25). If ssr’s can be regarded 
as tumour suppressor genes, it might be that ssr + subgroup is a distinct group of 
patients. Maybe speci c genetic alterations are associated with ssr-positive HCC’s 
and this may be another possible explanation for the con icting results regarding 
the e  cacy of SS analogues on survival in patients with HCC. 
The p53 oncosuppressor is the gene which has been found to be most frequently 
altered in human cancers. Moreover, it is the most commonly mutated gene in HCC 
(26-29). In a large study of Qin et al. (29), nuclear staining for p53 were found in 
50.5% of the cases (112 of the 222 cases). Some reports are indicating that p53 is 
an independent prognostic marker regarding survival (28,29). Among the known 
tumor suppressor genes, the inactivation of p16 is reported to be second only to 
p53 inactivation in human neoplasia (30). Also in human HCC, p16 is a major inac-
tivation target (31,32). Edamato et al. recently demonstrated that alterations in the 
RB1 pathways commonly occur in HCC’s (33). In a selected group of 45 patients we 
investigated whether any of the genetic alterations that are frequently observed in 
HCC’s (p53,p16 and RB1) were speci c for the ssr+ or ssr- subgroups. None of the 
investigated oncogenes are speci c for the subgroups. 
Conclusion: In 67% of the patients with HCC, sst2 could be detected in the tumour. 
No clinical characteristics were speci c for sst2 + or – tumours. There are no speci c 
genetic alterations, aneuploidy or proliferation markers associated with sst2-positive 
or -negative HCC’s
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The most common primary liver cancer is hepatocellular carcinoma (HCC). With an 
estimated 0.5 million new patients per year world-wide and about one million death 
yearly,  HCC is the  fth most common cancer in the world and the third most com-
mon cause of cancer mortality1. 
It is a disease with a highly uneven geographical distribution. In North America and 
several European countries, HCC is uncommon and the estimated death rate is less 
than 5/100.000 inhabitants/year 2,3 This in contrast to countries in the East and Af-
rica where the incidence rates exceeds 30/100.000/year. However, the incidence has 
been increasing in low-endemic areas, as has been reported for the United King-
dom4, France5 and the United States6. Publications describing epidemiological, treat-
ment and prognosis  gures of patients with HCC are mostly derived from a selected 
group of patients 7-10. This may be of limited relevance. In Chapter II the results are 
described of a population-based study in the Netherlands including all patients with 
HCC diagnosed between 1989 and 200011. In contrast to previous reports of sub-
populations in non-endemic areas, we found no rising incidence of HCC in the Neth-
erlands between 1989 and 2000. In 2000 the ESR for males was 1.6/100,000/year and 
for females 0.3/100,000/year. There was no change in treatment pattern (1989-1998). 
Remarkably 73% of patients with HCC received no cancer-related therapy during 
this period of analysis. A treatment with a curative intent, either partial liver resec-
tion or orthotopic liver transplantation was only noted in twelve percent of patients. 
There may be various explanations for this  nding. Without adequate surveillance 
programs the diagnosis may be made in a phase of the disease too late to o er a 
curative treatment. However, as many patients are visiting hospitals at a regular base 
for the treatment of the underlying liver disease, including viral or alcohol induced 
cirrhosis, it may also be speculated that there is a certain reluctance to o er such an 
aggressive therapy as liver resection or liver transplantation. Review of casus with 
HCC in specialised centres may be advocated to minimise the number of patients 
not receiving possible curative therapy 11. Within the near future an update will be 
done to expand the data and to review the outcome of the management of HCC in 
the Netherlands. 
Although solid experimental evidence for a single causative agent of HCC is lacking, 
there is a clear association of HCC with chronic in ammation. A large number of dis-
eases have been related to the carcinogenesis of HCC, including hepatitis B or C virus, 
a atoxin, alcoholic liver disease, haemochromatosis and tyrosinaemia. Epidemiolog-
ical evidence has lead to the hypothesis that cirrhosis resulting from any cause is the 
seedbed for HCC12. The occurrence of unknown co-factors is very likely to play a role 
in the likelihood to develop HCC. Moreover, a signi cant proportion of patients with 
HCC in a non-cirrhotic liver has no risk factor identi ed. In Chapter III we investigated 
a potential risk factor that may induce chronic hepatitis. In 1994 it was demonstrated 
for the  rst time in mice that infection with Helicobacter hepaticus resulted in hepa-
titis and hepatic tumour induction 13,14. In 1997 a signicantly higher prevalence of 
Ch
ap
te
r X
I
126
immunoglobulin G (IgG) antibody against H. pylori in patients with liver cirrhosis 
than in controls was reported 15. Various studies reported an increased prevalence 
of Helicobacter DNA in the liver of patients with HCC, further supporting the notion 
that Helicobacter might play a role in the carcinogenesis of HCC in humans 16-20. As 
these studies were based mostly on the analysis of biopsy materials from cirrhotic 
livers, it remained unclear whether the presence of Helicobacter species was the 
cause or merely the result of the cirrhosis. To address this issue, we studied the pres-
ence of Helicobacter DNA in liver samples of patients with HCC in non-cirrhotic livers 
and the detection of Helicobacter species in their stomach was explored. Analysis 
indicated that Helicobacter DNA was observed at a higher frequency in the non-
cirrhotic liver of patients with HCC (P < 0.004). Sequence analysis of PCR products 
obtained from HCC patients indicated that they were related most closely to the 16S 
rDNA sequence of Helicobacter pylori but that they always di ered at the same two 
positions. The same H. pylori subspecies was present in the stomach of patients with 
HCC. This  nding suggests that gastric Helicobacter colonization may play a role in 
the induction of HCC, either directly via colonization of the liver or indirectly, e.g. via 
secretion of specic toxins by Helicobacter residing in the stomach 21.
If patients have a liver tumor, with or without a known risk-factor, the imaging 
tests to make a diagnosis most commonly used are ultrasonography, angiography, 
computed tomography and magnetic resonance imaging. There is a growing inter-
est in the development of in vivo methods of assessing functional parameters and 
metabolism in normal and diseased tissues 22,23. Positron emission tomography with 
 uorine-18-deoxyglucose (18FDG-PET) is one example of such a technique. PET is 
currently not widely available, mainly because of its high costs. Recently, alternative 
techniques for 18FDG imaging have become available: SPECT using special high-
energy collimators 24 and coincidence detection using adapted multi-head gamma 
cameras 25.
In a pilot study (Chapter V) we prospectively evaluated if 18FDG Positron Coincidence 
Detection (PCD) and single photon emission computed tomography (SPECT) pro-
vide additional bene t to our conventional preoperative evaluation of patients with 
a suspected HCC (CT and ultrasonography). The literature regarding PET in patients 
with HCC has been reviewed. 
SPECT has a lower sensitivity for the detection of intrahepatic lesions compared to 
CT. After reviewing the literature, we concluded that PET has no additional value 
in detection intrahepatic HCC. PET is optional in detecting extra-hepatic disease. 
PET/SPECT/PCD is not a standard imaging modality in the work-up of patients with 
HCC.26
The most commonly used serum marker to detect HCC is serum alpha fetoprotein 
(AFP). A large case-control study displays a sensitivity of 62% and a speci city of 
89% with a cut o  value > 15 ng/ml. At a value of > 200 ng/ml, the sensitivity is 22%, 
with a speci city of 99%.27 Chapter VI depicts the sensitivity of AFP in patients with 
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a HCC in a non-cirrhotic liver. Of those patients treated in the ErasmusmMC, 55% had 
an AFP > 15 ng/ml.28 If there is a liver lesion suspected to be a HCC but the diagno-
sis cannot be con rmed by serum analysis or imaging techniques , a percutaneous 
biopsy can be performed. The risk of seeding by the needle track varied between 
2 and 5%. However even after histological examination the risk on a false negative 
outcome can be up to 23%.29 It may be di  cult to distinguish a well di erentiated 
HCC from liver lesion due to dysplasia in a cirrhotic liver or from an adenoma in a 
non-cirrhotic liver. Chapter IV describes the di erence in cell biological markers, 
DNA ploidy status and proliferative capacity between adenomas and HCC. The re-
sults suggest that adenomas can be distinguished from carcinomas, based on ploidy 
and proliferation characteristics.30
Despite the high numbers of patients diagnosed worldwide, HCC continues to pose 
challenging clinical problems. The assessment of the tumor and the decision on the 
most adequate treatment option may bene t from a multi-disciplinary approach in 
which the surgeon plays a central role. In 1970’s, a cirrhotic liver was a contraindica-
tion for partially liver resection. Nowadays, partial hepatic resection is the  rst treat-
ment option that is considered for a curative treatment of patients with HCC and a 
compensated liver cirrhosis. 
The prognosis for patients with HCC in a non-cirrhotic liver is not as clearly described 
as that for patients with HCC in a cirrhotic liver. Absence of underlying cirrhosis is 
found in approximately 30% of patients with HCC in Western countries. Chapter VI
describes the results of patients with a HCC in a non-cirrhotic liver, treated in Eras-
musMC. As the absence of cirrhosis leads to late presentation in the course of the 
disease, larger tumours are more likely to be seen in a patient with a non-cirrhotic 
than a cirrhotic liver.The median and mean tumour diameter of 40 patients analysed 
was 10 cm. We found that size of the tumour was not a signi cant factor to predict 
resectability. Despite the large resections performed no postoperative liver failure 
was observed This may be explained by the gradual growth of the large tumours 
which induces functional adaptation of the contralateral lobe. Independent of the 
diameter of the tumour the outcome of the surgical treatment of HCC in non-cirrhot-
ic livers may be correlated with  a  ve year survival rate of 68% in our series.28
Among patients who have cirrhosis, strict selection criteria for resection are required 
to avoid treatment related complications. Surgical resection is the golden standard 
of therapy and appears to be the only e ective way, aside from liver transplantation, 
to alter survival. However, due to advanced or decompensated liver cirrhosis, co-
morbidity and multifocality of the tumors, only 10-37% of the patients with HCC are 
considered to be candidates for surgical resection.11,12 Regional and local ablation 
techniques are accepted alternative therapies for unresectable HCC. Trans Arterial 
Chemoembolization (TACE), Interstitial Laser Coagulation (ILC), Cryotherapy, Micro 
Wave ablation, Percutaneous Ethanol injection (PEI) and Radiofrequency Ablation 
(RFA) are the most widely used. In Chapter VII the results of ILC in patients with HCC 
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in a cirrhotic liver are described treated in the ErasmusMC. To enhance the e  ciency 
of ILC, experimental studies in a pig model found that if the blood ow to the liver 
was temporarily interrupted the coagulated area was larger than without occlusion. 
Based on these  ndings a prospective clinical study was initiated to assess the ef-
fectiveness of long-term local control after treatment with ILC with temporary he-
patic arterial occlusion, in cirrhotic patients with HCC. Most of the procedures were 
done percutaneously. In the 24 tumours treated, 19 tumours had complete necrosis 
on CT-canning. The majority of the patients developed new lesions (intra and extra 
hepatic).31
Reports in the literature on the use of RF-ablation are increasing. The results of RFA in 
the ErasmusMC are described in Chapter VIII. RF-ablation can be safely performed 
to achieve adequate local control and survival rates. Time to local tumor progres-
sion was signi cantly related to initial size of the tumor and tumor load. The tumour 
should not exceed 3cm, to achieve good local control.32
If resectable intra-hepatic recurrences occur without extra-hepatic disease, partial 
liver resection and/or RFA is  rst choice with acceptable results.33 If there is extra-
hepatic recurrence, the surgical treatment remains controversial.  In Chapter IX the 
results of resection of extrahepatic HCC resection are described. The conclusion after 
a systemic review of the literature and our own data support an aggressive approach 
in case of extrahepatic HCC recurrence in selected cases de ned by  a completely re-
sectable metastasis, a well-preserved liver function,  and the absence of intracranial 
metastases. Of course complete treatment of the primary tumor is a prerequisite to 
consider the resection of extrahepatic metastases of HCC. Further research is war-
ranted because of the limited number of reports and the absence of randomised 
trials.34
HCC is relatively resistant to conventional chemotherapy and therefore chemotherapy 
is not used as (neo)adjuvant and/or palliative therapy.35 Because of the low response 
rates to chemotherapy, other drugs with immunomodulatory and anti-angiogenic 
properties are under investigation. The published studies regarding the e  cacy of 
somatostatine analogues (SS) on survival in patients with HCC are con icting. Some 
studies did not display an improved survival in patients with unresectable HCC’s 36,37
while others found a signi cant survival bene t 38-40. However, placebo controlled 
randomized trials did not show signi cant bene t of SS on patient survival 41,42. 
The number of studies investigating the somatostatin receptor in human HCC is 
limited. Chapter X describes our results on sst2 expression in HCC. We examined 
whether HCC’s expressing sst2 can be de ned as a distinct subgroup with genetic, 
clinical or pathological characteristics. We investigated sst-2 as Octreotide, an often 
used SS analogue, has a high binding a  nity with ssr-2 compared to the other ssr 
subtypes. In 67% of the patients with HCC, sst2 could be detected in the tumour. 
However, no clinical or pathological characteristics were speci c for sst2 positive 
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tumours; furthermore these tumors cannot be de ned as a distinct subgroup at the 
genetic level.43
New developments in Rotterdam
Partial liver resection, OLT, living related liver transplantation (LDLTx) and local ab-
lation methods are the four curative treatment options that can be o ered in the 
Erasmus MC. Recently the  rst living related liver transplantation was performed.44
Because of the absence of waiting-time, LDLTx may have an advantage compared 
to transplantation with a liver of a deceased donor. Others already postulated that 
HCC may become the prime indication for LDLTx.45 . It should be noted, however, 
that a number of reports have been published recently, indicating inferior results in 
survival after LDLTx in the treatment of HCC. As a waiting time may o er information 
on the biological behaviour of the malignancy a selection of patients with more or 
less aggressive tumors may be realized by observation while waiting. Thus patients 
with early vascular ingrowth and early metastasis may not bene t from LRLTx as the 
disease will recur soon after transplantation. A waiting time of three to six months 
seems advisable to select patients with HCC eligible for LDLTx.
Stereotactic Radiotherapy is a relatively new technique with promising results. The 
initial experience in ErasmusMC has been published recently.46 From pre-clinical 
studies it is known, that a combination of radiotherapy plus angiogenesis inhibi-
tors may be either additive or synergistic.47,48 Jain and co-workers found in in vivo 
experiments that angiogenesis inhibitors normalize the vasculature of tumors and 
alleviate hypoxia.49 Winkler et al. described a decrease in hypoxia using angiogenesis 
inhibitors in a mouse model of brain tumor 50 In humans ,a similar e ect may be 
expected and further exploration of the combination of stereotactic radiotherapy 
and angiogenesis inhibitors seems warranted. There will be an increase in the use 
of RFA in patients with HCC in the coming years. RFA as bridging to transplant or as 
potential curative treatment will be explored with the combination of TACE in our 
prospective database.
Others suggested that an isolated liver perfusion may be of bene cial value51. The 
magnitude of the procedure is a major drawback for wide clinical application. A new 
technique of hypoxic isolated liver perfusion has been developed in the Erasmus 
MC, with a median operation time of 3.5 hours, less than 1 litre bloodloss without 
peri-operative mortality. The  rst 25 patients have been treated and it might be ap-
plied to patients with HCC con ned to the liver in the near future.52  
The promising results of angiogenesis inhibitors in cancer treatment can not be dis-
regarded.53  For patients with unresectable disease, a prospective randomized trial 
is current, receiving doxorubicine regimen with or without thalomide. Another an-
giogenesis inhibitor is Sorafenib, a multitargeted tyrosine kinase inhibitor. Sorafenib 
has shown clinical activity in patients with renal cell cancer and hepatocellular 
cancer. In a recent phase III trial presented at ASCO 2007, treatment with Sorafenib 
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resulted in a signi cant survival bene t of 12 weeks in patients with metastatic HCC 
compared to placebo controls.54 Sorafenib was administered in the standard dose of 
400mg bd with limited toxicity. The response rate in this study was only 2.3% partial 
responses. At the same meeting another study reported that the standard dose of 
Sorafenib could be increased to 1600mg bd with managable toxicity and increased 
response rates. However, the primary tumor studied was renal cell cancer.55 Based on 
these  ndings, we hypothesize that the response rate of Sorafenib against HCC can 
be increased by escalating its dose. To study this hypothesis, we will develop a dose 
escalating study with Sorafenib for patients with resectable HCC. Furthermore, we 
will join European trials of Sorafenib in adjuvant setting and in combination of RFA. 
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Het hepatocellulair carcinoom (HCC) is de meest voorkomende vorm van primair 
leverkanker. Van alle maligniteiten is het HCC wereldwijd de vijfde meest voorko-
mende maligniteit en staat het derde op de lijst van de meest voorkomende oor-
zaak van kanker gerelateerde mortaliteit. Jaarlijks worden er ongeveer 0.5 miljoen 
mensen gediagnosticeerd met een HCC.1 De geogra sche spreiding van het HCC 
is opvallend met een hoge incidentie in Aziatische en in enkele Afrikaanse landen. 
In de westerse wereld is er een lage incidentie, met een geschatte mortaliteit van 
5/100.000 inwoners/jaar. 2,3 Er zijn recente publicaties die in een aantal ontwikkelde 
landen een stijging van de incidentie laten zien.4-6 Publicaties over epidemiologische 
cijfers, behandeling en prognose zijn vaak van subpopulaties.7-10 Deze cijfers kunnen 
minder relevant zijn. In Hoofdstuk II worden de resultaten beschreven van een studie 
naar de incidentie van het HCC in Nederland tussen 1989 en 2000. In Nederland is er 
een incidentie van 0.3/100.000/jaar voor vrouwen en 1.6/100.000/jaar voor mannen 
in het jaar 2000.11 In tegenstelling tot andere publicaties van laag-incidentie landen 
kan op basis van dit onderzoek worden geconcludeerd dat er tussen 1989 en 2000 
in Nederland geen stijging van incidentie bij de man of vrouw is waargenomen. Er 
was geen verandering in behandelinspatroon (1889-1998). Opvallend was dat 73% 
van de patiënten geen kanker-gerelateerde therapie kregen. Twaalf procent van de 
patiënten ondergingen een mogelijke curatieve behandeling middels levertrans-
plantatie of een partiele leverresectie. Zonder adequaat screenings programma kan 
het zijn dat de diagnose in een te late fase wordt ontdekt om de curatieve opties 
nog te kunnen aanbieden. Echter, omdat een groot percentage van de patiënten 
onder controle zijn bij hun ziekenhuis i.v.m. onderliggende leverziekte, zoals virale 
en alcoholische levercirrhose, kan het eventueel zo zijn, dat er misschien een zekere 
terughoudend is om aggressieve therapie aan te bieden, in de vorm van partiele 
leverresectie. Het lage percentage van 12%, suggereert dat patiënten met een HCC 
in een gespecialiseerd centrum moeten worden besproken.11 In de nabije toekomst 
zal de behandeling van patiënten met een HCC in Nederland opnieuw worden ge-
analyseerd.
Iedere oorzaak van levercirrhose is een risicofactor voor het ontstaan op HCC. He-
patitis B en Hepatitis C zijn de meest bekende virale oorzaken en alcohol de meest 
bekende niet-virale oorzaak. Andere risicofactoren voor het ontstaan op HCC zijn 
haemachromatose, tyrosinaemia en a atoxin B1.12 Het is zeer waarschijnlijk dat er 
co-factoren bestaan die het ontstaan van HCC bevorderen bij de bekende risico-
factoren. Daarbij ontstaat in de Westerse wereld het HCC in ongeveer 30% in een 
niet-cirrhotische lever. Bij deze groep tumoren ontbreekt vaak een van de bekende 
risicofactoren. In Hoofdstuk III wordt een potentiele risicofactor onderzocht. In 1994 
werd gepubliceerd dat een infectie met een Helicobacter Hepaticus resulteerde in 
hepatitis en tumor groei in muizen.13,14 In 1997 werd een hogere prevalentie van IgG 
antilichaam tegen Helicobacter Pylori beschreven in patiënten met een levercir-
rhose dan in een controle groep.15 Meerdere studies hebben laten zien dat in een 
cirrhotische lever met HCC, Helicobacter DNA kan worden geïsoleerd, waarmee de 
suggestie wordt gewekt dat Helicobacter een rol speelt bij het ontstaan van HCC.16-20
Het is nog onduidelijk of de aanwezigheid van Helicobacter een oorzaak of gevolg 
is van cirrhose. Om dit vraagstuk te onderzoeken werd er een studie verricht naar de 
aanwezigheid van een Helicobacter DNA in de niet cirrhotische lever van patiënten 
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met een HCC, en de aanwezigheid van dit Helicobacter DNA in de maag van die-
zelfde patiënten. Als controle groep werd leverweefsel gebruikt van patiënten met 
colorectale levermetastasen. In de groep van HCC patiënten werd signi cant vaker 
Helicobacter DNA in de lever gevonden dan bij patiënten met colorectale metas-
tasen. Dit correleerde met de aanwezigheid van Helicobacter DNA materiaal in de 
maag. Sequentie analyse liet zien dat het Helicobacter DNA het meest paste bij dat 
van Helicobacter Pylori, met echter een consistente afwijking in 2 speci eke base pa-
ren (in 16SrDNA). Deze studie suggereert dat maag Helicobacter een rol kan spelen 
in de inductie van HCC, direct via colonizatie van de lever of indirect, via secretie van 
speci eke toxines door een Helicobacter in de maag.21
Afbeeldend onderzoek speelt een belangrijke rol in het stellen van de diagnose HCC. 
Toegepaste onderzoeken zijn echogra e, angiogra e, CT-scan en MRI. Naast deze 
technieken is er een toename van interesse in de ontwikkeling van in vivo methoden 
voor de bepaling van functionele parameters en metabolisme in normaal en aange-
daan weefsel.24,25 Positron Emission Tomography (PET) met gelabelled deoxyglucose 
is een voorbeeld van zo´n techniek. De PET-scan is (nog) niet wereldwijd beschikbaar 
en is kostbaar in aanschaf. Een alternatief is de Single Photon Emission Computed 
Tomography (SPECT) en Positron Coindicence Detection (PCD).26,27 In Hoofdstuk V 
wordt een prospectieve studie beschreven over de diagnostische waarde van een 
SPECT/PCD en de uitkomst wordt vergeleken met die van echogra sch en CT on-
derzoek van patiënten met verdenking op HCC. De resultaten van de PET-scan bij 
HCC, zoals tot op heden gerapporteerd, worden nader besproken. De SPECT/PCD 
heeft een lagere sensitiviteit dan de CT-scan voor intrahepatisch HCC. PET scan 
heeft evenmin additionele waarde voor detectie van intra-hepatische laesies. Een 
mogelijke waarde van PET in de diagnose van HCC kan zijn de detectie van extra-
hepatische ziekte. Dit is optioneel en (nog) geen standaard beleid. Derhalve kan uit 
onze studie geconcludeerd worden dat PET/SPECT/PCD scan niet tot de standaard 
work-up hoort van het HCC.28
De meest gebruikte tumor marker in het serum is het α foetoproteine (AFP). Een 
grote case-control studie laat een sensitiviteit van 62% en een speci citeit 89% zien 
bij een grenswaarde van AFP >15 ng/mL. Bij een waarde > 200ng/ml wordt de sen-
sitiviteit 22% met een speci citeit van 99%.29 Hoofdstuk VI laat de sensitiviteit zien 
van het AFP bij patiënten met een HCC in een niet-cirrhotische lever. De patiënten 
die gezien zijn in het ErasmusMC met een HCC in een niet-cirrhotische lever, heeft 
55% een AFP > 15 ng/ml. 30 Bij twijfel aan de diagnose kan een punctie worden over-
wogen om histologisch materiaal te verkrijgen indien dit klinische consequenties 
heeft. De kans op entmetastasen is tussen de 2 en 5%. Vals negatieve uitslag na 
een punctie van kleine tumoren kan oplopen tot 23%.31 Met name het onderscheid 
tussen het goed gedi erentieerde HCC en het adenoom is moeilijk. In Hoofdstuk IV
worden de resultaten van een studie beschreven waarin de verschillen van biologi-
sche markers, DNA ploidy status en de proliferatieve capaciteit in adenomen, HCC 
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en dysplasie worden onderzocht. Op basis van deze studie kan er, indien het onder-
scheid tussen HCC en een adenoom moeilijk is, de diagnose worden ondersteund op 
basis van ploidy status en proliferatie karakteristieken.32
Ondanks het hoog aantal patiënten met een HCC, blijft dit een moeilijk te behandelen 
klinisch probleem. In 1977 was een cirrhotische lever nog een contra-indicatie voor 
een partiele leverresectie. Tegenwoordig is het de behandeling van eerste keus bij 
patiënten met een gecompenseerde levercirrhose en HCC, in de aanwezigheid van 
donor schaarste. De prognose van patiënten met een HCC in een niet-cirrhotische 
lever is niet zo uitgebreid beschreven als die voor patiënten met een onderliggende 
cirrhotische lever. In de Westerse Wereld ontstaat het HCC in 30% zonder onderli-
gende levercirrhose. In Hoofdstuk VI  worden de resultaten beschreven van de pa-
tiënten die zijn behandeld in het ErasmusMC. In deze studie was er een gemiddelde 
tumor diameter van 10 cm. In de gehele groep patiënten met een HCC in een niet 
cirrotische lever was de grootte van de tumor niet bepalend voor de operabiliteit. 
Derhalve moet iedere patient met een HCC in een niet cirrhotische lever beoordeeld 
worden door een leverchirurg, ongeacht de grootte. Ondanks de grote gemiddelde 
diameter van deze tumoren, kunnen de meeste patiënten een partiële lever resectie 
ondergaan, met een in onze studie behaalde 5-jaars overleving van 68% in de ge-
opereerde groep patiënten. 
De patiënten met een onderliggende levercirrose worden strenger geselecteerd 
voor partiële lever resectie om de kans op behandelings-gerelateerde complicaties 
te verlagen. 
Door ernstige levercirrhose, co-morbiditeit en/of multifocaliteit van de tumor, is tus-
sen de 10 en 37% van de patiënten met een HCC geschikte kandidaten voor partiele 
leverresectie. Regionale en Lokaal Ablatieve therapieen zijn geaccepteerde alterna-
tieve behandelingen bij patiënten met niet resectabele HCC’s. 
In Hoofdstuk VII worden de resultaten beschreven van interstitiele laser coagulatie 
bij patiënten met een HCC in een cirrhotische lever. Om de e ectiviteit van de ILC te 
vergroten, hebben experimentele studies op varkens laten zien, indien de bloedtoe-
voer naar de lever tijdelijk wordt onderbroken, het gecoaguleerde gebied groter was 
dan zonder tijdelijke occlusie. Gebaseerd op deze resultaten is een prospectieve, 
klinische studie gestart de e ectiviteit op locale controle te evalueren na ILC en tij-
delijke arteriele occlusie, in patiënten met een HCC en onderliggende levercirrhose. 
De gehele procedure werd bij voorkeur percutaan verricht. In 19 van de 24 tumoren 
werd een complete tumor necrose vastgesteld dmv CT-scan. De meerderheid van de 
patiënten ontwikkelden nieuwe laesies elders (intra- of extrahepatisch).45
Wereldwijd is RFA nu de meest gebruikte techniek. De resultaten van RFA in het 
ErasmusMC worden beschreven in Hoofdstuk VIII. Deze resultaten bevestigen de 
veiligheid van RFA echter benadrukken dat het succes vooral wordt bepaald door de 
grootte van de tumoren en geconcludeerd wordt dat RFA gebruikt kan worden voor 
tumoren < 3 cm.46
Indien er een intrahepatisch recidief ontstaat, en dit is resectabel en/of te behande-
len met een locaal ablatieve methode, is dit een geaccepteerde behandeling en de 
eerste therapie keuze mits geen extrahepatische ziekte.35 De meningen zijn meer 
verdeeld indien er sprake is van resectabel extra-hepatisch recidief. In Hoofdstuk IX
worden de resultaten in het ErasmusMC besproken van de resecties van het extra-
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hepatisch recidief van het HCC en de bestaande literatuur wordt onderzocht. Als 
eindconclusie kan gesteld worden dat indien een extra-hepatisch recidief kan wor-
den gereserceerd, dit kan resulteren in lange-termijn overleving, onder voorwaaar-
de dat er een optimale behandeling voor de primaire tumor kan worden verricht. 
Hersenmetastasen zijn hierop een uitzondering en moeten als “inoperabel” worden 
beschouwd. Verder onderzoek is nodig omdat publicaties ten aanzien van dit onder-
werp schaars zijn en er geen gerandomiseerde trials zijn.36
Systemische chemotherapie voor HCC is uitgebreid onderzocht en wordt als niet ef-
fectief gezien (palliatief danwel (neo)-adjuvant).49 Enkele studies laten goede resul-
taten zien van Octreotide behandelingen in palliatieve setting echter de resultaten 
kunnen niet worden behaald in prospectieve gerandomiseerde studies. Er zijn maar 
een zeer gering aantal die gekeken hebben naar de aanwezigheid van somatosta-
tine receptoren in het HCC. In Hoofdstuk X worden de resultaten beschreven van 
een studie naar de somatostatine receptoren in het HCC. In 67% van de patiënten 
met een HCC werd een somatostatine receptor subtype 2 (ssr-2) geconstateerd in 
de tumor. Op basis van dit onderzoek werd geen relatie gevonden met klinische, 
pathologische of biologische parameters en het aanwezig zijn van een ssr-2.57
NIEUWE ONTWIKKELINGEN IN ROTTERDAM
Partiële leverresectie, ortothope levertransplantatie (OLT), leverdonatie bij leven 
(LDLTx) en lokaal ablatieve methoden zijn de 4 curatieve opties die geboden kun-
nen worden in het ErasmusMC. Recent is de eerste leverdonatie bij leven verricht.44
Er is een potentieel verschil in wachtlijst voor patiënten die een levertransplantatie 
moeten ondergaan tussen leverdonatie bij leven en OLT. Sommige centra hebben 
al gepostuleerd dat een leverdonatie bij leven de eerste keus zou moeten zijn bij 
patiënten met een HCC. 45 Recent zijn er ook meerdere artikelen verschenen die een 
inferieur resulaat lieten zien na LDLTx voor patiënten met een HCC. Omdat de wacht-
tijd voor een orgaan, informatie kan geven over het biologisch gedrag van het HCC, 
is er een natuurlijke selectie met meer of minder aggressieve HCC’s gedurende de 
wachttijd. Patiënten met microscopische vaatingroei en vroege metastasen zullen 
geen voordeel hebben van een LDLTx vanwege het vroege recidief na transplantatie. 
Een wachttijd van 3 tot 6 maanden lijkt de aangewezen tijdsduur om patiënten te 
selecteren voor LDLTx.
Stereotactische Radiotherapie is een relatief nieuwe techniek met veelbelovende 
resultaten. De eerste ervaringen zijn gepubliceerd.46 Mogelijk dat het gebruik van de 
“cyber-knife” in stereotactische radiotherapie de resultaten nog beter maakt. Vanuit 
pre-klinische studies weten we dat de angiogenese remmers additief en synergis-
tisch kunnen werken in combinatie met radiotherapie47,48 Jain en collegae lieten in 
in-vivo experimenten zien dat bij gebruik van angiogenese remmers vasculatuur al-
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lereerst normaliseert en hiermee de tumor hypoxie opheft.49 Winkler beschreef over 
hersen tumoren in een muizenmodel, dat het toedienen van angiogenese remmers 
de hypoxie afnam.50 In de humane situatie kan men veronderstellen dat dit hetzelfde 
e ect heeft en derhalve zou de combinatie van stereotactische radiotherapie en 
angiogenese remmers verder moeten worden onderzocht. Het gebruik van RFA zal 
in de komende jaren nog verder toenemen. De resultaten van RFA als “brug” naar 
transplantatie (ter voorkoming van progressie gedurende de wachttijd) en als po-
tentiele curatieve optie in combinatie met TACE zullen worden geregistreerd in onze 
prospectieve database.
Sommige onderzoeksgroepen suggereerden het nut van geïsoleerde leverperfusie 
bij patiënten met een HCC51. De morbiditeit en mortaliteit van de ingreep is een 
groot nadeel van de procedure, en daarom is er terughoudendheid om de techniek 
wereldwijd toe te passen. Een nieuwe techiek voor geïsoleerde, hypoxische lever-
perfusie is ontwikkeld in het ErasmusMC, met een mediane operatie duur van 3.5 
uur, minder dan 1 liter bloedverlies, zonder peri-operatieve mortaliteit. De eerste 25 
patiënten zijn behandeld en het zou gebruikt kunnen worden bij patiënten met een 
HCC in de nabije toekomst.52
De veelbelovende resultaten van de angiogene remmers in de behandeling van 
patiënten met een maligniteit kunnen niet meer worden genegeerd.53 Voor patiën-
ten met een gevorderd HCC, is een prospectieve studie lopende in het ErasmusMC 
waarbij er een randomisatie plaatsvindt tussen wel of geen thalomide gecombi-
neerd met doxorubicine. Een andere angiogenese remmer is Sorafenib (Nexavar), 
een multi tyrosine kinase remmer. In een gerandomiseerde fase III studie (recent 
gepresenteerd op ASCO 2007) heeft Sorafenib een signi cant overlevings voordeel 
van 12 weken aangetoond bij patiënten met een niet resectabel HCC ten opzichte 
van een placebo.54 Sorafenib werd tweemaal daags gegeven in een dosis van 400 
mg. In 2.3% van de patiënten was er maar sprake van een partiele respons. Op het-
zelfde congres werden de resultaten gepresenteerd van een studie waarbij de dosis 
Sorafenib werd verhoogd tot 2 daags 800 mg met beperkte toxiciteit en een hoger 
respons percentage bij patiënten met niercel carcinoom.55 Gebaseerd op deze bevin-
dingen, is er een vraag ontstaan of er bij patiënten met een HCC, een hoger respons 
percentage kan worden bereikt, indien de dosis Sorafenib wordt opgehoogd. Om dit 
te onderzoeken, proberen we een prospectieve studie op te zetten bij patiënten en 
een resectabel HCC met een stapsgewijze verhoging van Sorafenib in de wachttijd 
tot resectie. Verder zullen we participeren in Europese studies waarbij Sorafenib als 
adjuvante therapie wordt gegeven en in combinatie met RFA. 
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NAWOORD
Vele mensen hebben een bijdrage aan de totstandkoming van dit proefschrift gele-
verd. Zonder hun hulp zou het niet gelukt zijn en daarom is de dank aan hen groot. 
Een aantal mensen wil ik toch in het bijzonder noemen. Ik had me voorgenomen om 
het nawoord zeer kort en bondig te houden. Tsja, het is best lang geworden, story 
of my life………
Allereerst mijn ouders die, ondanks allerei omzwervingen van hun jongste zoon, 
altijd net bleven doen, alsof ze er vertrouwen in hadden dat het wel goed zou ko-
men. 
Dank jullie wel!!!!! Ik ben blij dat jullie er bij zijn.
Hooggeleerde heer IJzermans, beste Jan, dank om mij in aanraking te brengen met 
de lever- en transplantatiechirurgie. Wat heb ik nu bewondering voor je geduld 
(voor je technical skills had ik dat al), om mij destijds de technische vaardigheden 
van de lever- en transplantatie chirurgie bij te brengen. Daarbij lag een promotie-
onderwerp op dit gebied voor de hand en dank dat je me destijds getipt hebt om 
het Hepatocellulair Carcinoom bij de hoorns te nemen onder jouw begeleiding.
Dr de Man, beste Rob, dank voor de kritische beoordelingen en zeer nuttige advie-
zen bij de geschreven artikelen; onmisbaar. Grote dank dat je als co-promotor mij 
terzijde hebt gestaan.
Hooggeleerde heren Kuipers, Eggermont en Tollenaar, beste Ernst, Lex en Rob, har-
telijke dank voor de getoonde interesse en beoordeling van dit proefschrift.
De mede-auteurs van de gebruikte artikelen zijn van grote waarde geweest. Hoofd-
stuk 2 zou niet gelukt zijn zonder de hulp van de Intergrale Kanker Centra. Speci-
ale dank gaat uit naar Prof dr Jan-Willem Coebergh en dr Marieke Janssen-Heijnen 
van het IKZ en dr Otto Visser van het IKN. Voor het artikel in hoofdstuk 3 heeft de 
MDL-onderzoeksgroep van dr Hans Kusters meer gedaan dan alleen maar alle be-
palingen. Hans Kusters en Raymond Pot, veel dank voor jullie toewijding, geduld en 
grote inzet. Zonder alle scan beoordelingen, correcties en schrijfwerk van dr Roelf 
Valkema (nucleair geneeskundige), had Hoofdstuk 4 niet bestaan. De pathologie 
groep, o.a. bestaande uit Josiane Wink, Ronald van Marion, Kees Vissers hebben een 
grote bijdrage geleverd aan de hoofdstukken 5 en 10. De 2 pathologen, dr Herman 
van Dekken (hoofdstukken 5 en 10) en dr Pieter Zondervan (hoofdstukken 3, 5, 6 en 
10) zijn meer dan alleen (co-)auteurs. De kunde van de interventie-radiologen is on-
misbaar in onze dagelijkse praktijk. Ook voor de hoofdstukken 7 en 8 waren drs Jan 
Willem Kuipers, Prof dr Peter Pattynama van groot belang. Hoofdstuk 10 is tot stand 
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gekomen door een goede samenwerking met de groep van dr Leo Ho and (Endocri-
nologie). Verder wil ik mijn waardering uitspreken voor het vele werk van drs Fabian 
Holman en drs Vincent de Meijer. Joos Heisterkamp, groot dokter, groot doctor, en 
meest belangrijke persoon van hoofdstuk 7. Prof dr HW Tilanus, dr G Kazemier en dr 
IPJ Alwayn, gewaardeerde co-auteurs van hoofdstuk 6 en 8. Beste Huug, je enthousi-
asme en nimmer a atende werklust zullen me altijd bij blijven. Dank voor je vele oplei-
dings momenten, de “10M tijd” is onwisbaar! Beste Geert en Ian, naast co-auteurs ook 
participanten van de leverwerkgroep. Ik ben ervan overtuigd dat de sterkte van een 
werkgroep afhankelijk is van de individuen, en daarom mag de werkgroep zich geluk-
kig prijzen met jullie in de gelederen. Als laatste co-auteur, die nog niet genoemd is, 
wil ik dr Casper van Eijck bedanken. Casper, tijdens mijn opleidingstijd heb ik op vele 
vlakken veel van je geleerd. (ik wist al dat rood en wit DE kleuren waren) Ik ben blij dat 
ik nog steeds een “achterwacht” heb, waar ik voor klinische en chirurgisch-technische 
problematiek op terug kan vallen. (Jaja, die  es wijn komt echt nog wel) 
Paranymfen: dr JHW de Wilt (tevens mede-auteur van dit proefschrift) en dr GD Slooter. 
Vrienden, oud collega-assistenten, golfgenoten, cabaretmakers, kaftdelers en vakbroe-
ders in één. De zeer goede opleidingstijd in het Zuiderziekenhuis en het Dijkzigt, heeft 
o.a. een basis gelegd voor onze vriendschap. Ik ben zeer vereerd dat jullie aan mijn 
zijde willen staan. We hebben met zijn drieën al vele mooie momenten meegemaakt 
en ik hoop dat er nog vele zullen volgen! 
Cas van Oort, Rudolf Tutein Nolthenius, Tom Gerard Pablo Piet Fred Collet. Dank aan 
jullie voor de bijna jaarlijkse “ruime week” sessies in Spanje te La Xara. Dag en nacht 
wordt er dan over wetenschap nagedacht en gesproken met zijn 4’en in de wei, aan de 
kaarttafel en rechtop in het mandje. Ik hoop oprecht dat we dit jaarlijkse uitstapje nog 
in lengte van jaren zullen doen, ondanks dat de promotie nu is afgerond.
Verder dank ik alle collegae chirurgen, assistenten en fellows, internisten, radiologen, 
radiotherapeuten, gynaecologen, urologen, medewerkers op de O.K., verpleegafde-
lingen en polikliniek in het ErasmusMC centrum lokatie en lokatie Daniel den Hoed 
voor de goede samenwerking. Veel dank aan het secretariaat in de DDHK. Het was de 
afgelopen jaren niet altijd rozegeur en bekende maneschijn door personeels tekort, 
maar het werk werd wel gedaan en de patiënten zijn vol lof over jullie. Toch nog een 
speciale dank aan Nelis, die altijd alle zaken regelde, ondanks alle chaos bij mij. Corine, 
sterkte….. en dank nu al voor al je inspanningen. Ik ben trots op de afdeling Chirurgi-
sche Oncologie en het geeft een goed gevoel om daarbij te mogen horen.
Omdat de voltooiing van het proefschrift enige tijd geduurd heeft, zijn er vele mensen 
geweest die interesse hebben getoond en op zeer stimulerende wijze hebben ge-
vraagd wanneer het nu dan wel kwam. Een aantal wil ik toch nog even noemen; Prof 
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dr Henk Verheul (staat goed!), Xander van’t Ho , Eduard Prins, Gerrit Dekker, Stefan Nix 
en Peter Jan de Koning (t’is toch gewoon een scriptie?), mijn broer Rob en zus Marion 
(oh leuk, dan zie ik die en die eens!) en nog veel meer dierbaren.
Ja, nu kom ik bij jou, Heike. Misschien toch nog allereerst een paar woorden aan dr 
Laurens Stassen, de intimi zullen begrijpen waarom. Laurens, zeer veel dank voor de 
“tip”. Je had er echter bij moeten zeggen dat ze Duits was………..
Heike, je bent het mooiste en belangrijkste in mijn leven en je hebt me het mooiste en 
belangrijkste in mijn leven gegeven; de drie fantastische jongens. 
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